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Abstract  
Single nucleotide polymorphisms (SNPs), copy number variations (CNVs) and DNA methylation patterns 
play a role in the susceptibility to obesity. Despite the alarming figures of obesity in the Arab world, the 
genetics of obesity remain understudied in Arabs.  
Here, I recruited ten multigenerational Qatari families segregating obesity, and generated genome-wide 
SNP genotyping, whole genome sequencing and genome-wide methylation profiling data using Illumina 
platforms to investigate the role of rare mutations, CNVs, and DNA methylation patterns in the 
susceptibility to obesity. 
For the identification of obesity mutations, I first identified candidate obesity regions through linkage 
and run of homozygosity analyses, and then investigated these regions to detect potential deleterious 
mutations. These analyses highlighted putative rare variants for obesity risk at PCSK1, NMUR2, CLOCK 
and RETSAT. The functional impact of the PCSK1 mutation on obesity was previously demonstrated 
while for the other candidates further work is needed to confirm their impact. 
For the identification of common obesity CNVs, I performed a genome-wide CNV association analysis 
with BMI and identified a common duplication of ~5.6kb on 19p13.3 that associates with higher BMI. 
Moreover, I investigated large (≥500kb) rare CNVs and identified a ~618kb deletion on 16p11.2 in the 
most extremely obese subject in my samples, which confirms the contribution of the previously 
reported 16p11.2 deletions to severe obesity beyond European populations. 
For the identification of DNA methylation changes in obesity, I attempted to replicate known 
associations with BMI from large EWASs. I replicated the associations at ABCG1 (P-value=6.3X10-3) and 
CPT1A (P-value=8.7X10-5) and compared the effects observed to the TwinsUK cohort through a meta-
analysis. I observed low heterogeneity between the two studies, and that increased the associations at 
ABCG1 (P-value=2.5x10-13) and CPT1A (P-value=1.9x10-15).  
In conclusion, the work represents the first genetic and epigenetic study of obesity in an Arab 
population. I replicated known genetic and epigenetic obesity susceptibility loci and also discovered 
novel potential loci. 
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Preface 
Major advances in the field of genetic research have been achieved with the development of high 
throughput technologies. These technologies were employed to better understand the phenotypic 
variation between humans especially in relation to diseases. In this thesis, I investigate the role of 
several sources of genetic variations including single nucleotide polymorphisms, copy number variations 
and DNA methylation patterns in the susceptibility to obesity.   
Chapter one introduces obesity and the genetic and epigenetic research in the field of obesity. This 
includes the relevant literature and the progress that have been made in this filed in terms of findings, 
strategies and technologies, and providing justification for the research carried out in this thesis.   
Chapter two gives a description of the materials and methods used to perform the experimental and 
analytical work of this thesis. 
Chapter three shows the results and discussions of linkage, run of homozygosity and rare variants 
analyses for the purpose of the identification of rare obesity mutations. 
Chapter four presents the results and discussions of the CNV analyses that were carried out for the 
identification of common and rare obesity CNVs. 
Chapter five describes the results and discussions of the DNA methylation analysis that was performed 
to identify differentially methylation CpG sites with BMI.  
Chapter six discusses the work presented in this thesis in a wider context and describes potential future 
research directions to provide better understanding of the contribution of genetic and epigenetic 
changes to obesity predisposition. 
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1. Introduction 
1.1 Epidemic of Obesity 
The prevalence of obesity has reached epidemic levels globally. In 2014, there were more than 1.9 
billion overweight adults (age of 20 years or older) and of these more than 600 million were obese 
(World Health Organization 2015a). In addition, in 2013 there were more than 42 million overweight 
children, under the age of 5 years, with a higher rate of increase (more than 30%) observed in 
developing countries compared to developed countries (World Health Organization 2015a). Obesity is 
characterized by excessive fat accumulation in the body as a result of imbalance between energy intake 
and expenditure. Both in clinical medicine and in research, obesity is commonly monitored through 
measuring the Body Mass Index (BMI), which is calculated as weight in kilograms divided by the square 
of the height in meters squared. According to the World Health Organization (WHO), adults with a BMI 
of 25kg/m2 or above are classified as overweight while adults with a BMI of 30kg/m2 or above are 
considered obese (World Health Organization 2015a). For subjects below the age of 20 years, the WHO 
defines overweight and obesity as BMI of more than one standard deviation (SD) and two SDs 
respectively, above the mean BMI for the specific age and gender (World Health Organization 2015b). 
The increasing incidence of obesity has become a major health concern since obesity is a prominent risk 
factor for other public-health burdening conditions such as type 2 diabetes mellitus (T2D), 
cardiovascular diseases, hypertension and certain forms of cancer (Haslam and James 2005). In addition 
to the medical consequences, obesity is associated with significant social and economic challenges 
particularly in terms of the cost required for treatment of these obesity-associated diseases (Wang et al. 
2011).  
Obesity is a complex disease, which results from compound interactions between genetic and 
environmental factors such as diet and physical activity. Genetic risk factors are thought to predispose a 
proportion of the population to complex diseases like obesity, while environmental risk factors are 
believed to modulate the disease progression and severity (Panoutsopoulou and Zeggini 2009). 
1.2 Obesity in Qatar 
The State of Qatar is a peninsula located amid the western coast of the Arabian Gulf with an area of 
11,521 square kilometers. The population size is about two million residents (Tadmouri et al. 2009), of 
which ~300,000 Qataris owe their ancestry to a combination of three major subgroups: The Bedouin, 
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who originally migrated from the Nagid Plateau, the Persian who originally migrated along the coast of 
the Arabian Gulf, and the Africans who originally migrated to Qatar from Africa through trading routes 
or brought as slaves (Hunter-Zinck et al. 2010). 
Similar to many modern societies, the Qatari population is facing increasing rates of complex disorders 
such as obesity, T2D and cardiovascular diseases. Today, Qatar is one of the countries with highest 
obesity prevalence in the world with 42% of the Qataris being obese and 70% being overweight (World 
Health Organization 2015c). The country is also ranked high in the incidence of obesity-associated 
diseases such as T2D, in which the country ranks first globally with an estimated incidence of 23% 
among Qataris (Scully 2012). 
A major contributor to the problem is the rapid urbanization in the country after the discovery of oil and 
gas, resulting in lifestyle changes towards reduced physical activity and increased food consumption. 
However, as seen in other populations, genetic factors are likely to play a role in determining individual 
susceptibility to obesity, in such an “obesegenic” environment.  
One of the hypotheses proposed by geneticists to explain the burden of metabolic diseases such as 
obesity and T2D and the differential susceptibility between different ethnic populations is the thrifty 
gene hypothesis (Diamond 2003; Neel 1999). The hypothesis suggests that variants which predispose 
individuals to such diseases were historically advantageous in societies with food scarcity; therefore 
evolutionary pressures have favoured their persistence to prevent starvation (Neel 1999; Walley, Asher, 
Froguel 2009). This hypothesis might be relevant for the Qatari society, which has experienced long 
periods of food scarcity in the past, before the discovery of oil and gas, followed continuous abundance 
of food in the last 50 years following the rapid development in the country due to oil and gas revenues.  
However, the thrifty gene hypothesis has not been supported by genetic studies which showed absence 
of variation in the prevalence of some obesity risk variants, like those close to FTO, in isolated 
populations with high obesity prevalence (Walley, Asher, Froguel 2009). 
Demographic studies suggest that the rapid increase in obesity incidence in the globe within the last 2-3 
generations cannot be explained by genetic processes only, and the genetic studies which showed that 
obesity risk variants cannot account for much of the disease heritability have supported this idea (Drong, 
Lindgren, McCarthy 2012; Jaenisch and Bird 2003; Manolio et al. 2009). Epigenetic processes such as 
changes in DNA methylation patterns are believed to contribute to the susceptibility of complex disease 
(Drong, Lindgren, McCarthy 2012; Jaenisch and Bird 2003). DNA methylations patterns can be affected 
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by genetic factors as well as environmental factors including intra-uterine conditions and early life 
exposures. In addition, DNA methylation patterns might also show transgenerational inheritance (Drong, 
Lindgren, McCarthy 2012; McRae et al. 2014). 
Despite the alarming figures of obesity in the Qatari population, no genetic or epigenetic studies on 
obesity have been performed on the Qatari population so far making this study the first in that area. 
Conducting such studies on the Qatari population has many advantages. First, it can identify novel 
obesity variants, genes, and/or pathways, since the population has been understudied in the obesity 
research field, and can also highlight conserved findings from studies on other ethnicities.  Second, it 
confers a good opportunity to map recessive obesity genetic variants due to the high rates of 
consanguinity in the population, which is estimated at about 54% (Bener and Alali 2006). Third, the 
Qatari population has more uniform genetic and environmental backgrounds, compared to outbred 
populations, which may simplify the study of complex traits like obesity. Fourth, Qatari families are 
usually large intact families, due to cultural traditions and reduced rates of emigrations among Qataris, 
which is advantageous for conducting family-based studies in particular.  
1.3 Physiology of Obesity 
The physiological mechanisms underlying obesity are complex and involve multiple organ systems and 
signalling regulators, and pathways.  One of the key players in the process are the adipocytes which 
store surplus fat in the body as triacylglycerol and release non-esterified fatty acids into the 
bloodstream when fat stores are mobilized (Walley, Asher, Froguel 2009). Both adipocytes number and 
size have been found to be important in relation to obesity. A striking study conducted by Spalding et al. 
(Spalding et al. 2008) has shown that the number of adipocytes in the human body increases steadily 
during childhood and adolescence irrespective of weight while it remains constant during adulthood, 
which suggests that changes in fat mass in adults are determined by adipocytes size rather than number. 
Also, it means that people with early-onset obesity have a larger number of adipocytes when they reach 
adulthood compared to lean children. This may explain why about 75% of obese children remain obese 
during adulthood while only 10% of lean children become obese as adults (Freedman et al. 2001). 
Recently, obesity has also been viewed as a neuroendocrine disorder of energy balance controlled 
mainly by the brain. The process involves the interpretation and integration of several neural and 
hormonal signals, from different tissues, in the arcuate nucleus of the hypothalamus, which contains 
two sets of neurons: neuropeptide Y (NPY) and agouti-related protein (AGPR) neurons, and the pro-
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opiomelanocortin (POMC) and cocaine-and amphetamine-related transcript (CART) neurons (Barsh and 
Schwartz 2002). Activation of NPY/AGPR neurons has orexigenic effect, promoting food intake and 
reducing energy expenditure, while the activation of the POMC/CART neurons has the opposite 
anorexigenic effect (Barsh and Schwartz 2002).  
For example, leptin, which is secreted from adipose tissue, and insulin, which is secreted from the 
pancreas exert their anorexigenic effect through the activation of the POMC/CART neurons and the 
inhibition of the NPY/AGPR neurons (Friedman and Halaas 1998). Another anorexigenic signalling 
molecule in the process is the peptide YY3–36 (PYY3–36), which is secreted from the distal 
gastrointestinal tract, and exerts an inhibitory influence on the NPY/AGRP neurons though Y2 receptors 
(Y2Rs) present on those neurons. On the other hand, the orexigenic peptide ghrelin, which is secreted 
primarily by the stomach and duodenum, activates the NPY/AGPR neurons through their hormone 
secretagogue receptors (GHSRs) and consequently promotes food intake (Bell, Walley, Froguel 2005; 
Kohno et al. 2003). Moreover, the NPY/AGRP neurons exhibit an inhibitory influence on the POMC/CART 
neurons mediated through the release of gamma-aminobutyric acid (GABA). 
The signals produced by POMC/CART neurons and NPY/AGPR neurons are then sent to downstream 
effector neurons including the melanin-concentrating hormone (MCH) neurons, orexin or hypocretin 
neurons and thyrotrophin-releasing hormone (TRH) neurons, that express receptors including Y1 
receptor (Y1R) and the melanocortin 4 receptor (MC4R) (Bell, Walley, Froguel 2005). These neurons also 
receive further input signals from dopamine, serotonin and endocannabinoid to ultimately determine 
the balance between energy expenditure and food intake. The physiological regulation of energy 
balance via the arcuate nucleus neurons is summarized in Figure 1. 
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Figure 1. The physiological regulation of energy balance. Detailed description of the figure is given in 
Section 1.3. Figure is reproduced from Bell et al (Bell, Walley, Froguel 2005) with permission (See 
Appendix 2.1). 
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1.4 Heritability of Obesity 
Although the increasing prevalence of obesity worldwide has been driven by environmental changes, 
particularly changes in diet and lifestyle leading to over-nutrition and reduced physical activity, inter-
individual differences in susceptibility or resistance to obesity is strongly influenced by genetic factors. 
Early indications of the genetic component of obesity came from the observation of variation in obesity 
prevalence between different racial groups, from about 5% among Caucasian and Asian populations to 
about 50% in Pima Indians and South Sea Island populations (Knowler et al. 1990), as well as the long-
noted familial aggregation of obesity occurrence. 
Twin and adoption studies have estimated the heritability of obesity, the proportion of phenotypic 
variance attributable to genetic variance, at 40-70% (Elks et al. 2012; Maes, Neale, Eaves 1997). Even 
though these estimates might be inflated, they show that obesity is one of the strongest genetically 
influenced traits (Willyard 2014). In addition, the existence of a number of rare monogenic and 
syndromic forms of obesity has clearly highlighted the genetic aspect of obesity, as will be discussed in 
Sections 1.5.1 and 1.5.2 respectively. 
Environmental factors also play a role in modulating the effect of some of the genetic risk factors in 
obesity. For example, it has been shown that changes in lifestyle and physical activity can dilute or 
amplify the effect of the obesity risk variants near the fat mass and obesity-associated (FTO) gene 
(Silventoinen et al. 2009). Moreover, other factors like age and gender, which can be assimilated as 
specific environmental conditions, have also been reported to modulate the effect of obesity risk 
variants. For example, carriers of pathogenic obesity mutations in melanocortin 4 receptor (MC4R), 
which cause a monogenic form of obesity, have displayed age-dependent penetrance where the 
likelihood of obesity increases with age, as well as, gender-dependent effect on BMI where females tend 
to have twice the variant effect size seen in males (Stutzmann et al. 2008). Such gender-specific 
differences in the effect sizes of risk obesity variants may reflect in part the fact that females are at 
higher risk of developing morbid obesity than males (Ogden et al. 2006). These studies highlight the 
existence of interaction between genetic and environmental factors in determining obesity 
susceptibility, and hence underscore the complexity of the disease. 
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1.5 Genetic Basis of Obesity 
On the genetic level, obesity can be classified into three groups: 1) Monogenic obesity, which results 
from single gene mutations, 2) Syndromic obesity, where obesity presents in some genetic syndromes as 
a central clinical feature (Perrone et al. 2010), and 3) Polygenic obesity, which is associated with genetic 
variants at multiple loci conferring susceptibility to obesity. These classes of obesity will be introduced in 
sections 1.5.1, 1.5.2 and 1.5.3 respectively.  
1.5.1 Monogenic Forms of Obesity 
Monogenic forms of obesity provided direct evidence for the genetic role in the development of obesity, 
and contributed to our understanding of some of the cellular pathways involved in obesity development 
and in body weight regulation. Monogenic obesity represent about 2% of obesity cases and 5-6% of 
severe obesity cases (Froguel and Blakemore 2008), and it is usually caused by rare mutations (minor 
allele frequency (MAF) < 1%) with large effect size. Cases of monogenic obesity exhibit an extreme 
obesity phenotype with early onset and they often have other associated features like hyperphagia 
(Froguel and Blakemore 2008; Walley, Asher, Froguel 2009). 
1.5.1.1 The Role of Leptin and Leptin Receptor in Obesity 
Animal studies of monogenic obesity gave the first confirmation that single gene mutations can result in 
obesity. Studies of a severely obese strain of mice, ob/ob, provided early insights about the first obesity 
gene (Ingalls, Dickie, Snell 1950). In 1994, this strain has been characterized by a recessive mutation in 
the ob gene, which is expressed predominantly in white adipose tissue (Ingalls, Dickie, Snell 1950). The 
cloning and characterization of the ob gene facilitated the identification of its homologue in humans, the 
leptin gene (LEP) (Zhang et al. 1994). 
Leptin is a hormone-like protein that is secreted primarily by adipocytes in concentrations proportional 
to body adipose stores (Considine et al. 1996), and it acts as a key component of the leptin-melanocortin 
system, which regulates food intake and energy homeostasis (Farooqi et al. 2003). This system involves 
the secretion of leptin by adipocytes in the bloodstream. Circulating leptin in the bloodstream binds to 
leptin receptors (LEPR) in the hypothalamic arcuate nucleus leading to the activation of the POMC/CART 
neurons and the inhibition of the NPY/AGPR neurons, and the regulation of the expression of many key 
genes encoding downstream effectors in the pathway.  One of the genes that are up-regulated is pro-
opiomelanocortin (POMC). The POMC protein is usually cleaved by prohormone convertases (PC1 and 
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PC2) to generate the α-melanocyte-stimulating hormone (α-MSH), the ligand for the melanocortin 4 
receptor (MC4R). The binding of α-MSH to MC4R results in the activation of downstream signals to 
inhibit anabolic pathways and to stimulate catabolic pathways, leading to reduced food intake and 
increased energy expenditure, respectively (Farooqi et al. 2003). 
Further studies on the ob/ob strain have shown that the exogenous administration of recombinant 
leptin results in complete reversal of the obesity phenotype in this strain (Campfield et al. 1995; Halaas 
et al. 1995). The recombinant leptin is also currently applied as a treatment in humans (Farooqi et al. 
1999). 
In relation to obesity in humans, one of the first breaks came in 1997, with the identification of a rare 
homozygous mutation in LEP in patients with severe early-onset obesity (Montague et al. 1997). This 
discovery provided the first evidence that monogenic obesity also exist in man. The mutation was 
identified in two obese cousins from a highly consanguineous family of Pakistani origin. The mutation 
resulted in very low serum leptin (< 1ng/ml) levels in these patients despite their elevated fat mass, a 
condition termed as congenital leptin deficiency (Montague et al. 1997). This condition is usually 
associated with hyperphagia, hyperinsulinaemia, hypothyroidism and hypogonadism (Gibson et al. 2004; 
Ozata, Ozdemir, Licinio 1999; Saeed et al. 2012; Strobel et al. 1998). Screening subjects with severe 
early-onset obesity for mutations in LEP, as a candidate gene, allowed the identification of additional 
mutations causing leptin deficiency (Gibson et al. 2004; Ozata, Ozdemir, Licinio 1999; Saeed et al. 2012; 
Strobel et al. 1998). These mutations include missense, nonsense as well as farmeshift mutations and 
they are usually inherited in an autosomal recessive manner. 
Currently, recombinant leptin is available as a treatment to reverse the phenotypic aspects of leptin 
deficiency and about 30 patients worldwide were cured of their obesity phenotype so far (Farooqi et al. 
1999). Despite the rarity of this condition, the ability to provide effective personalized medicine for this 
group of patients represents a successful and motivating example in the field of translational medicine 
in obesity. 
Animal studies on another strain of mice (db/db) with severe diabetes, obesity and dislipidaemia, have 
revealed a causative recessive mutation in the ob (leptin) receptor gene (Chua et al. 1996). The leptin 
receptor (LEPR) is abundantly expressed in the hypothalamus. The same study showed that the 
administration of leptin could not reverse the obesity phenotype in this strain consistent with the 
molecular phenotype (Chua et al. 1996). Homozygous mutations in the LEPR have also been found in 
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patients with severe obesity usually associated with some other features such as hyperphagia, reduced 
insulin-like growth factor (IGF-1), growth abnormalities and delayed or absent puberty (Clement et al. 
1998; Farooqi et al. 2007; Mazen et al. 2011). Similar to mutations in LEP, LEPR mutations also showed 
an autosomal recessive pattern of inheritance. 
1.5.1.2 The Role of other Leptin-Melanocortin Pathway Genes in Obesity 
Further investigations of patients with severe early-onset obesity have shed light on four monogenic 
obesity genes other than LEP and LEPR. Interestingly, these genes also encode for effectors involved in 
the leptin-melanocortin pathway. One of these monogenic obesity genes is POMC in which homozygous 
loss of function mutations resulting in POMC deficiency have been identified in subjects with severe 
early onset obesity, and with other associated features such as red hair pigmentation, pale skin and 
hyperphagia (Challis et al. 2002; El-Sayed Moustafa and Froguel 2013; Krude et al. 1998; Krude and 
Gruters 2000). These mutations displayed a recessive mode of inheritance. Similar to the phenotype of 
POMC-deficient patients, pomc knock-out mice are characterized with obesity, defective adrenal 
development and altered pigmentation, which supports the conserved role of POMC across different 
species (Yaswen et al. 1999). 
Furthermore, homozygous, compound heterozygous and heterozygous loss-of-function mutations in 
proprotein convertase subtilisin/kexin type 1 (PCSK1) gene, which encodes the enzyme responsible for 
the cleavage of POMC, were also reported to cause severe obesity (Farooqi et al. 2007; Jackson et al. 
1997; Philippe et al. 2015). Phenotypes associated with obesity due to PCSK1 mutations include 
abnormal glucose homeostasis, reduced plasma insulin, hypogonadism and hypocortisolaemia (Farooqi 
et al. 2007; Jackson et al. 1997). The causative mutations in PCSK1 showed autosomal recessive or 
autosomal dominant modes of inheritance (Farooqi et al. 2007; Jackson et al. 1997; Philippe et al. 2015). 
In addition, heterozygous mutations causing partial PCSK1 deficiency confer increased risk for obesity 
(Creemers et al. 2012). Surprisingly, pcsk1 knock-out mice do not develop obesity and are characterized 
with dwarfism and defects in growth hormone processing (Zhu et al. 2002), suggesting a potential 
variation in the function of PCSK1 across different species. However, LIoyd et al. (Lloyd, Bohan, Gekakis 
2006) have reported a novel mutation in pcsk1 in mice (N222D) that leads to impaired catalytic activity 
of PC1, reduced levels of α-MSH, and the development of obesity, similar to PCSK1 deficiency in 
humans. 
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In addition, mutations in the melanocortin 4 receptor (MC4R) are the most common cause of 
monogenic obesity affecting 2-4% of severely obese individuals (Farooqi et al. 2003; Hinney et al. 2006; 
Vaisse et al. 1998; Yeo et al. 1998). Loss of function mutations in MC4R have been identified in subjects 
with severe obesity (Dubern et al. 2001; Farooqi et al. 2000; Lubrano-Berthelier et al. 2006; Stutzmann 
et al. 2008). Unlike most of the monogenic obesity forms discussed above, which are recessively 
inherited, mutations in MC4R are inherited in autosomal dominant, co dominant or even autosomal 
recessive manner (Dubern et al. 2001; Farooqi et al. 2000; Hinney et al. 2006; Saeed et al. 2012; 
Stutzmann et al. 2008; Vaisse et al. 1998). 
Knock out studies of mc4r in mice have demonstrated that the disruption of a single copy of the gene 
can result in increased food intake, severe obesity, and hyperinsulinemia, which confirmed the 
preserved role of MC4R in the regulation of body weight across species (Huszar et al. 1997). Rhythm, a 
pharmaceutical company based on Boston, has developed a compound called ”RM-493” for the 
treatment of obesity in patients with MC4R deficiency due to heterozygous  mutations in MC4R gene 
(Rhythm 2013). The compound is a novel MC4R agonist that aims to restore MC4R function through 
increasing the signalling activity of the normal copy of the receptor. In 2013, the company launched a 
clinical trial to investigate the effect of RM-493 on weight loss in obese subjects with normal copies of 
MC4R, and they demonstrated its efficacy on increasing energy expenditure and weight loss (Rhythm 
2013). The follow-up clinical trials will address the same question but in patients with MC4R deficiency. 
Furthermore, monogenic obesity can result from loss of function mutations in single-minded family 
bHLH transcription factor 1 (SIM1) gene, which encodes a transcription factor that has essential role in 
neurogenesis (Bonnefond et al. 2013; Holder, Butte, Zinn 2000; Montagne et al. 2014; Ramachandrappa 
et al. 2013; Zegers et al. 2014). This transcription factors is believed to act upstream and downstream of 
MC4R, and contributes to the regulation of energy homeostasis. Severely obese subjects due to 
mutations in SIM1 are characterized by other associated features such as hypotonia and developmental 
delay (Bonnefond et al. 2013; Holder, Butte, Zinn 2000; Montagne et al. 2014). Functional studies have 
shown that Sim1 deficiency is sufficient to cause hyperphagic obesity in mice and have highlighted the 
role of sim1-expressing neurons in regulating food intake through the leptin-melanocortin pathway 
(Kublaoui et al. 2006; Tolson et al. 2010). The genes involved in the monogenic forms of obesity to date 
are summarized in Table 1. 
 
1. Introduction 
31 
 
Collectively, monogenic obesity studies have drawn a picture of obesity as a neuroendocrine disorder 
controlled mainly by the functioning of the hypothalamus and caused by appetite dysfunction due to the 
leptin-melanocortin pathway impairment.  In addition, the large effect size of the various monogenic 
obesity mutations gives them useful predictive value in clinical setting at the level of individual cases. 
Thus, genetic screening for known monogenic obesity mutations can be useful particularly in cases with 
extreme early onset obesity, and especially in cases displaying other features such as hyperphagia or 
developmental delay (Blakemore and Froguel 2010; El-Sayed Moustafa and Froguel 2013). 
Gene (gene 
symbol) 
Cytoband Protein role Mode of 
inheritance 
 
Knock-
out 
animal 
models 
Reference 
Leptin (LEP) 7q31.3 A hormone-like protein 
involved in regulation of 
food intake and energy 
expenditure, through leptin-
melanocortin pathway. 
Autosomal 
recessive 
Obese (Gibson et al. 2004; Montague 
et al. 1997; Ozata, Ozdemir, 
Licinio 1999; Saeed et al. 2012; 
Strobel et al. 1998) 
Leptin Receptor 
(LEPR) 
1p31 A receptor for leptin 
involved in hypothalamic 
signaling and appetite 
control. 
Autosomal 
recessive 
Obese (Clement et al. 1998; Farooqi 
et al. 2007; Mazen et al. 2011) 
Melanocortin-4 
receptor 
(MC4R) 
18q21.32 A receptor for melanocortin 
family, integral in 
hypothalmatic signaling for 
appetite control. 
Autosomal 
dominant/     
co-dominant/ 
recessive 
Obese (Dubern et al. 2001; Farooqi et 
al. 2000; Huszar et al. 1997; 
Lubrano-Berthelier et al. 2006; 
Saeed et al. 2012; Stutzmann 
et al. 2008) 
Pro-
opiomelanocortin 
(POMC) 
2p23.3 A polypeptide hormone 
precursor for MC4R ligand 
(α-MSH), a key player in 
leptin-melanocortin 
pathway. 
Autosomal 
recessive 
Obese (Challis et al. 2002; El-Sayed 
Moustafa and Froguel 2013; 
Krude et al. 1998; Krude and 
Gruters 2000; Yaswen et al. 
1999) 
Pro-hormone 
convertase 
subtilisin/kexin 
type 1 
(PCSK1) 
5q15 An enzyme involved in post-
translational processing of 
POMC. 
Autosomal 
dominant/ 
recessive 
Not 
obese 
(Farooqi et al. 2007; Jackson et 
al. 1997; Philippe et al. 2015; 
Zhu et al. 2002) 
Single-minded  
homolog 1 (SIM1) 
6q16.3 A DNA-binding protein that 
acts upstream and 
downstream of MC4R with 
essential role in 
neurogenesis and regulation 
of energy homeostasis. 
Autosomal 
dominant 
Obese (Bonnefond et al. 2013; 
Holder, Butte, Zinn 2000; 
Kublaoui et al. 2006; 
Montagne et al. 2014; 
Ramachandrappa et al. 2013; 
Tolson et al. 2010; Zegers et al. 
2014) 
Table 1.Genes involved in monogenic forms of obesity. 
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1.5.2 Syndromic Forms of Obesity 
Unlike monogenic forms of obesity in which obesity is present as the principle clinical phenotype, 
syndromic forms of obesity are characterized with obesity as an associated clinical feature with a group 
of complex clinical phenotypes such as mental retardation, dysmorphic features and developmental 
delay. To date, there are more than 30 genetic syndromes associated with obesity due to genetic 
defects or chromosomal abnormalities (O'Rahilly et al. 2003).  
Prader-Willi syndrome (PWS) is the most common example of obesity syndromes that occurs in 
approximately 1 out of 50,000 people (Farooqi 2005). PWS is neurodevelopmental syndrome 
characterized by developmental delay, inflate hypotonia, hypogonadism and early onset obesity 
associated with hyperphagia.  PWS is caused by deletions or defects at an imprinted region on 
chromosome 15 (q11-q13), which is usually paternally expressed (Farooqi 2005).  This region contains 
several protein coding genes as well as multiple non-coding snoRNAs.  The gene responsible for the PWS 
phenotype in the region is believed to contain the HBII-85 snoRNA cluster, suggesting a role of this 
particular family of non-coding RNAs in growth and energy homeostasis (de Smith et al. 2009).  
Bardet-Biedl syndrome (BBS) is a rare syndrome characterized with obesity, retinopathy, renal and 
cardiac defects, polydactyly, learning disabilities and hypogonadism. The prevalence of BBS is 1 in 
125,000–160,000 in people of European descent and is higher in consanguineous populations (Guo and 
Rahmouni 2011). About 80% of BBS cases result from mutations in BBS genes (BBS1-BBS15) encoding 
BBS proteins that are involved in leptin signalling in the hypothalamus (Guo and Rahmouni 2011). In 
addition, a case-control association study between variants in the BBS genes and obesity revealed 
association between single nucleotide polymorphisms (SNPs) in BBS2, BBS4 and BBS6 with common 
obesity (Benzinou et al. 2006), suggesting a role of BBS genes even in non-syndromic obesity.  
1.5.3 Polygenic Form of Obesity 
Monogenic and syndromic forms of obesity account for only a small proportion of obesity cases. The 
majority of obesity cases, on the other hand, are polygenic, resulting from complex interactions 
between susceptibility variants in multiple genes with environmental risk factors where each individual 
susceptibility variant has subtle effect on weight (Froguel and Blakemore 2008). 
Until 2006, studies aiming to define susceptibility loci underlying complex diseases like common obesity 
were mainly based on linkage and candidate gene approaches. However, these approaches have been of 
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limited utility in revealing genes underlying common obesity. The main advances in the field of common 
obesity came with the development of high throughput genotyping array platforms, which allow the 
implementation of hypothesis-free association approaches at the genome-wide level. These approaches, 
known as genome-wide association studies (GWASs), have dramatically increased the speed of gene 
discovery in the field (Locke et al. 2015; Shungin et al. 2015). These different types of genetic 
approaches are described below. 
1.5.3.1 Linkage Studies on Obesity 
Linkage analysis is a family-based approach that aims to locate a genomic region that is co-inherited 
with a trait of interest in families. This approach can be performed at the genome wide level or at 
particular candidate regions, and it usually involves the genotyping of family members for polymorphic 
markers such as SNPs or microsatellites (El-Sayed Moustafa and Froguel 2013). This type of analysis 
takes advantage of the inverse relationship between the frequency of recombination events between 
any two genomic loci and their physical distance. Thus, the co-inheritance of markers with the trait of 
interest suggests that these markers are located close to the trait/disease locus.  
Over 60 genome-wide linkage scans have been performed for different obesity-related traits, and they 
revealed 253 putative obesity quantitative trait loci (QTLs) (Rankinen et al. 2006). These QTLs are 
mapped to all chromosomes except the Y chromosome and are summarized in the “Human Genome 
Map” (Rankinen et al. 2006). Although some functionally promising candidates were identified through 
linkage signals, replication of these results has proved difficult as only 20% of signals were supported by 
more than one study (Rankinen et al. 2006). A large meta-analysis that combined data from 37 
independent obesity linkage studies containing more than 31,000 individuals, have been conducted to 
increase the statistical power for linkage detection. However, no regions with consistently significant 
evidence for linkage have been identified (indicated by logarithm of odds score (LOD score) of 3.3 or 
more) and few suggestive linkage signals (indicated by LOD score of 1.9 or more) were detected at 
13q13.2-13q33.1, 12q23-12q24.3 and 16q12.2 (Saunders et al. 2007). The lack of linkage evidence, 
despite sufficient detection power, suggests high heterogeneity underlying obesity and small effect size 
of common risk variants on the phenotype. Some of the linkage signals for obesity-related traits have 
been observed in multiple studies (El-Sayed Moustafa and Froguel 2013) including the signals on 1p36 
(Deng et al. 2002; Gorlova et al. 2003; Liu et al. 2004a; Norris et al. 2005; Wilson et al. 1991), 2p21-2p23 
(Cai et al. 2004; Moslehi et al. 2003; Palmer et al. 2003; Rotimi et al. 1999), 2q14 (Deng et al. 2002; Fox 
et al. 2004; Liu et al. 2004b), 3q27 (Kissebah et al. 2000; Luke et al. 2003; Vionnet et al. 2000; Walder et 
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al. 2000; Wu et al. 2002), 6q21-6q23 (Atwood et al. 2002; Fox et al. 2004; Meyre et al. 2004), 7q31-7q32 
(Cai et al. 2004; Liu et al. 2004b; Moslehi et al. 2003; Palmer et al. 2003; Rotimi et al. 1999), 10p11-
10p12 (Hager et al. 1998; Hinney et al. 2007; Price et al. 2001), 11q14-11q24 (Atwood et al. 2002; 
Hanson et al. 1998; Norman et al. 1997) and 20q11-20q13 (Dong et al. 2003; Hunt et al. 2001; Lee et al. 
1999; Norman et al. 1998). 
1.5.3.2 Candidate Gene Association Studies on Obesity 
Candidate gene approach is a hypothesis-driven approach that tests the association between 
a trait of interest (either discrete or quantitative) and markers in a predefined candidate 
gene. Candidate genes might be selected based on gene function , pathway information, 
evidence from linkage or association studies, and/or animal model studies (El-Sayed Moustafa 
and Froguel 2013). Unlike linkage analysis, candidate gene approach can be carried out in 
unrelated individuals.  
Hundreds of candidate gene association studies have been performed for obesity or obesity -
related traits in the past two decades, and they revealed associations with markers in more than 
127 candidate genes. Most of these associations were not consistent across different studies. 
However, the most widely replicated associations were with variants in MC4R (Chambers et 
al. 2008; Loos et al. 2007; Ma et al. 2004), PCSK1 (Benzinou et al. 2008; Creemers et al. 2012), 
brain-derived neurotrophic factor (BDNF) (El-Gharbawy et al. 2006; Gray et al. 2006; Ribases 
et al. 2005; Shugart et al. 2009), peroxisome proliferator-activated receptor γ gene (PPARγ) (Deeb et 
al. 1998; Ristow et al. 1998; Tonjes et al. 2006) and β-adrenergic receptor 3 (ADRB3) (Fujisawa et 
al. 1998; Kurokawa et al. 2008). Most of the associations identified through candidate gene 
studies did not reach genome-wide significance, which is the association P-value threshold 
after adjustment for multiple testing (the number of pairwise asso ciation tests performed at 
genome-wide level), using well-established statistical approaches such as Bonferroni correction (Bland 
and Altman 1995), even in meta-analyses. This suggested that genetic variations at many of the 
candidate obesity genes have modest effect sizes on obesity.  
Recently, lchimura et al. (Ichimura et al. 2012) performed a candidate gene study on the G-
protein coupled receptor 120 (GPR120) gene, which encodes for an omega-3 fatty acids 
receptor involved in several biological processes including inflammation, adipogenesis and 
appetite control. The study identified a rare non-synonymous mutation (p.R270H) in GPR120 that 
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confers an increased risk of obesity in European populations. In vitro and in vivo functional studies on 
this variant demonstrated that it results in the loss of function of the receptor, as a sensor of dietary fat, 
in a dominant negative fashion which highlighted the importance of environmental sensors as 
obesity candidates. 
1.5.3.3 Genome-Wide Association Studies (GWASs) on Obesity 
The international HapMAP project, which aimed to catalogue the common genetic variation (MAF ≥ 5%) 
in the human genome, served as a foundation for the implementation of genome-wide association 
studies (GWASs) (International HapMap Consortium 2003). Information on the common genetic variants 
and the patterns of linkage disequilibrium (LD), which is the non-random association of alleles located in 
adjacent chromosomal locations, were utilized by companies such as Illumina Inc. (San Diego, USA) and 
Affymetrix Inc. (Santa Clara, USA) for the development of array-based genome-wide genotyping 
platforms (International HapMap Consortium 2005; International HapMap Consortium et al. 2007). Such 
platforms facilitated the genotyping of hundreds of thousands SNPs for large number of samples in a 
fast, efficient and cost effective manner, making the implementation of GWASs possible (McCarthy et al. 
2008). Both the Illumina and Affymetrix platforms have the same genotyping principle that relies on 
using high-density oligonucleotide arrays and comparing the signal intensity from each of the two SNP 
alleles for each SNP oligonucleotide to derive a genotyping call, but they apply different chemistries in 
their workflow.   
GWASs are hypothesis-free approach that test for the association between a trait of interest 
(either discrete or quantitative) and common allelic variants  (MAF ≥ 5%) at the genome level. In 
GWASs, the genotype frequencies at each of these SNPs are tested for association with the trait of 
interest. Associations are considered significant only when they reach genome-wide levels, therefore a 
large number of samples is typically needed to enhance the power of association detection (Ku et al. 
2010). Association hits that are obtained from GWASs are not necessarily causative but are instead in 
strong LD with the causal variants (Ku et al. 2010; Walley, Asher, Froguel 2009). A group of variants or 
genes are usually selected from the initial GWAS for replication and follow-up purposes.  
One of the limitations of the GWASs is that they rely on the common disease–common variant (CDCV) 
hypothesis. This hypothesis argues that the major contributors to the genetic susceptibility to common 
diseases are common genetic variations, with relatively low effect sizes, and this hypothesis has recently 
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been challenged (McCarthy et al. 2008). Despite that, GWASs had major contribution towards the 
identification of genetic variants associated with several common complex diseases. 
The first important association to common obesity was mapped to chromosome 16q12 close to the fat 
mass and obesity-associated (FTO) gene (Dina et al. 2007). The association with the FTO locus was 
initially discovered in a GWAS of T2D conducted in 2007 (Frayling et al. 2007). However, the association 
with T2D was not detected with matched BMI, which suggested that FTO effect on T2D is through its 
effect on BMI (Frayling et al. 2007). Since then, associations with the FTO locus were the strongest and 
most widely replicated with obesity and BMI (Bradfield et al. 2012; Cotsapas et al. 2009; Dorajoo et al. 
2012; Heard-Costa et al. 2009; Meyre et al. 2009; Paternoster et al. 2011; Scherag et al. 2010; Scuteri et 
al. 2007; Tan et al. 2008; Wang et al. 2012).  
The risk allele of the FTO SNP rs9939609 has the strongest known effect on increased BMI, particularly 
within European populations (Frayling et al. 2007). Homozygous individuals for the A risk allele show 
approximately 3kg increase in weight compared to individual homozygous for the normal allele, and 
have a 1.67-fold increased risk of developing obesity (Frayling et al. 2007). However, this variant 
accounts for only about 1% of the total heritability estimated for BMI (Frayling et al. 2007). 
Currently, the function of FTO is largely unknown despite the fact that its effect on obesity has been 
extensively demonstrated even in animal models (Church et al. 2010; Fischer et al. 2009). Studies on 
mice have shown that fto is widely expressed in the brain, particularly in the hypothalamus (Gerken et 
al. 2007), and that its overexpression induces obesity (Church et al. 2010), while the lack of its 
expression protects from obesity (Fischer et al. 2009; Speakman 2010), suggesting the involvement of 
FTO in the regulation of energy homeostasis and metabolism. However, no direct connection has been 
made between the obesity-associated variants close to FTO and the expression or function of the gene. 
Smemo et al. (Smemo et al. 2014) has recently shown that the real effect of the risk variants close to 
FTO is actually driven by altering the expression of another gene located at a megabase distance from 
FTO and involved in neural development, called Iroquois homeobox 3 (IRX3). Such long-range 
interactions between FTO intron and IRX3 were also conserved in other vertebrate genomes. Moreover, 
the study showed that Irx3-deficient mice have a reduction in body weight of 25 to 30% compared to 
wild types, demonstrating the role of IRX3 as a regulator of body mass and composition. 
Meta-analyses of GWASs, which combine data from multiple independent GWASs, have been 
conducted in order to achieve large sample size and increase the statistical power for association 
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detection. The first meta-analysis conducted by the Genetic Investigation of ANthropometric Traits 
(GIANT) consortium has identified a strong association between SNPs located near MC4R and BMI (Loos 
et al. 2008). In parallel, the SNPs near MC4R were reported in association with waist circumference in 
Indian Asians (Chambers et al. 2008). Associations of MC4R variants in relation to obesity have also been 
reported by other studies (Bradfield et al. 2012; Dorajoo et al. 2012; Heard-Costa et al. 2009; Locke et al. 
2015; Meyre et al. 2009; Paternoster et al. 2011). 
 A larger meta-analysis carried out by the GIANT consortium (Willer et al. 2009) identified six novel 
obesity loci including transmembrane protein 18 (TMEM18), potassium channel tetramerization domain 
containing 15 (KCTD15), glucosamine-6-phosphate deaminase 2 (GNPDA2), SH2B adaptor protein 1 
(SH2B1), mitochondrial carrier homolog 2 (MTCH2) and neuronal growth regulator 1 (NEGR1).  
Further effort by researchers from deCODE genetics (Thorleifsson et al. 2009) confirmed the 
associations at TMEM18, NEGR1, KCTD15 and SH2B1 with BMI and reported additional associations at 
SEC16 homolog B (S. Cerevisiae) (SEC16B), brain-derived neurotrophic factor (BDNF) and near Ets variant 
5 (ETV5). Smaller GWASs (Cotsapas et al. 2009; Meyre et al. 2009; Scherag et al. 2010) have confirmed 
the associations observed at FTO, TMEM18 and MC4R, and identified novel associations at v-maf avian 
musculoaponeurotic fibrosarcoma oncogene homolog (MAF), phosphotriesterase related (PTER), 
niemann-pick disease type c1 (NPC1), serologically defined colon cancer antigen 8 (SDCCAG8), tankyrase 
trf1-interacting ankyrin-related adp-ribose polymerase (TNKS), and methionine sulfoxide reductase a 
(MSRA). 
In addition, a larger meta-analysis study on BMI was conducted by the GIANT consortium and it 
consisted of 46 GWASs and 249,769 individuals (Speliotes et al. 2010). The study revealed 32 SNPs 
robustly associated with BMI, 14 of these associations were previously reported while 18 were novel. 
The largest and most recent meta-analysis with BMI carried out by the GIANT consortium included 
339,224 individuals from 125 GWASs and has expanded the catalogue of BMI-associated loci to 97 loci 
(Locke et al. 2015). Of these loci, 41 were previously reported (Berndt et al. 2013; Bradfield et al. 2012; 
Guo et al. 2013; Kilpelainen et al. 2011; Locke et al. 2015; Monda et al. 2013) while 56 were novel (Locke 
et al. 2015), as summarized in Table 2. The associations detected provided strong support for the role of 
the central nervous system in obesity susceptibility as well as other new pathways involved in insulin 
function, glutamate signalling, adipogenesis and others (Locke et al. 2015).  
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Interestingly, GWASs have provided links between monogenic and polygenic forms of obesity as they 
have demonstrated that some common variants located in or near previously recognized monogenic 
obesity genes modulate BMI and confer risk for common obesity. For example, common variants in 
MC4R have been reported in association with BMI, waist circumference, insulin resistance and other 
obesity related traits (Bradfield et al. 2012; Chambers et al. 2008; Dorajoo et al. 2012; Heard-Costa et al. 
2009; Locke et al. 2015; Loos et al. 2008; Meyre et al. 2009; Paternoster et al. 2011). In addition, 
Wheeler et al. (Wheeler et al. 2013) have identified a common variant in LEPR in association with severe 
early-onset obesity. This suggests that monogenic obesity genes are good candidates for common 
obesity, and this also highlights the importance of the leptin-melanocortin 4 receptor pathways and the 
central nervous system in modulating obesity. 
The rapid shift towards the application of GWASs had a major contribution in identifying several 
putative genes and variants that contributes to the pathogenesis of obesity. However, the 97 SNPs 
robustly associated with BMI all together, for example, accounts only for 2.7% of phenotypic variance of 
BMI (Locke et al. 2015). The modest effect size of these variants limits their utility in clinical prediction.  
In addition, the functional relevance of many of these variants to obesity is unclear since most of them 
are mapped to intergenic or intronic regions (Drong, Lindgren, McCarthy 2012). Therefore, additional 
follow-up studies are necessary to fully understand the genes and mechanisms deriving the effect on 
obesity, as in the case of the FTO locus. 
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SNP Chr. Position (bp) Nearest gene Risk 
allele 
Risk allele 
frequency 
P-value Variance 
explained 
rs1558902 16 52,361,075 FTO A 0.413 7.51X10
-153
 0.325% 
rs6567160 18 55,980,115 MC4R C 0.238 3.93X10
-53
 0.111% 
rs13021737 2 622,348 TMEM18 G 0.827 1.11X10
-50
 0.103% 
rs10938397 4 44,877,284 GNPDA2 G 0.429 3.21X10
-38
 0.079% 
rs543874 1 176,156,103 SEC16B G 0.194 2.62X10
-35
 0.072% 
rs2207139 6 50,953,449 TFAP2B G 0.174 4.13X10
-29
 0.058% 
rs11030104 11 27,641,093 BDNF A 0.789 5.56X10
-28
 0.056% 
rs3101336 1 72,523,773 NEGR1 C 0.609 2.66X10
-26
 0.053% 
rs7138803 12 48,533,735 BCDIN3D A 0.384 8.15X10
-24
 0.047% 
rs10182181 2 25,003,800 ADCY3 G 0.460 8.78X10-
24
 0.047% 
rs3888190 16 28,796,987 ATP2A1 A 0.402 3.14X10
-23
 0.046% 
rs1516725 3 187,306,698 ETV5 C 0.871 1.89X10
-22
 0.045% 
rs12446632 16 19,842,890 GPRC5B G 0.866 1.48X10
-18
 0.038% 
rs2287019 19 50,894,012 QPCTL C 0.806 4.59X10
-18
 0.041% 
rs16951275 15 65,864,222 MAP2K5 T 0.781 1.91X10
-17
 0.033% 
rs3817334 11 47,607,569 MTCH2 T 0.408 5.15X10
-17
 0.033% 
rs2112347 5 75,050,998 POC5 T 0.633 6.19X10
-17
 0.032% 
rs12566985 1 74,774,781 FPGT-TNNI3K G 0.442 3.28X10
-15
 0.029% 
rs3810291 19 52,260,843 ZC3H4 A 0.665 4.81X10
-15
 0.036% 
rs7141420 14 78,969,207 NRXN3 T 0.522 1.23X10
-14
 0.028% 
rs13078960 3 85,890,280 CADM2 G 0.196 1.74X10
-14
 0.028% 
rs10968576 9 28,404,339 LINGO2 G 0.317 6.61X10
-14
 0.027% 
rs17024393 1 109,956,211 GNAT2 C 0.037 7.03X10
-14
 0.033% 
rs657452 1 49,362,434 AGBL4 A 0.392 5.48X10
-13
 0.025% 
rs12429545 13 53,000,207 OLFM4 A 0.133 1.09X10
-12
 0.026% 
rs12286929 11 114,527,614 CADM1 G 0.522 1.31X10
-12
 0.023% 
rs13107325 4 103,407,732 SLC39A8 T 0.071 1.83X10
-12
 0.030% 
rs11165643 1 96,696,685 PTBP2 T 0.582 2.07X10
-12
 0.023% 
rs7903146 10 114,748,339 TCF7L2 C 0.713 1.11X10
-11
 0.022% 
rs10132280 14 24,998,019 STXBP6 C 0.682 1.14X10
-11
 0.023% 
rs17405819 8 76,969,139 HNF4G T 0.700 2.07X10
-11
 0.021% 
rs6091540 20 50,521,269 ZFP64 C 0.719 2.15X10
-11
 0.014% 
rs1016287 2 59,159,129 LINC01122 T 0.286 2.25X10
-11
 0.021% 
rs4256980 11 8,630,515 TRIM66 G 0.644 2.90X10
-11
 0.020% 
rs17094222 10 102,385,430 HIF1AN C 0.209 5.94X10
-11
 0.021% 
rs12401738 1 78,219,349 FUBP1 A 0.353 1.15X10
-10
 0.020% 
rs7599312 2 213,121,476 ERBB4 G 0.724 1.17X10
-10
 0.019% 
rs2365389 3 61,211,502 FHIT C 0.581 1.63X10
-10
 0.019% 
rs205262 6 34,671,142 C6orf106 G 0.270 1.75X10
-10
 0.019% 
 
1. Introduction 
40 
 
SNP Chr. Position (bp) Nearest gene Risk 
allele 
Risk allele 
frequency  
P-value  Variance 
explained 
rs2820292 1 200,050,910 NAV1 C 0.557 1.83X10
-10
 0.019% 
rs12885454 14 28,806,589 PRKD1 C 0.639 1.94X10
-10
 0.020% 
rs9641123 7 93,035,668 CALCR C 0.430 2.08X10
-10
 0.018% 
rs12016871 13 26,915,782 MTIF3 T 0.203 2.29X10
-10
 0.029% 
rs16851483 3 142,758,126 RASA2 T 0.066 3.55X10
-10
 0.029% 
rs1167827 7 75,001,105 HIP1 G 0.559 6.33X10
-10
 0.020% 
rs758747 16 3,567,359 NLRC3 T 0.266 7.47X10
-10
 0.020% 
rs1928295 9 119,418,304 TLR4 T 0.549 7.91X10
-10
 0.018% 
rs9925964 16 31,037,396 KAT8 A 0.620 8.11X10
-10
 0.017% 
rs11126666 2 26,782,315 KCNK3 A 0.278 1.33X10
-09
 0.017% 
rs2650492 16 28,240,912 SBK1 A 0.304 1.92X10
-09
 0.018% 
rs6804842 3 25,081,441 RARB G 0.579 2.48X10-
09
 0.017% 
rs12940622 17 76,230,166 RPTOR G 0.570 2.49X10
-09
 0.016% 
rs7164727 15 70,881,044 LOC100287559 T 0.688 3.92X10
-09
 0.014% 
rs11847697 14 29,584,863 PRKD1 T 0.043 3.99X10
-09
 0.019% 
rs4740619 9 15,624,326 C9orf93 T 0.544 4.56X10
-09
 0.016% 
rs492400 2 219,057,996 USP37 C 0.425 6.78X10
-09
 0.012% 
rs13191362 6 162,953,340 PARK2 A 0.876 7.34X10
-09
 0.016% 
rs3736485 15 49,535,902 DMXL2 A 0.455 7.41X10
-09
 0.015% 
rs17001654 4 77,348,592 SCARB2 G 0.154 7.76X10
-09
 0.024% 
rs11191560 10 104,859,028 NT5C2 C 0.090 8.45X10
-09
 0.015% 
rs2080454 16 47,620,091 CBLN1 C 0.400 8.60X10
-09
 0.014% 
rs7715256 5 153,518,086 GALNT10 G 0.420 8.85X10
-09
 0.013% 
rs2176040 2 226,801,046 LOC646736 A 0.370 9.99X10
-09
 0.009% 
rs1528435 2 181,259,207 UBE2E3 T 0.632 1.20X10
-08
 0.015% 
rs2075650 19 50,087,459 TOMM40 A 0.850 1.25X10
-08
 0.017% 
rs1000940 17 5,223,976 RABEP1 G 0.316 1.28X10
-08
 0.016% 
rs2033529 6 40,456,631 TDRG1 G 0.288 1.39X10
-08
 0.015% 
rs11583200 1 50,332,407 ELAVL4 C 0.392 1.48X10
-08
 0.015% 
rs7239883 18 38,401,669 LOC284260 G 0.388 1.51X10
-08
 0.013% 
rs2836754 21 39,213,610 ETS2 C 0.620 1.61X10
-08
 0.013% 
rs9400239 6 109,084,356 FOXO3 C 0.693 1.61X10
-08
 0.015% 
rs10733682 9 128,500,735 LMX1B A 0.474 1.83X10
-08
 0.015% 
rs11688816 2 62,906,552 EHBP1 G 0.525 1.89X10
-08
 0.015% 
rs11057405 12 121,347,850 CLIP1 G 0.902 2.02X10
-08
 0.017% 
rs9914578 17 1,951,886 SMG6 G 0.209 2.07X10
-08
 0.013% 
rs977747 1 47,457,264 TAL1 T 0.392 2.18X10
-08
 0.013% 
rs2121279 2 142,759,755 LRP1B T 0.147 2.31X10
-08
 0.015% 
rs29941 19 39,001,372 KCTD15 G 0.671 2.41X10
-08
 0.015% 
rs11727676 4 145,878,514 HHIP T 0.912 2.55X10
-08
 0.021% 
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SNP Chr. Position (bp) Nearest gene Risk 
allele 
Risk allele 
frequency  
P-value  Variance 
explained 
rs3849570 3 81,874,802 GBE1 A 0.357 2.60X10
-08
 0.016% 
rs9374842 6 120,227,364 LOC285762 T 0.744 2.67X10
-08
 0.013% 
rs6477694 9 110,972,163 EPB41L4B C 0.364 2.67X10
-08
 0.014% 
rs4787491 16 29,922,838 INO80E G 0.510 2.70X10
-08
 0.013% 
rs1441264 13 78,478,920 MIR548A2 A 0.604 2.96X10
-08
 0.015% 
rs7899106 10 87,400,884 GRID1 G 0.053 2.96X10
-08
 0.015% 
rs2176598 11 43,820,854 HSD17B12 T 0.249 2.97X10
-08
 0.015% 
rs2245368 7 76,446,079 PMS2L11 C 0.178 3.19X10
-08
 0.030% 
rs17203016 2 207,963,763 CREB1 G 0.196 3.41X10
-08
 0.014% 
rs17724992 19 18,315,825 PGPEP1 A 0.744 3.42X10
-08
 0.014% 
rs7243357 18 55,034,299 GRP T 0.817 3.86X10
-08
 0.014% 
rs16907751 8 81,538,012 ZBTB10 C 0.918 3.89X10
-08
 0.019% 
rs1808579 18 19,358,886 C18orf8 C 0.535 4.17X10
-08
 0.014% 
rs13201877 6 137,717,234 IFNGR1 G 0.141 4.29X10
-08
 0.013% 
rs2033732 8 85,242,264 RALYL C 0.747 4.89X10
-08
 0.014% 
rs9540493 13 65,103,705 MIR548X2 A 0.452 4.97X10
-08
 0.015% 
rs1460676 2 164,275,935 FIGN C 0.172 4.98X10
-08
 0.011% 
rs6465468 7 95,007,450 ASB4 T 0.307 4.98X10
-08
 0.012% 
Table 2. Summary of BMI-associated loci identified through the latest GIANT meta-analysis of GWASs. 
Coordinates are given according to the GRCh36/hg18 genome assembly, allele coding based on the 
positive strand and P-value represent the most significant P-value obtained.  
 
Many scientists expected that the heritability of obesity and other common diseases would be explained 
by common genetic variants, as described by the common disease-common variant (CDCV) hypothesis.  
However, GWASs proved that the situation is more complex. Most common variants individually or in 
combination confer relatively modest effect sizes and explain only a small proportion of the heritability. 
The 97 BMI variants detected through the largest meta-analysis of GWASs, for example, can explain only 
2.7% of the phenotypic variance of BMI (Locke et al. 2015). Such mismatch between the high heritability 
estimates for BMI and the small proportion of variation explained through the variants identified in 
GWASs is descried by the phenomenon of “missing heritability” which is also seen in other common 
diseases (Manolio et al. 2009).  
Various sources have been proposed for the missing heritability. A recent study suggested that the 
accumulated effect of many hundreds of associated loci, including weaker associations that do not reach 
genome-wide significance, may explain about 20% of the total variance in BMI (Yang et al. 2012). Other 
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explanations include the interaction of risk variants with environmental conditions, which are not taken 
into account in GWASs. For instance, the risk effect of the FTO variant is reduced in physically active 
people, and this has only become clear with the follow-up studies on the FTO variant (Willyard 2014). 
Other sources of genetic variation including rare SNPs (MAF <1%) and copy number variations (CNVs), 
and epigenetic variations such as DNA methylation are also believed to play a role in obesity 
susceptibility, as will be discussed in Sections 1.7, 1.8 and 1.9 respectively. 
1.7 The Role of Rare Mutations in the Development of Obesity 
The missing heritability of complex diseases is largely believed to be attributable to moderately highly 
penetrant rare mutations (MAF< 1%) of relatively recent origin, that have not been identified through 
GWASs (Bodmer and Bonilla 2008; Pritchard 2001; Schork et al. 2009). This hypothesis is known as the 
common disease-rare variant (CDRV) hypothesis. Under this hypothesis, the severity of the disease in 
the subjects carrying the risk disease variants may be modified by other genetic loci or by environmental 
factors (Bodmer and Bonilla 2008; Steinberg and Adewoye 2006). In relation to obesity, it has been 
shown that rare variants can drive monogenic obesity cases, as discussed in Section 1.5.1, and they are 
also implicated in more common forms of obesity, as will be discussed in Section 1.7.2. 
1.7.1 Detection Methods of Rare Mutations 
Rare mutations are not detected in GWASs since SNP genotyping arrays are usually designed to capture 
common SNPs with MAF≥ 5% in the general population (Drong, Lindgren, McCarthy 2012). The 
detection and investigation of the role of rare variants is possible using sequencing technologies. Recent 
advances in next generation sequencing (NGS) technologies are allowing researchers to extend their 
genome-wide analyses beyond common SNPs to assess the contribution of rare variants in disease 
predisposition in a fast way. However, population-based approaches to mapping rare variants for 
complex disease from NGS data require a large number of samples (thousands or many thousands) to 
provide sufficient statistical power for rare variants detection (Cirulli and Goldstein 2010). The reason 
for that is the dilution of the frequency of the rare variants and their effect sizes at the population level 
as a result of the high locus and allelic heterogeneity (Cirulli and Goldstein 2010; Heinzen et al. 2012; 
Need et al. 2012) 
Until the cost of whole genome sequencing (WGS) drops enough for conducting population-based whole 
genome association studies with large number of samples, study designs based on extreme phenotypes 
and/or families can be exploited (Cirulli and Goldstein 2010). This is because these study designs offer an 
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opportunity for increasing the frequency of rare variants (and their effects) in the study and such 
enrichment results in improved power for variants detection.  
Extreme phenotype study designs involves the sequencing of a small number of individuals at the ends 
of the extremes of the phenotype distribution from the general population, and the identification of 
rare variants that are enriched in frequency in cases versus controls (Cirulli and Goldstein 2010). 
Candidate rare disease variants are then selected based on their potential functional impact and typed 
in larger case-control population cohorts for confirmation. 
Family-based study designs involve the sequencing of multiple affected individuals in families, and the 
screening of the list of variants that are shared between affected individuals to identify candidate rare 
disease variants. This enrichment for rare variants between affected individuals in families results in 
increased locus specific heritability and improved power for detection of causal variants. Candidate rare 
variants are usually selected based on features like the expected variant effect, gene function and co-
segregation evidence with diseases in families (Cirulli and Goldstein 2010). Co-segregation evidence of a 
candidate variant with disease in other families or association evidence in large case-control cohorts is 
usually required for successful variant discovery (Cirulli and Goldstein 2010).  
In addition, family-based designs offer the possibility of performing linkage analysis and determining the 
genetic basis of the linkage signals using sequencing. This approach could facilitate the identification of 
genes involved in obesity that are otherwise undetectable using case-control designs (Cirulli and 
Goldstein 2010). For example, Sobreira et al. (Sobreira et al. 2010) applied this strategy to 
metachondromatosis, a dominantly inherited Mendelian disease with incomplete penetrance, and 
successfully identified the causing variant, which was located within the second-highest LOD score of 
linkage regions.  
In this study, I have applied a similar strategy to obesity in order to identify rare obesity variants in 
families with multiple obese individuals from Qatar. My strategy involved the identification of candidate 
obesity genomic regions through performing linkage analysis and run of homozygosity (ROH) analyses, 
using high-density SNP genotyping data. ROH regions are long stretches of consecutive homozygous 
genotypes that probably reflect identity by descent segments and are likely to be enriched for 
deleterious variants (Szpiech et al. 2013). Then, I have screened the candidate obesity regions and genes 
for harbouring potential rare obesity variants using WGS data, and attempted to replicate the identified 
variants in a Qatari population cohort, as will be discussed in details in Chapter 3. 
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1.7.2 Rare Mutations and Obesity 
There is now sufficient evidence that both common and rare variants contribute to common complex 
diseases. Rare variants of strong effect have been reported to influence the susceptibility to several 
complex diseases including infectious diseases (Khor et al. 2007), type I diabetes (Nejentsev et al. 2009) 
as well as obesity (Blakemore et al. 2009; Creemers et al. 2012; Ichimura et al. 2012; Pearce et al. 2013).  
For example, Pearce et al. (Pearce et al. 2013) have recently explored the kinase suppressor of ras 2 
(KSR2) gene, which encodes an intracellular scaffolding protein involved in multiple regulatory 
pathways, as a candidate obesity gene in humans. They performed whole exome sequencing on 2,101 
individuals with severe early-onset obesity and 1,536 controls, and identified multiple rare variants in 
KSR2 that disrupt the signalling of the protein through the Raf-MEK-ERK pathway. Carriers of the 
mutation exhibited hyperphagia during childhood, low heart rate, low basal metabolic rate as well as 
severe insulin resistance. The study underscored the role of KSR2 as a regulator of energy intake and 
expenditure in humans and, in general, the role of rare variants in common obesity. 
Another interesting example that illustrates the wide spectrum of variants contributing to obesity is the 
PCSK1 gene.  As discussed before, rare loss-of-function mutations in PCSK1 cause recessive (Farooqi et 
al. 2007; Jackson et al. 1997) and dominant (Philippe et al. 2015) monogenic early-onset obesity. 
Moreover, common coding variants in PCSK1 were found to mildly increase the risk for common obesity 
(Benzinou et al. 2008; Villalobos-Comparan et al. 2012). In addition to that, rare heterozygous PCSK1 
mutations causing partial prohormone convertase 1 deficiency were reported to confer an increased risk 
for obesity (Creemers et al. 2012; Pickett et al. 2013).  
Given the role of rare variants in obesity predisposition, I have searched for potential obesity variants in 
my Qatari families’ dataset. To achieve this goal, I have combined linkage and ROH evidence in these 
families to focus my search for rare obesity variants to a reduced number of genomic regions and thus 
variants to those that are most promising, as will be discussed in details in Chapter 3. 
1.8 The Role of Copy Number Variations (CNVs) in the Development of Obesity 
Copy number variations are DNA segments of 1kb or more that exist in variable numbers within the 
genome and they usually refer to deletions and duplications. CNVs have been identified in humans as 
well as in other organisms (Shastry 2009), and they have emerged as a notable source of genetic 
variation that is present in high abundance in the human genome, including coding and non-coding 
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regions (Beckmann, Sharp, Antonarakis 2008). Yeo et al. have shown that CNV with a size of about 
500kb are present in 5-10% of the population (Yoo et al. 2005). As many CNVs encompass genes and/or 
regulatory regions, they may result in alteration of gene dosage and/or disruption of gene structure 
and/or regulation (Stranger et al. 2007). Therefore, CNVs may account for significant normal phenotypic 
variation within a species, susceptibility or resistance to disease, variation in drug response as well as 
the evolution of genomes (Shastry 2009; Stranger et al. 2007). 
1.8.1 Mechanisms of CNV Formation 
CNV structure can be simple with stable regions flanked by consistent boundaries, or more complex, 
containing multiple CNVs with overlapping boundaries, called copy number variant regions (CNVRs). 
Although the mechanisms of CNV formation are not fully elucidated, these different types of CNVs may 
arise through different processes (de Smith et al. 2008). 
For example, about 50% of reported CNVs are associated with regions of segmental duplication (Cooper, 
Nickerson, Eichler 2007; Redon et al. 2006; Sharp et al. 2005). These are genomic regions of > 1kb that 
have sequence similarity of >90% with another genomic region (Conrad and Hurles 2007). The formation 
of this type of CNVs is likely to be mediated by a process known as non-allelic homologous 
recombination (NAHR), whereby crossing over occur between non-allelic regions of high sequence 
similarity, such as segmental duplications (Conrad and Hurles 2007) resulting in copy number changes. 
Complex CNVs have a greater enrichment of segmental duplications compared to more simple CNVs, 
therefore they are likely to occur via NAHR (Redon et al. 2006). 
Other non-homology-based mechanisms have been proposed to explain the formation of other CNVs. 
One of these mechanisms is the non-homologous end joining (NHEJ), which is driven by errors in DNA 
break repair mechanisms (Korbel et al. 2007; Perry et al. 2008). A recent study of the breakpoint 
junctions of CNVs suggests that the majority of CNVs were formed through this mechanism (Perry et al. 
2008). A recent analysis on the origin of common deletion variants in the genome have suggested a role 
of Alu repeats in CNV formation (de Smith et al. 2008). The study reported an enrichment of Alu repeats 
at the break points of this group of CNVs. These repeats are prone to single or double strand breakage 
that could result in NHEJ and hence CNV formation. The role of Alu repeats in CNV formation is likely to 
be greater in gene CNVs than non-gene CNVs since Alu repeats correlate with CG rich genomic regions 
(de Smith et al. 2008; Lander et al. 2001). 
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It is apparent that the distribution of CNVs in the genome is not random, with the existence of hot and 
cold CNV spots (Cooper, Nickerson, Eichler 2007). In particular, CNVs are more frequent towards 
centromeres and telomeres (Nguyen, Webber, Ponting 2006). This variation might be due to differences 
in the type and number of nearby repeat elements, such as Alu repeats and segmental duplications, in 
the genome. The nature of the sequence at a particular region could also influence the type of CNVs 
they may overlap. For instance, complex CNVRs are more likely to exist in highly repetitive regions, while 
ancient stable CNVs that are inherited with conserved boundaries are likely to present in less repetitive 
regions (de Smith et al. 2008). 
Family studies have shown that CNVs may vary in their inheritance. The majority of CNVs are inherited 
from parents but CNVs may also occur de novo during meiosis (Locke et al. 2006). In addition, recent 
studies have reported CNVs between monozygotic twins (Bruder et al. 2008) and also between tissues 
within the same individual (Piotrowski et al. 2008) suggesting that not all CNVs arise during meiosis. The 
mechanisms underlying the formation of somatic CNVs are unknown, which adds a further complexity to 
the CNV field. 
1.8.2 Methods of CNV Detection 
Several technologies can be used to study copy number variations. One of the earliest methods was the 
comparative genomic hybridisation (CGH) technology, developed in 1992 (Kallioniemi et al. 1992). This 
method compares the fluorescence ratio between a test and a reference DNA sample, each labelled 
with a particular fluorescent dye, hybridised to a metaphase chromosome spread from a healthy 
individual. The low resolution of the conventional CGH technology (5-10Mb) was a major disadvantage, 
therefore the technology was further developed in 2004 to replace the metaphase spread with 
microarrays (Carter 2007). The new wave of technology was called array comparative genomic 
hybridisation (aCGH), and they provided greater resolution (down to ~30kb) and less labour-intensive 
procedure for the detection of CNVs (Carter 2007). One of the popular arrays was the bacterial artificial 
chromosome (BAC) array CGH, in which DNA obtained from BAC clones was spotted on the array (Ren et 
al. 2005b). In addition, other types of arrays that implement oligonucleotide probes were developed 
such as Representational Oligonucleotide Microarray Analysis (ROMA) (Lucito et al. 2003). In 2006, high-
resolution CGH (HR-CGH) arrays were developed that can detect CNVs at a resolution of 200bp (Urban 
et al. 2006). 
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In 2004, two striking studies on CNVs were published. The first study used BAC array CGH and identified 
255 CNVs in 39 subjects (Iafrate et al. 2004), while the other study used ROMA and found 76 CNVs in 20 
individuals (Sebat et al. 2004). These two studies have shown that CNVs are more common in the 
genome than previously speculated, giving further appreciation of CNVs as a frequent and widespread 
source of genetic variation that may have phenotypic effect. Iafrate et al. also developed the Database 
of Genomic Variants (DGV) to catalogue the CNVs in the human genome (Iafrate et al. 2004).  
A number of CNV studies have been published after that, using a variety of CNV detection techniques 
(Conrad et al. 2006; Hinds et al. 2006; Korbel et al. 2007; McCarroll and Altshuler 2007; Mills et al. 2006; 
Redon et al. 2006; Tuzun et al. 2005; Wong et al. 2007). These studies have revealed a wealth of CNVs in 
the genome, many of which overlap with multiple genes. Some of these studies (Conrad et al. 2006; 
Hinds et al. 2006; Korbel et al. 2007; McCarroll and Altshuler 2007; Mills et al. 2006; Redon et al. 2006; 
Tuzun et al. 2005; Wong et al. 2007) were carried out using high-resolution genome-wide SNP 
genotyping arrays.  
The principle behind CNV prediction from high-density SNP genotyping platforms is based on the signal 
intensity measures. For each SNP probe, the total signal intensity from each of the two alleles is 
normalised and processed to calculate Log R Ratio (LRR) and B Allele Frequency (BAF) (Peiffer et al. 
2006). LRR is a measure proportional to the total signal intensity and it reflects the copy number at a 
particular position while the BAF is a measure of the relative contribution of the B allele to the total 
signal intensity and it reflects the allelic composition at each SNP. Analysis of these measures for the 
probes across the genome is used to identify CNVs and to determine their copy number states (Peiffer 
et al. 2006). 
One of the advantages of using the SNP arrays for CNV detection is the ability to utilize the genotyping 
data generated for other purposes such as linkage analyses and GWASs. In addition, there are many 
well-established CNV detection algorithms from SNP array data including PennCNV (Wang et al. 2007), 
FamCNV (Eleftherohorinou et al. 2011), CNVHap (Coin et al. 2010) and CNV Partition (Peiffer et al. 2006). 
Following the development of next generation sequencing technologies, CNV analyses can be performed 
today at the nucleotide level using whole exome sequencing (WES) and whole genome sequencing 
(WGS) technologies. Several computational approached have been developed for CNV prediction from 
these sequencing based-technologies such as CNV-seq (Xie and Tammi 2009), SegSeq (Chiang et al. 
2009) and readDepth (Miller et al. 2011), and they are usually based on short read information. Due to 
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the relatively young age of these approaches, efforts have also been made to compare their 
performance for different study designs and purposes (Duan et al. 2013).   
1.8.3 Copy Number Variations and Obesity 
One of the key effects of CNVs is that they can result in alteration of gene expression patterns. It has 
been estimated that at least 17.7% of the heritable variation in gene expression is due to CNVs (Stranger 
et al. 2007). This suggests that CNVs may account for a substantial proportion of phenotypic variations 
including susceptibility to diseases. CNVs have been found to be involved in a broad range of human 
diseases. This includes genetic disorders such as Charcot-Marie-Tooth disease and DiGeorge syndrome 
(Baldini 2005; Lupski et al. 1991), in which large deletions and duplications result in distinct syndromic 
phenotypes, as well as other non-syndromic disorders such as schizophrenia (Stefansson et al. 2008) and 
autism (Kumar et al. 2008). 
In relation to obesity, several common (observed in more than 5% of the population) bialleleic CNVs 
have been reported in association with BMI and obesity (Jarick et al. 2011; Sha et al. 2009; Speliotes et 
al. 2010; Willer et al. 2009). Similar to common SNPs, the identified common CNVs had small effect sizes 
on obesity risks. Recently, Falchi et al. identified a common multi-allelic CNV at the salivary amylase 
(AMY1) locus associated with BMI in European and Asian adults, through a CNV association study of 
gene expression levels in adipose tissue (Falchi et al. 2014). This study showed that low copy number of 
AMY1 results in decreased salivary amylase levels and increased risk of obesity, with relatively high odd 
ratio of about 1.19 per copy of AMY1. The association was even stronger than the associations observed 
for FTO SNPs with BMI, and was also recently replicated in Mexican children (Mejia-Benitez et al. 2015). 
Salivary amylase functions as a key catalytic enzyme for the initiation of carbohydrate digestion in the 
oral cavity and interestingly, earlier studies reported low blood amylase levels in obese humans (Kondo 
et al. 1988) and rats (Schneeman, Inman, Stern 1983). The study underscores the importance to AMY1 
CNV locus in particular and CNVs in general in relation to obesity. 
On the other hand, rare CNVs (present in less than 1% of the population) have been found to cause 
highly penetrant forms of obesity (Bochukova et al. 2010; Glessner et al. 2010; Walters et al. 2013; 
Wang et al. 2010a; Yu et al. 2011). The most well-known CNVs in relation to obesity are at the 16p11.2 
locus. The short arm of chromosome 16 is enriched for large segmental duplication that can facilitate 
the occurrence of the nonallelic homologous recombination (NAHR), and hence the formation of 
recurrent CNVs at this particular region. Bochukova et al. (Bochukova et al. 2010) performed CNV 
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analysis on 300 Caucasian children with early-onset obesity (half of them had also developmental delay) 
and reported a rare heterozygous deletion of 220kb at 16p11.2 (28.7-28.9 Mb, hg18; NCBI build 36) 
associated with obesity. 
The minimal deleted region encompasses nine annotated genes; some of them involved in neurological 
diseases and immunity. Interestingly, the region contains SH2B adapter protein 1 (SH2B1), which 
encodes an adaptor protein involved in leptin and insulin signalling (Jamshidi et al. 2007; Ren et al. 
2007). Knockout of sh2b1 in mice results in extreme obesity, hyperphagia and insulin resistance (Ren et 
al. 2005a), and SNPs within this gene have also been associated with BMI (Speliotes et al. 2010). These 
findings suggest a potential involvement of this particular gene in causing the obesity phenotype in 
subjects carrying the deletion.  
Our group (Walters et al. 2013) identified a separate deletion on 16p11.2 (29.5-30.1Mb.hg18; NCBI build 
36) associated with a highly penetrant form of obesity. The deletion was initially identified in 2.9% (9 out 
of 312) of the study subjects who had malformations and/or developmental delay (DD) in addition to 
obesity, and was also investigated in other independent cohorts for obesity and/or DD.  The data from 
the obesity cohorts was pooled with data obtained from general population cohort (of 11,856 subjects) 
and a case-control association analysis was carried out, giving association at genome-wide significance.  
This deletion confers about 43-fold increased risk of severe obesity in adults and interestingly, 
Jacquemont et al. has recently found that reciprocal duplication at the 16p11.2 confers an increased risk 
(about 8.3 fold) for being underweight, showing that gene dosage at this particular locus have opposing 
effect on BMI (Jacquemont et al. 2011). The same study carried out expression analyses in carriers of the 
16p11.2 deletions and duplications and found that the expression levels of 27 genes in the region (out of 
29 genes) are positively correlated with gene dosage.  
The 16p11.2 deletions demonstrate the potential importance of rare variants in the susceptibility to 
common diseases like obesity. In addition, the large effect size of some of the rare CNVs, including the 
16p11.2 deletions, makes them a useful platform for clinical disease prediction similar to monogenic 
obesity variants (El-Sayed Moustafa and Froguel 2013). Conducting functional studies is crucial to fully 
characterize the functionally relevant loci within CNVs in relevance to the disease phenotype, 
particularly, large CNVs that may encompass multiple potential disease loci. 
Given the significant role of both common and rare CNVs in relevance to obesity, I have decided to 
investigate obesity CNVs in my Qatari families, using the intensity data from the high-density SNP 
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genotyping arrays. I have carried out a genome-wide CNV association analysis with BMI to identify 
common obesity CNVs, and I have also searched for potential large rare obesity CNVs in my dataset, as 
will be discussed in details in Chapter 4. 
1.9 The Role of DNA Methylation Patterns in the Development of Obesity 
Epigenetics is the study of changes in the genome that do not alter the primary DNA sequence itself. The 
major epigenetic modifications are DNA methylation, histone methylation and chromatin modifications 
and they are believed to provide a biological link between an individual’s environmental exposures and 
phenotypes (Drong, Lindgren, McCarthy 2012). DNA methylation was the first epigenetic modification to 
be discovered (HOTCHKISS 1948) and it is the most studied so far. Historically, DNA methylation was 
recognized as DNA restriction-modification mechanism in bacteria that protects host DNA from being 
cleaved by their cognate restriction enzymes that digests unmodified foreign DNAs like viral DNAs 
(Meselson, Yuan, Heywood 1972). 
In humans, the predominant form of DNA methylation occurs on the 5th carbon of the cytosine in the 
cytosine–guanine nucleotide pair (CpG) sites along the DNA chain (Liu et al. 2010). However, CpH 
methylation (where H=C/A/T) also exists mainly in embryonic stem cells (Ramsahoye et al. 2000). The 
total number of CpG sites in the human genome is estimated to be around 28 million CpGs present in a 
nonrandom distribution throughout the genome, and 60–80% of them are generally methylated (Smith 
and Meissner 2013). Less than 10% of CpGs occur in CG-rich regions, known as CpG islands. These CpG 
islands accounts for most of the nonmethylated CpG sites and they are prevalent at transcription start 
sites of housekeeping genes as well as developmental regulator genes (Deaton and Bird 2011). On the 
other hand, CpG sites that exist outside CpG islands are largely methylated (Deaton and Bird 2011). 
In 1975, it has been proposed that DNA methylation might be responsible for maintaining expression 
patterns through mitosis (Holliday and Pugh 1975; Riggs 1975). Since then, DNA methylation has gained 
a lot of attention and it became apparent that hypomethylated DNA regions are involved in active 
transcription, while the hypermethylated DNA regions tend to have an opposing effect on gene 
expression (Jaenisch and Bird 2003; Razin and Cedar 1977; Stein et al. 1983; Urnov and Wolffe 2001; 
Wolffe and Matzke 1999). For example, CpG regions at the promoter regions of tissue-specific genes are 
usually highly unmethylated in their tissue of expression while they are highly methylated in other 
tissues where they are not expressed (Jaenisch and Bird 2003). Similarly, housekeeping genes were 
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found to have constitutively unmethylated CpG islands at their promoters regardless of tissue types 
(Smith and Meissner 2013; Stein et al. 1983). 
In some instances, the effect of DNA methylation on gene expression is mediated through blocking the 
binding sites of transcription factors. However, since most transcription factors do not have CpGs in 
their binding sites, the effect of DNA methylation is believed to be largely mediated through affecting 
gene accessibility at the level of chromatin structure, where methylated CpGs result in closely packed 
chromatin and unmethylated CpGs result in more open chromatin structure (Razin and Cedar 1977). For 
example, the presences of a methyl groups can enhance the binding of methyl-binding proteins such as 
MeCP2 and MBD2 (Klose and Bird 2006) and/or prevent the binding of other types of proteins such as 
the chromatin proteins CTCF and Cfp1 (Thomson et al. 2010). Given its critical effect on gene expression, 
DNA methylation is considered a key mechanism that contributes to normal development, phenotypic 
variations as well as susceptibility to diseases. 
1.9.1 Formation Mechanisms of DNA Methylation Patterns 
DNA methylation is mainly mediated by two types of methyltransferases: (i) DNMT1, which is 
responsible for methylation after every cellular DNA replication cycle to maintain DNA methylation 
patterns, and (ii) DNMT3a and DNMT3b, which are responsible of de novo methylation early in 
development (Thompson, Fazzari, Greally 2010). 
Although the precise mechanism of DNA methylation is not fully elucidated, studies have shown that 
DNA methylation modifications are typically established during early developmental stages. In the 
gametes and preimplantation embryo, almost all methylation modifications are erased, but imprinting 
regions preserve their methylation on one allele (and also throughout development). At the time of 
implantation, the entire genome gets methylated but CpG islands stay unmethylated. Postimplantation, 
pluripotency genes undergo de novo methylation. The postimplantation development is also 
characterized by changes in DNA methylation patterns that are tissue specific, where tissue-specific 
genes get unmethylated in their tissues of expression. This phenomenon of acquiring two or more 
different epigenetic states at a particular genomic locus in different cells or tissues within the same 
organism is known as epigenetic mosaicism and it adds a further complexity to the field of DNA 
methylation as it can contribute to phenotypic variation among people (Stoger 2008). Changes in 
methylation patterns may also arise in reaction to environmental exposures or as a function of aging, 
resulting in global and/or local changes of methylation patterns (Ng et al. 2010; Radford et al. 2014). 
1. Introduction 
52 
 
The process of erasure and reestablishment of DNA methylation modification in early developmental 
stages is known as “DNA methylation programing”. A recent study has shown that methylation patterns 
at some genomic regions can escape the reprogramming process and thus can be inherited through 
generations (Hackett et al. 2013). 
There are two types of inheritance of epigenetic state: i) the genetic inheritance where the individual’s 
underlying genetic sequence affects the epigenetic state, for example, as in the case of the occurrence 
of genetic variations within a CpG locus which disrupts the methylation site, and ii) the epigenetic 
inheritance which refers to the sequence-independent transmission of epigenetic mark that may 
happen through escaping the methylation reprogramming events (McRae et al. 2014). 
Bell et al. (Bell et al. 2012) investigated the heritability of methylation in twins using methylation profiles 
derived from whole blood-DNA. Monozygotic twins have a significantly higher genome-wide average 
correlation in methylation levels compared to dizygotic twins. This supported the idea of the heritability 
of methylation patterns and the heritability estimate obtained was about 18%. However, a recent study 
conducted by McRae et al. (McRae et al. 2014) has investigated the heritability of DNA methylation in 
whole-blood DNA using multigenerational families, which allowed the conductance of both within and 
across generations’ comparisons of heritability patterns. The study showed that the heritability of DNA 
methylation is actually largely driven by the underlying genetic sequence (i.e. type i of methylation 
inheritance).  
1.9.2 Detection Methods of DNA Methylation Patterns 
Similar to other research fields, the development in the field of epigenetics is technology-driven. 
Technologies that are based on repeat interspersed regions, namely Alu and Long Interspersed 
Nucleotide Element 1 (LINE-1), like MethyLight (Weisenberger et al. 2005), or based on restriction 
enzymes like the Luminometric assay (LUMA) (Karimi et al. 2006) were able to estimate DNA 
methylation at the global level. For site-specific information on DNA methylation, several methods 
including Methylation-specific PCR (MS PCR) (Herman et al. 1996) and Pyrosequencing (Colella et al. 
2003) were developed. These methods rely on bisulfite treatment of DNA, which converts the vast 
majority of unmethylated cytosines to uraciles, whereas the methylated cytosines remain protected 
from the conversion, and are usually used to investigate the methylation status of candidate genes or 
regions.  
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The genome-wide assessment of DNA methylation states became feasible with the development of two 
groups of technologies. The first group identifies enriched DNA methylation sites through utilizing 
methylation-sensitive restriction enzymes such as Methylated DNA Binding Domain sequencing (MBD-
seq) technology (Lan et al. 2011), or through immunoprecipitation with antibodies against the 
methylated cytosines as in Methylated DNA Immunoprecipitation (MeDIP) (Mohn et al. 2009). The 
second group relies on using bisulfite-converted DNA such as Bisulfite Conversion Followed by 
Sequencing (BS–seq) (Lister et al. 2009) and Reduced Representation Bisulfite Sequencing (RRBS-seq) 
(Gu et al. 2010). In both groups of technologies, microarray and sequencing approaches have been 
implemented (Ladd-Acosta et al. 2010). 
Genome-wide sequencing-based approaches of DNA methylation can provide comprehensive 
information of the methylation state of every cytosine in the entire genome, including repetitive 
sequences, in a sequence specific way. However, the high cost of these approaches is still limiting their 
utility in epigenetic research. On the other hand, microarray-based profiling approaches allow the 
analysis of large number of samples at an affordable cost.  Illumina Infinium HumanMethylation450 
BeadChip, which is designed to target more than 450,000 CpG sits across the genome, is currently a 
common option for genome-wide DNA methylation studies (Bibikova et al. 2009; Bibikova et al. 2011).  
Despite the advancement in the methylation profiling technologies, designing appropriate DNA 
methylation studies remains challenging due to the instability of the epigenetic marks over time and 
also between different cell and tissue types, and in response to environmental changes (Sandholt, 
Hansen, Pedersen 2012). DNA methylation profiles from whole blood for example does not necessarily 
reflects the profiles in more disease relevant tissues such as adipose tissues in the case obesity, and also 
different cellular subtypes within whole blood for example can have distinct methylation profiles 
(Houseman et al. 2012). As studies can be limited by the available type of sample or tissue, these issues 
should be considered and addressed in the study design (Houseman et al. 2012; Michels et al. 2013). 
1.9.3 DNA Methylation Patterns and Obesity 
Epigenetic abnormalities have been found to be causative factors in different diseases including cancer, 
autoimmune diseases and aging (Drong, Lindgren, McCarthy 2012). In addition, the epigenetic effect has 
long been known in syndromic obesity as in the case of Prader-Willi Syndrome that is caused by 
deletions of an imprinted region on chromosome 15 (Farooqi 2005), as was discussed in Section 1.5.2. 
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I addition, the rapid increase of the prevalence of common diseases including obesity and T2D in the 
past 2-3 generations, as well as the missing heritability seen for such diseases suggested a role of 
epigenetic changes triggered by environmental changes as a potential mechanism driving this 
phenomenon. Therefore, several studies have been conducted to investigate the effect of epigenetic 
changes in relation to common diseases.  
A study conducted in Pima Native American community in Arizona has shown that offsprings of mothers 
with T2D during their pregnancy are at higher risk for developing T2D and obesity compared to 
offspring’s of mothers without diabetes during pregnancy (Pettitt et al. 1983). Moreover, offspring’s 
born to mothers with T2D are at higher risk of obesity compared to their siblings who were born when 
the mother had no T2D. The variation observed was preserved in children born to the same mother 
after the mother was diagnosed with T2D compared to their siblings born when the mother was 
nondiabetic, which suggests that that the variation observed is unlikely to completely reflect genetic 
transmission (Dabelea et al. 2000). Some studies on animal models suggest that such effect of intra-
uterine environment on the susceptibility of T2D and obesity can be mediated through epigenetic 
processes (Morgan et al. 1999; Seki et al. 2012). 
Morgan et al. has described the epigenetic inheritance at the agouti locus in mice, which is responsible 
for fur coat colour (Morgan et al. 1999). Mutations at this locus have pleiotropic effects that include 
obesity and yellow coat in mice. The study by Morgan et al. showed that despite identical genetic 
makeup of mice carrying the viable yellow Avy allele at the agouti locus, their fur coat colours ranges 
from yellow to brown due to an epigenetic modification at the Avy allele. The variation in fur colour was 
also correlated with adult body weight. The epigenetic modification at the Avy allele was inherited trans-
generationally through the female germline. This gives an example of an inherited epigenetic 
modification that skips the reprogramming process during early developmental stages. 
1.9.3.1 Candidate Gene Methylation Studies on Obesity 
To date, a small number of studies have investigated the role of epigenetic variations, particularly DNA 
methylation, in relation to obesity susceptibility and many of them were conducted on candidate genes 
for obesity (Godfrey et al. 2011; Groom et al. 2012; Kuehnen et al. 2012; Relton et al. 2012; Souren et al. 
2011; Stepanow et al. 2011; Zhao, Goldberg, Vaccarino 2013), as summarized in Table 3. For example, 
Kuehnen et al. (Kuehnen et al. 2012) studied the methylation status of POMC, a monogenic obesity gene 
that encodes for proopiomelanocortin involved in the melanocortin 4 receptor pathway, in blood 
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leukocytes of obese children. They reported a hypermethylation variation associated with obesity. The 
methylation status at this position influences the binding activity of the histone acetyltransferase P300 
complex, required for gene activation, and thus the expression of POMC. This illustrates how changes in 
DNA methylation can affect gene expression patterns and subsequently susceptibility to disease. In 
addition, it shows that for a key obesity gene like POMC both genetic as well as epigenetic mechanisms 
can modulate obesity predisposition. 
1.9.3.2 Genome-Wide Methylation Studies on Obesity 
The development of DNA methylation profiling microarrays such as the Illumina HumanMethylation450 
BeadChip (Bibikova et al. 2009), and the next generation sequencing technologies coupled with bisulfide 
treatment, paved the way for conducting DNA methylation analysis at the genome wide level, widely 
recognized as epigenome-wide association studies (EWASs). The era of EWASs using large number of 
samples has begun and is expected to provide a more comprehensive view of the contribution of DNA 
methylation to disease pathogenesis (Drong, Lindgren, McCarthy 2012).  
In relevance to obesity, few EWASs have been performed to date (Almen et al. 2012; Almen et al. 2014; 
Feinberg et al. 2010; Sun.D. et al. 2014; Wang et al. 2010b), as summarized in Table 3. Recently, a 
seminal paper by Dick et al. (Dick et al. 2014) has provided a systematic analysis of the association 
between variation in DNA methylation and BMI. Their initial discovery cohort consisted of 479 European 
individual who were typed, using whole-blood DNA, with the Infinium HumanMethylation450 array. 
They reported a replicated significant association between three probes, targeting CpG sites within the 
first intron of hypoxia inducible factor 3, alpha subunit (HIF3A), and BMI. HIF3A is a component of the 
hypoxia inducible transcription factor that regulates the cellular and physiological response to hypoxia 
through regulating the expression downstream target genes (Greer et al. 2012). For the most 
significantly associated probe, cg22891070, every 10% increase in methylation gives about 3.6% 
increase in BMI, which is about 0.98kg/m2. This paper highlighted the importance of HIF3A pathway in 
relation to obesity as well as the role of epigenetic variations in determining susceptibility to obesity.  
Given the important role of DNA methylation patterns in the susceptibility to obesity as well as the lack 
of methylation studies on obesity in Arab populations, I have sought to attempt replicating known 
associations between DNA methylation and BMI from large EWASs (Dick et al. 2014; Sun.D. et al. 2014) 
in my Qatari dataset. This will help identifying conserved associations between Caucasians and Arabs 
and could highlight key obesity genes. For this purpose, I have performed differential methylation 
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analysis with BMI in my sample set using the genome-wide DNA methylation profiling data generated 
with the Infinium HumanMethylation450 BeadChip, as will be discussed in details in Chapter 5. 
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Study target 
 
 
Trait 
 
 
Samples 
case/control 
(c/c) or 
quantitative(qt) 
DNA source 
 
 
Technology  
 
 
Replication 
case/control (c/c) or 
quantitative (qt) 
 
Reference 
 
 
ALOX12, ALPL, BCL2A1, CASP10, 
CAV1, CCL3, CD9, CDKN1C, DSC2, 
EPHA1, EVI2A, HLA, IRF5,KRT1, 
LCN2, MLLT4, MMP9, MPL, NID1, 
NKX31, PMP22, S100A12, TAL1, 
VIM 
BMI, fat mass, and lean 
mass 
 
 
qt: 178 
 
 
 
Umbilical cord blood 
 
 
GoldenGate® Cancer Panel I Array 
 
 
 
 - (Relton et al. 2012) 
 
 
KCNQ1OT1, H19, IGF2, GRB10, 
MEST, SNRPN,  GNAS 
BMI (discordance in 
twins) 
c/c: 16/16  
 
Saliva  
 
Bisulfite sequencing 
 
 - (Souren et al. 2011) 
MCHR1  BMI  qt: 49   Whole blood  Bisulfite sequencing  - (Stepanow et al. 2011) 
POMC  Obesity  c/c: 71/36  Whole blood  Bisulfite sequencing c/c: 54/100  (Kuehnen et al. 2012) 
IL8, NOS3, PIK3CD, RXRA, SOD1 
 
Fat mass and %fat mass  qt: 78  
 
Umbilical cord tissue  SequenomMassARRAY 
 
qt: 239  (Godfrey et al. 2011) 
SLC6A4  
 
BMI, weight, and waist 
circumference 
qt: 168  Peripheral blood 
leukocytes 
Bisulfite pyrosequencing 
 
 - (Zhao, Goldberg, 
Vaccarino 2013) 
TACSTD2  Fat mass  qt: 94  Whole blood  Bisulfite pyrosequencing qt: 161 (Groom et al. 2012) 
EWAS 
 
BMI  
 
qt: 64 
 
 Lymphocytes  
 
Comparative array-based relative 
methylation (CHARM) 
 - (Feinberg et al. 2010) 
EWAS  
 
Obesity  
 
c/c: 7/7  
 
Peripheral blood 
leukocytes 
Infinium HumanMethylation27 
BeadChip 
c/c: 46/46  
 
(Wang et al. 2010b) 
EWAS  
 
Obesity  
 
c/c: 23/24  
 
Whole blood  
 
Infinium HumanMethylation27 
BeadChip 
 - (Almen et al. 2012) 
EWAS 
 
BMI 
 
qt:479 
 
whole blood 
 
Infinium HumanMethylation450 
BeadChip 
qt:339, qt:1789 (Dick et al. 2014) 
EWAS 
 
Obesity 
 
c/c: 48/48 
 
Whole blood 
 
Infinium HumanMethylation450 
BeadChip 
- 
 
(Xu et al. 2013) 
EWAS 
 
Obesity 
 
c/c: 24/22 
 
Whole blood 
 
lInfinium HumanMethylation27 
BeadChip 
- (Almen et al. 2014) 
 
EWAS 
 
BMI 
 
qt: 830 
 
Whole blood 
 
Infinium HumanMethylation450 
BeadChip 
qt:138 
 
(Sun.D. et al. 2014) 
Table 3.Candidate gene studies and epigenome-wide association studies of DNA methylation on obesity
1. Introduction 
 
58 
 
1.10 Aims 
Despite the alarming figures of obesity in the Arab world, the genetics of obesity remain understudied in 
Arab populations. Studies mainly performed on Caucasians have shown that single nucleotides 
polymorphisms, copy number variations as well as DNA methylation patterns contribute to the 
susceptibility to obesity in humans. Therefore, I sought to study these various contributors to obesity 
predisposition in an Arab population. This may identify novel contributions to obesity susceptibility 
and/or underscore conserved contributions found in other populations. 
The specific steps to achieve this goal were to: 
1- Start the collection of DNA from multigenerational Qatari families segregating obesity for the 
purpose of the study. 
2- Perform genome-wide SNP genotyping (using the HumanOmni2.5-8 Beadchip), whole genome 
sequencing (using the Hiseq2500 platform) and genome-wide methylation profiling (using the 
Infinium Human Methylation450 Beadchip) through Illumina using whole-blood DNA. 
3- Identify candidate obesity regions in the families through linkage and run of homozygosity 
analyses. 
4- Identify novel or known rare variants possibility contributing to obesity risk in these families 
using variant prioritization analyses.  
5- Identify copy number variants genome-wide in my sample set and screen predicted common 
and large rare CNVs for association with BMI. 
6- Perform genome-wide association analysis of DNA methylation with BMI in my Qatari dataset to 
attempt replicating known associations. 
7- Investigate the impact of differing genetic background and lifestyle on the replicated DNA 
methylation associations by comparing the effects observed in the Qatari dataset to the 
TwinsUK cohort. 
Collectively, the work of this thesis represents the first genetic and epigenetic study on obesity in 
Qatar and the Arab countries, and it can serve as a pilot for future studies. 
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2. Materials and Methods 
2.1 Ethical Approval of the Study 
Ethical approval was obtained from Weill Cornell Medical College in Qatar (WCMC-Q) Institutional 
Review Board (IRB) on the 26thof September 2012 for the purpose of this study (IRB number: 2012-
0025). This is in concordance with the Helsinki declaration of ethical principles for medical research 
involving human materials. The application forms, consents, and required documentations were 
prepared by the author. Ethical approval is provided in Appendix 1.1. 
2.2 Selection of Study Subjects 
Study subjects were identified through collaboration between WCMC-Q and Qatar Diabetes Association 
(QDA); a health centre that provides secondary care for diabetic patients as well as awareness programs 
on the management and prevention of diabetes and obesity in Qatar. Qatari obese probands (adults: 
BMI≥30, children: BMI>2SD above the mean for age-gender) with familial history of obesity were initially 
contacted to participate in the study, during their visits to the QDA. Probands were introduced to the 
study and asked to fill an information sheet with their personal information and contact details, for 
arranging home visits for family recruitment. A team consisting of the author and a nurse visited the 
families at home for recruitment. All family members including cases and controls were introduced to 
the study objectives and protocols, and a written informed consent was obtained from all participants 
(and their parents if participant’s age was between 13-18 years). A total of 96 subjects from ten families 
participated in the study. 
2.3 Samples Collection 
Venous blood samples (~7ml) were drawn from participants by a specialized nurse and were kept in 
Ethylenediaminetetraacetic acid (EDTA) anticoagulant tubes for DNA extraction. Within 24 hours of 
collection, blood samples were aliquoted into 2ml tubes and stored at -80C.  
2.4 Phenotypic Data Collection 
Anthropometric data like age, sex, height, and waist circumference were recorded for study 
participants. In addition, measurements of weight, BMI, fat mass (FM), fat mass percentage (FM %), fat-
free mass (FFM), fat-free mass percentage (FFM %), muscle mass, muscle mass percentage, bone mass 
and basal metabolic rate (BMR) were obtained using a high capacity body composition analyser Bc-
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420MA device (Tanita, UK LTD.). BMI was calculated as weight in kilograms divided by the square of the 
height in meters squared. BMI is an inexpensive and simple measure for obesity where excess body 
weight relative to height indicates excessive fat mass. However, excess body weight that given by BMI 
measures could also indicate high bone or muscle mass, therefore in this study I also obtained the body 
composition measurements, which are based on the bio-impedance analysis. 
The participants also filled a short questionnaire on health and lifestyle to get general information about 
their health status, and to also ensure that none of the affected subjects have a genetic syndrome. In 
addition, detailed information about the family structure was collected and checked with the 
participants during the visits, to generate family pedigrees, using Haplopainter (Thiele and Nurnberg 
2005). The overall characteristics of the study participants are provided in Table 4, and the family 
pedigrees are shown in Figure 2. 
 
Characteristics 
  
Males 
N=39 (40.6%) 
Females 
N=57 (59.4%) 
Age (years) 34.2±16.9 36.5±15.7 
 
BMI(kg/m
2
) 30.3±7.7 29.3±6.4 
 
Phenotype 10 normal, 8 overweight, 21 obese 16 normal,13 overweight, 28 obese 
 
Fat mass (kg) 26.8±13.1 25.7±13.6 
 
Fat mass percentage (%) 28.4±17.7 33.2±11.0 
 
Fat free mass (kg) 57.7±15.9 45.8±6.2 
 
Fat free mass percentage (%) 70.1±9.7 66.6±11.2 
 
Bone mass (kg) 3.1±0.4 3.3±0.3 
 
Muscle mass (kg) 56.3±11.3 43.2±5.9 
 
Muscle mass percentage (%) 68.0±0.4 62.9±11.0 
 
Basal metabolic rate (kJ) 7843.2±1215.1 5944.3±759.7 
 
Waist circumference (inches) 39.7±7.70 
 
35±6.6 
 
T2D status 
 
3 diabetics, 34 nondiabetics, 2 unknowns 9 diabetics, 48 nondiabetics 
 
Smoking status 
 
8 smokers, 29 nonsmokers, 2 unknowns 
 
 57 nonsmokers 
 
Table 4. Characteristics of the study participants. 
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Family 1 
Family 2 Family 3 
Family 4 Family 5 
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Family 10 
 
Figure 2. Pedigrees of ten Qatari families participated in the study. Obese subjects are shown in black, 
overweight in blue, normal in white and unknowns in grey. The probands are indicated with arrows. 
Sample ID, age and BMI are given below the individual symbol, respectively. The  
Family 6 Family 7 
Family 8 Family 9 
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 label beside some individuals indicates the availability of genotyping, sequencing and methylation data 
for these subjects, while the M label indicates the availability of methylation data only.   
2.5 Extraction of Genomic DNA 
I performed the extraction of genomic DNA at WCMC-Q clinical laboratory, from 2ml of whole blood 
using QIAamp Blood Midi Kit (Qiagen, Crawley, UK). This procedure was carried out according to the 
manufacturer instruction including the recommended proteinase K and RNase A digestions. DNA 
concentration and purity were measured using NanDrop 2000c/2000 UV-Vis Spectrophotometer 
(NanoDrop, Thermo Fisher Scientific Inc.). In addition, the samples were quantified using Qubit 2.0 
fluorometer from Invitrogen with the Qubit dsDNA BR Assay Kit (Invtrogen Life Technologies, USA) for 
accurate quantification. DNA samples were stored frozen at -80C. 
2.6 Generation of Genomic Data 
This section will explain how SNP genotyping data, whole genome sequencing data and array-based 
methylation profiling data were generated. This was carried out at Illumina on a fee-for-service basis.  
A total of 63 samples belonging to 8 families were selected for performing WGS. 5ug of DNA were 
prepared per sample in a total volume of 100ul (concentration= 50ng/ul based on Qubit readings) and 
shipped frozen in dry ice to Illumina Fast Track service to perform paired-end whole genome 
sequencing, using Hiseq2500 platform. In addition, these samples were also used to perform genome-
wide SNP genotyping using HumanOmni2.5-8 arrays, as a quality control step by Illumina for their WGS 
service.  
In addition, 96 samples belonging to 10 families were sent for genome-wide DNA methylation profiling, 
using the Infinium Human Methylation450 Beadchip. For that, 7ug of DNA were prepared per sample in 
a total volume of 100ul (concentration=70ng/ul based on Qubit readings), in a separate plate and sent 
frozen to Illumina. Table 5 summarizes the types of data generated for the purpose of this study. 
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Data type Subjects Method Platform Features Assay DNA 
required 
SNP-array 
genotyping 
8 families 
(n=63) 
HumanOmni2.5-
8BeadChip  
iScan or 
HiScanSQ 
2,379,855  
SNPs (1kGP;MAF>2.5%) 
Infinium 
LCG 
200ng 
Whole genome 
sequencing 
8 families 
(n=63) 
WGS from short-insert 
paired end reads 
HiSeq 
2500  
Minimum of 35× 
average coverage 
Truseq 
DNA (PCR 
–free) 
3-5ug 
DNA 
methylation 
10 families 
(n=96) 
Infinium 
HumanMethylation450 
BeadChip 
iScan or 
HiScanSQ 
> 485,577 methylation 
sites within and outside 
CpG islands 
Infinium 
HD (PCR 
free) 
500ng (1 µg 
with 
automation) 
Table 5.Summary of the genome-wide datasets generated in this study. 
 
2.6.1 Genome-Wide SNP Genotyping using the HumanOmni2.5-8 Beadchip 
The Beadarray® technology forms the fundamental basis of the high throughput SNP genotyping arrays 
developed by Illumina. This technology involves the assembly of hundreds of thousands of copies of 50-
mer oligonucleotides that are complementary in their sequence to the sequences immediately adjacent 
to target SNPs onto 3-micron silica beads (Illumina 2015). These beads are self-assembled in microwells 
of fiber optic bundles with uniform spacing of ~5.7 microns and each bead is designed to be specific for 
tagging a particular SNP (Illumina 2015).  
The HumanOmni2.5-8 Beadchip features 2,379,855 SNPs across the genome to provide comprehensive 
coverage of infrequent and common variants from the 1000 genome project (1kGP) with MAF > 2.5%. 
These SNP markers serve as tag SNPs for other highly correlated markers within their haplotype blocks, 
and they were selected to be maximally informative for diverse world populations (Illumina 2013). In 
addition, the high density of the HumanOmni2.5-8 Beadchip, with average distance of 1.19 kb between 
SNPs, makes it a powerful platform for studying copy number variations (Illumina 2013). 
Due to the high efficiency, accuracy and robustness of the array genotyping technology (Steemers et al. 
2006), Illumina performed genome-wide SNP genotyping, as a quality control step for their WGS service, 
to validate sequencing accuracy and sample identity. Figure 3 shows the workflow for performing the 
SNP genotyping using Illumina Infinium Assay. Briefly, DNA samples were whole-genome amplified, 
fragmented, precipitated and resuspended according to the Infinium LCG Assay Guide (Illumina). The 
samples were then loaded on the HumanOmni2.5-8 arrays (eight samples per array) for hybridisation to 
the oligonucleotide probes, followed by a washing step to remove the unhybridised or the non-
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specifically hybridised DNA. A two-colour single-base extension step was then carried out in which 
differentially labelled nucleotides were added to the oligonucleotide probes in a complementary 
manner to the nucleotide present in the hybridised sample DNA. The HiScan or iScan system then 
scanned the beadchip by laser to excite the fluorophore of the extended base, and high resolution 
images of the fluorophores emitted light were recorded. The output images and intensity files were 
imported into GenomeStudio software (Illumina) to extract the genotype information.  
The SNP array genotyping data generated will be utilized in this study to perform linkage analysis and 
ROH analysis as well as CNV analysis. 
 
 
Figure 3. Workflow for genome-wide SNP genotyping using the Illumina Infinium assay. Figure is 
reproduced from Illumina.com (see Appendix 2.2). 
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2.6.2 Whole Genome Sequencing (WGS) from Paired-End Reads 
Paired-end sequencing is an advanced technology that allows rapid and parallel sequencing of genomic 
segments which produces massive number of short sequencing reads that represents together the 
sequence of the whole genome. The sequencing technology implemented by Illumina is based on the 
fundamental idea of sequencing by synthesis (SBS) technology, in which single bases are sequenced as 
they are incorporated into the growing DNA strand, as illustrated in Figure 4. 
In this study, 63 samples were whole genome sequenced by Illumina using the Hiseq 2500 platform with 
a minimum of 35x average coverage. The service process involves quantification of DNA samples using 
PicoGreen (Quant-iT PicoGreen dsDNA Reagent, Invitrogen, Catalogue #: P11496) on Spectromax Gemini 
XPS (Molecular Devices), to ensure good sample quantity, prior to library construction. Then, paired-end 
libraries were generated with 1ug of genomic DNA using the Illumina TruSeq DNA Sample Preparation 
Kit (Catalogue #: FC-121-2001), according to the TruSeq DNA PCR-Free Sample Preparation Guide. 
Libraries were then subjected to quality control step using gel electrophoresis to check their sizes and 
were then quantified. This was followed by denaturation, dilution and clustering of libraries onto v4 flow 
cells using the Illumina cBot™ system, according to cBot User Guide.  
The clustered flow cells were processed using HiSeq 2500 instruments and sequenced at a minimum of 
100bp paired-end runs, following the instructions in HiSeq 2500 User Guide. Real-time image analysis 
and base calling for the Hiseq runs was performed using Illumina HiSeq Control Software (HCS) and Real-
Time Analysis (RTA). The sequences generated were then processed through Illumina’s bioinformatics 
pipeline to obtain a full range of called variants for each sample. In this study, the raw sequencing data, 
generated by Illumina, was processed using the analysis pipeline implemented in the Bioinformatics core 
at WCMC-Q as will be discussed in Section 2.8.1.3, and was used for the purpose of identifying rare 
obesity variants as will be discussed in Chapter 3. 
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Figure 4. Schematic diagram of Illumina sequence by synthesis next-generation sequencing platform. 
Figure was reproduced with permission from Ross et al. (2011) (Ross and Cronin 2011), as given in 
Appendix 2.3. 
 
2.6.3 Genome-Wide Methylation Profiling using Infinium HumanMethylation450 BeadChip 
The Infinium HumanMethylation450 BeadChip offers a cost-effective analysis of DNA methylation at 
genome-wide level. This technology features more than 485,577 CpG sites covering 99% of RefSeq 
genes with an average of 17 CpG sites per gene region (Bibikova et al. 2009; Bibikova et al. 2011). These 
CpG sites targets 96% of CpG island regions in the genome and are distributed across promoter regions, 
5’UTR, 3’UTR as well as gene body (Illumina 2012a). 
The Infinium assay technology relies on quantifying sodium bisulfite induced C to T conversions at 
defined genomic positions using a combination of two assays; Infinium I and Infinium II (Illumina 2012b). 
1) 2) 3) 
5) 4) 
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As illustrated in Figure 5, Infinium I assay uses especially designed two bead type probes per CpG locus; 
one is complementary to the unconverted (methylated) sequence and the other is complementary to 
the C-to-U-converted (unmethylated) sequence and base extension is the same for both alleles. The 
design of this assay is based on the co-methylation assumption within a 50 bp span from CpG query sites 
(Illumina 2012b).  On the other hand, Infinium II assay uses a single bead type per CpG locus, and the 
methylation status of the query site is determined by a single base extension step after hybridisation.  
With Infinium II assay, the underlying CpG sites (up to 3) are usually represented by “degenerate” R-
base, allowing the assessment of the methylation status at the query sites independently from 
neighbouring sites (Illumina 2012b). These two assays were employed in the HumanMethylation450 
BeadChip to enhance breadth and coverage. 
In this study, 96 samples were submitted to Illumina to perform the methylation profiling using the 
Infinium HumanMethylation450 BeadChip, as a service. The procedure was carried out according to the 
Infinium HD Assay Methylation Protocol Guide. Briefly, DNA was bisulfite converted using bisulfite 
conversion kit (Illumina). The bisulfite-converted DNA was then denatured; neutralised, whole genome 
amplified and then fragmented using an enzymatic process. The fragmented DNA was precipitated, 
resuspended and loaded into the Infinium HumanMethylation450 BeadChip for hybridisation overnight. 
This beadchip has an 8-sample format that allowed the processing of eight samples per chip. The 
beadchip was then washed and as single-base extension step using fluorescently labelled bases was 
carried out to distinguish between a C or a T nucleotide in the converted DNA. The HiScan or iScan 
system was used to scan and record fluorescent images of the beadchip, which were then processed 
through the methylation module of GenomeStudio to extract the methylation information, as will be 
discussed in Section 2.8.3.1. 
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Figure 5. The two assays employed in the Infinium HumanMethylation450 BeadChip. A) Infinium I 
assay employs two bead types per CpG site, one for the methylated and the unmethylated states. B) 
Infinium II assay uses one bead type per CpG site, and the methylation state is determined by single 
base extension step after hybridisation. Figure is reproduced from Illumina.com (see Appendix 2.2). 
 
 
 
 
 
2. Materials and Methods 
71 
 
2.7 Additional Genomic Data Sets 
2.7.1 Data for 108 Qatari Genomes 
In this study, I utilized existing data from 108 unrelated Qatari subjects recruited by the team of Drs 
Ronald Crystal and Khalid Fakhro at WCMC-Q. The purpose was to replicate findings from Chapters 3 
and 4 of this thesis. The dataset for the 108 Qatari genomes was initially collected to conduct population 
studies on the Qatari population. The dataset consists of genome-wide SNP genotyping data (using the 
HumanOmni2.5 SNP array) and WGS data (using the Hiseq 2500 platform) that were generated by 
Illumina on fee-for-service basis. The sample set includes 87 adults with BMI data (52 obese, 27 
overweight and 8 normal). The CNV analysis of the 108 Qatari genomes was carried out using PennCNV 
by the author (data are not shown). 
2.7.2 Data from Adult Obesity and Childhood Obesity Case-Control Cohorts 
I tried to replicate CNV findings from Chapter 4 using the CNV results from the PhD work of my 
colleague Julia Sarah El-Sayed Moustafa available in her thesis entitled “Genomic Structural Variation 
and its Impact on the Human Phenotype”. In particular I used the CNV information on the child and 
adult obesity cases and controls which consisted of 646 child obesity cases and 589 child controls, and 
709 adult obesity cases and 197 adult controls. These samples were genotyped on the Illumina 
HumanCNV370-Duo chip and the CNVs were called using PennCNV (Wang et al. 2007) and cnvHap (Coin 
et al. 2010). 
2.7.3 Data from the Saudi Extreme Obesity and Mental Retardation Case-Control Sample Set 
I aimed to replicate CNV findings from Chapter 4 using the CNV calls given in the PhD thesis of my 
colleague Haya Al-Saud, which is entitled “The Genetics of obesity in Saudi Arabian Population”. The 
sample set consisted of adults and children with a total of 85 cases and 72 controls. These samples were 
genotyped using Affymetrix arrays (Affymetrix 6.0, Axiom GWH-96 and CytoScan HD), and the CNVs 
were called using PennCNV.  
2.7.4 Data from Qatari Families with T2D 
My DNA methylation data was analysed together with another DNA methylation dataset that was 
generated by my colleague Wadha Al Muftah to study DNA methylation patterns in relation to T2D. The 
dataset consists of methylation and WGS data for a total of 27 subjects from 6 Qatari Families. Both 
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datasets have matching sample ethnicity, sample type (whole blood), DNA extraction method (QIAamp 
blood midi kit), and methylation profiling technology (Infinium HumanMethylation450 Beadchip). 
Therefore, the two datasets were combined to increase sample size. The combined dataset consists of a 
total of 123 subjects from 16 Qatari families. This dataset will be analysed for the purpose of identifying 
differentially methylated sites with BMI as will be discussed in Chapter 5 of this thesis, and for the 
purpose of identifying differentially methylated sites in T2D as discussed by my colleague Wadha Al 
Muftah in her PhD thesis, which is entitled “The Genetics and Epigenetics of T2D among Qatari 
Families”.  
2.7.5 Data from TwinsUK Cohort 
The TwinsUK cohort was established in 1992 (Moayyeri et al. 2013) and it currently consists of more 
than 13,000 MZ and DZ twin participants (with same gender), the majority (82.7%) of whom are healthy 
Caucasian females. The genome-wide methylation data (using the Infinium HumanMethylation450 
BeadChip) for 810 twin participants (with BMI information) was used to replicate methylation loci 
associated with BMI in my Qatari dataset. In addition, the data was used to investigate the impact of 
genetic background and lifestyle/environmental pressures on these associations by comparing the 
effects observed in the Qatari and TwinsUK datasets in a meta-analysis framework, as will be discussed 
in Chapter 5. Details on the experimental approaches carried on the TwinsUK methylation data was 
previously described by Tsaprouni (Tsaprouni et al. 2014). 
2.8 Data Processing and Analysis 
This section will explain how SNP genotyping data, whole genome sequencing data and array-based 
methylation profiling data were processed and analysed to achieve the study objectives. Therefore, this 
section is divided into three major sub-sections: identification of rare obesity mutations, identification of 
common and rare obesity CNVs, and identification of differentially methylated sites with BMI.  
2.8.1 Identification of Rare Obesity Mutations 
As introduced earlier, one of the aims of this study was to identify rare obesity variants. The strategy I 
applied to achieve this goal involved two major steps. The aim of the first step was to identify candidate 
obesity regions that may harbour rare variants through linkage analysis, and to prioritize the candidate 
linkage regions further through run of homozygosity (ROH) analysis as it might help identifying 
homozygous obesity variants. The rationale behind identifying candidate obesity regions as a first step 
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before searching for rare obesity variants was to narrow down the search to a reduced number of 
genomic regions and thus variants to those that are most promising.  Linkage and ROH analyses were 
carried out using the high density SNP genotyping data. The aim of the second step was to look for 
potential rare obesity variants within monogenic obesity genes as well as the candidate obesity regions 
identified through linkage and ROH analyses. This second step was carried out using the WGS data. 
2.8.1.1 Linkage Analysis 
2.8.1.1.1 Extraction of SNP Genotyping Data 
Genotypes were extracted from the raw HumanOmni2.5-8 SNP array intensity profiles using the 
genotyping module of GenomeStudio software (Illumina), and were exported in Plink format using Plink 
Input Report Plug-in tool. This generated a pedigree (.ped) file containing family ID, individual ID, 
paternal ID, maternal ID, gender and affection status followed by the genotypes for all markers, and a 
map file (.map) providing information about the SNP markers including chromosome, marker name, 
genetic position in centimorgan (CM) and physical position in base pairs (bp). The SNP genotyping 
dataset contained a total of 63 subjects from 8 families. 
2.8.1.1.2 Quality Control of SNP Genotyping Data 
Before performing linkage analysis, quality control was performed on the SNP genotyping data using 
Plink (Purcell et al. 2007), Pedstats (Abecasis and Wigginton 2005), Pedwipe and Merlin (Abecasis et al. 
2002). 
The first group of QC steps was performed with Plink (available at 
http://pngu.mgh.harvard.edu/purcell/PLINK/). First, gender check was carried out to ensure that the 
gender inferred from the genotyping data matches the clinical records, using the option --check-sex.  All 
genotyped samples had matching gender information, therefore none were excluded. Second, samples 
with more than 5% missing genotypes were supposed to be excluded, as this can be an indication of 
sample genotyping failure, however, all samples had call rates > 95% and thus none were dropped out 
based on this criterion. Third, SNPs with more than 5% missing genotypes were excluded (31,404 SNPs) 
as they indicate SNP genotyping failure. Fourth, SNPs with minor allele frequency (MAF) of <5% 
(calculated on the founders only) were excluded (1,049,751 SNPs) because the small size of the 
homozygous and the heterozygous clusters makes calling these variants difficult and thus they might 
present as false positives. Fifth, SNPs that failed the Hardy-Weinberg equilibrium (HWE) test at a 
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significance level of 1X10-6 were removed (9 SNPs) as they might be indicative of genotyping error. Sixth, 
SNPs with more than 5% Mendelian errors were excluded (2 SNPs) as they may also indicate genotyping 
error. 
Next, Pedstats was used to identify genotypes showing Mendelian inconsistencies and Pedwipe was 
used to remove those genotypes from the dataset. Since Merlin can only analyse markers with unique 
genetic positions for performing linkage analysis, markers that map to the same genetic position were 
excluded (248,057 SNPs). The number of SNP markers was then reduced further to be suitable for 
performing linkage analysis. The reason for that was to avoid the bias in the linkage statistics that may 
arise from the existence of high linkage disequilibrium (LD) between markers (Abecasis and Wigginton 
2005).  
The first method applied to do that (Method A) was to select markers based on information content (IC), 
which is also known as information extraction, and LD measures. Information content is an estimation of 
the amount of information that can be derived from family linkage using a particular set of markers and 
it is the probability of heterozygosity expected under HWE (Kruglyak 1997). Herein, IC was calculated, 
using the --information option in Merlin (Abecasis et al. 2002), and then the 25% least informative SNPs 
were excluded, using Plink --exclude option, in order to ensure high informativeness of linkage markers. 
In addition, LD was calculated between pairs of markers in a window using the --independent-pairwise 
option in Plink, and one of a pair of SNPs was pruned out, using the --exclude option, if LD was greater 
than 0.1 in order to reduce marker-marker LD bias in the marker set. 
The data was also checked for hidden non-Mendelian errors, which are genotypes that imply the 
occurrence of excessive unlikely recombination events between closely linked markers as they may 
reflect genotyping errors. The hidden errors were detected using Merlin and were wiped with Pedwipe 
(Abecasis et al. 2002). This method gave a total of 20,872 SNPs to be used for linkage analysis. Figure 6 
summarizes the quality control and markers’ selection steps using Method A.  
In an effort to maximize the IC of linkage markers and hence the power of linkage detection,  I selected a 
second set of markers using a different method (Method B) and tested the IC compared to Method A.  
Method B markers were selected based on Illumina’s V panel linkage marker set, since they were 
optimized to ensure high IC level and thus higher likelihood for detecting recombinant events (Murray et 
al. 2004). The high information content given by those markers throughout the genome was obtained 
through the selection of markers with high heterozygosity and with appropriate density (Murray et al. 
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2004). According to Illumina, the average heterozygosity of the linkage V panel markers is 43% in 
Caucasians, 36% in the Han/Japanese population and 33% in the Yoruba population and the average 
genetic distance between the markers is 0.62 cM (Illumina 2007).  
Therefore, after performing the fifth QC step (Mendelian errors detection), I extracted the V panel 
linkage markers from my dataset, using Plink. A total of 2,521 markers out of the published 6,056 
linkage V panel markers were present in the dataset. These markers were used with their genetic and 
physical positions provided by Illumina linkage V panel map, which gives accurate physical and genetic 
positions. Similar to the steps applied for Method A, markers that map to same genetic positions and 
genotypes presenting hidden non-Mendelian errors were excluded prior to running linkage analysis. This 
gave a total of 63 subjects and 2,456 SNP markers for linkage analysis. Figure 7 summarizes the quality 
control and markers’ selection steps using Method B.  
For each of the 22 autosomes, Method A marker set (20,872 SNP markers) gave higher density and was 
slightly more informative than Method B (2,456 SNP markers), as shown in Figures 8 and 9. The average 
genome-wide information content for Method A markers was 0.80 while for Method B was 0.72, with 
average distance between markers of 0.13 and 1.70 cM for Method A and Method B respectively. Since 
Method A marker set was more informative, and it also provided higher marker density through the 
genome, I used Method A markers to carry out the linkage analysis. 
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Figure 6. A summary of quality control and marker selection steps using Method A. Blue boxes shows steps common between Method A and 
Method B (also given in Figure 7), while green boxes shows steps specific to Method A. 
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Figure 7. A summary of quality control and marker selection steps using Method B. Blue boxes shows steps common between Method A (also 
given in Figure 6) and Method B, while yellow boxes shows steps specific to Method B. 
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Figure 8. Information content for Method A compared to Method B for chromosomes 1, 2 and 3. Plots 
on the left side are for Method A while plots on the right are for Method B. The plots for all 
chromosomes are given in Appendices 1.2 and 1.3. 
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Figure 9. Information Content (IC) for Method A compared to Method B. Method A is shown in blue 
while Method B is shown in red. 
 
2.8.1.1.3 Non-parametric Linkage Analysis 
To test for co-segregation of marker loci with obesity, as a discrete trait, nonparametric multipoint 
linkage analysis (NPL) was carried out using Merlin. NPL evaluates allele sharing among affected 
individuals without making any assumptions about the mode of inheritance of the disease trait and thus 
it is a suitable approach for pedigree studies of complex diseases like obesity, in which a number of 
genetic and environmental factors affect disease etiology (Abecasis et al. 2002). Subjects with BMI of 
≥30 were considered as affected (n=34) and subjects with BMI of <25 were considered as unaffected 
(n=18) while overweight subjects (30>BMI≥ 25) were considered as unknowns (n=11). NPL was carried 
out using the –npl option for nonparametric linkage and the –rsq of 0.1, which calculates pairwise 
correlation coefficient (r2) between neighbouring markers, and creates a cluster of markers with r2 >0.1 
and all intervening markers, since LD between closely spaced markers can inflate linkage calculations. 
Age and gender were included as covariates in the analysis and linkage results were expressed as LOD 
scores, logarithm of the odds (to the base 10). The LOD score provides an estimate of the likelihood that 
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two loci lie near each other on a chromosome and are thus co-inherited. LOD scores ≥3.3 are considered 
as significant linkage signals as it means that the odds are more than a thousand to one in favour of 
genetic linkage (Lander and Kruglyak 1995). The per family analysis option --perFamily in Merlin was 
applied to obtain information on the contribution of each family to linkage signals. In addition, the 
simulation option --simulate was used to generate datasets with simulated genotypes but preserving the 
actual family structure, allele frequencies, marker spacing and patterns of missing data. Linkage analysis 
on the simulated datasets indicates how often the real linkage peaks might arise by chance, and that is 
given as empirical P-values. Linkage regions were defined as the region within a drop of 1 LOD score on 
both sides of the detected linkage peaks.  
2.8.1.1.4 Variance Component Linkage Analysis 
In addition to NPL, I performed variance component (VC) linkage analysis with ten obesity-related 
quantitative traits in order to identify quantitative trait loci related to obesity using BMI, fat mass (FM), 
fat mass percentage (FM%), fat-free mass (FFM), fat-free mass percentage (FFM%), muscle mass, muscle 
mass percentage, basal metabolic rate (BMR), bone mass and waist circumference. The analysis was 
performed using the 63 subjects with genotyping data including 34 obese subjects, 18 lean subjects as 
well as the 11 overweight subjects who were considered as unknowns in the NPL. VC linkage was carried 
out using the option --vc in Merlin (Abecasis et al. 2002). As VC linkage analysis are designed for 
normally distributed traits, the normalisation option --inverseNormal in Merlin was applied to perform 
quantile normalisation on each of the quantitative traits prior to running VC linkage (Abecasis et al. 
2002).  
2.8.1.2 Run of Homozygosity (ROH) Analysis 
Since this study was performed in families from an inbred population, it is expected that some of the 
obesity susceptibility variants to be in homozygous state. Therefore, ROH analysis was carried out to 
identify shared ROH regions between affected subjects to help prioritizing candidate linkage regions, for 
the purpose of identifying potential obesity variants. ROH analysis was performed using the SNP array 
data since the homozygosity regions are expected to be long enough to be detected by SNP arrays (Kirin 
et al. 2010) and as there are several established methods for ROH detection from array data.  
ROH analysis was performed with Plink using the SNP array genotyping data after being cleaned for SNPs 
with: >5% missing genotypes, MAF <0.05, deviation from HWE (at significance level of 1X10-6) and 
Mendelian errors, giving a total of 1,233,008 SNPss. The parameters for ROH detection was set to 50 
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SNPs as sliding window size (--homozyg-window-snp 50), allowing 3 heterozygotes (--homozyg-window-
het 3) and 15 missing SNPs (--homozyg-window-missing 15) within a window. Homozygosity window 
threshold of 0.05 (--homozyg-window-threshold 0.05) was used to define a given SNP as in homozygous 
segment, and a minimum of 300 SNPs (--homozyg-snp 300) with a minimum density of 1 SNP/50kb (--
homozyg-density 50) was used to call a final segment as homozygous. In addition, the option (--
homozyg-gap 1000) was applied to split a segment in two if two SNPs within a window were too far 
apart, and the option --homozyg-group was used to obtain pools of overlapping segments. The ROH 
pools with more obese subjects than lean were then cross checked with the candidate linkage regions. 
The overlapping linkage and homozygosity regions were prioritized as top candidates but also non-
overlapping linkage and ROH regions were still considered as candidate regions of interest.  
2.8.1.3 Processing of WGS Data 
The raw sequencing reads for the samples were delivered by Illumina along with the complete set of 
variants in each sample. The average genomic coverage for the 63 samples in my dataset was 39.5. 
Coverage is the number of time a particular base in the genome has been covered by sequencing reads, 
and usually multiple reads per base are needed to generate reliable base call. The Illumina pipeline for 
processing the raw sequencing reads (average of 659,841,529 reads per genome) consisted mainly of 
the Illumina tool ELAND for alignment of sequence reads against the human reference genome (NCBI 
build 37) and CASAVA -1.9.0al_110909 pipeline (Illumina) for SNP calling. With CASAVA, the SNPs and 
genotypes were called for each sample individually (single-sample calling). In this study, the raw 
sequencing data were processed using the in-house WGS pipeline implemented in the Bioinformatics 
core at WCMC-Q, which consists mainly of Bowtie2 (Langmead and Salzberg 2012) for alignment and 
Genome Analysis Toolkit (GATK) (McKenna et al. 2010), developed by the Broad Institute, for variant 
calling. 
The GATK pipeline is being used extensively in academia and in big research projects such as the 1000 
genome project (1kGP) (Clarke et al. 2012). The advantage of using an open source WGS pipeline like 
GATK over commercial WGS pipelines like CASAVA is that it is highly customizable. However, it requires 
expertise to set-up optimally. In addition, the use of the GATK pipeline allows performing multi-sample 
SNP calling rather than single-sample calling, in order to distinguish whether non-variant genotypes are 
homozygous reference genotypes or are missing genotypes (Kumar et al. 2014).  
2. Materials and Methods 
82 
 
Here, I used the multi-sample calling approach which was also used in the 1kGP (Clarke et al. 2012). This 
was done in collaboration with my colleague Dr Pankaj Kumar who implemented the GATK pipeline at 
the Bioinformatics core at WCMC-Q. Based on my families’ data and data from other research groups at 
WCMC-Q, we found that the GATK multi-sample calling identifies more variants than CASAVA single-
sample calling (Kumar et al. 2014). However, both pipelines had highly similar performance in terms of 
calling putatively causative variants (Kumar et al. 2014). The downstream analyses presented in this 
thesis are using the in-house WGS pipeline which implements the GATK multi-sample calling approach. 
2.8.1.3.1 In-house WGS Pipeline 
The Fastq files, which contain the raw short sequence reads, were aligned to the human reference 
Genome Build 37 using Bowtie2 (Langmead and Salzberg 2012). This generated the sequence alignment 
map (SAM) files which were compressed into binary alignment map (BAM) files. The BAM files were 
sorted and indexed using Novosort tool for multi-threaded sorting and indexing. This was followed by 
removal of duplicate reads, multiple read pairs with identical coordinates that might represent PCR bias, 
and retaining the pair with the highest mapping quality, using Picard tools (available at 
http://picard.sourceforge.net/command-live-overview.shtml). The aligned BAM files were then locally 
realigned around insertions and deletions (indels) to correct for any misalignment that may occur due to 
their presence. This was done using the GATK walker Realigner Target Creator and Indel Realigner 
(McKenna et al. 2010). The base quality Phred scores, which evaluate the quality of individual bases in 
DNA sequences, were recalibrated in the realigned BAM files using GATK Base Score Recalibrator and 
Print Reads (McKenna et al. 2010). This recalibration step aims to correct for variation in Phred scores 
with machine sequencing cycle and sequence context giving more accurate scores. After that, the 
recalibrated BAM files were used as input for performing genotype calling with GATK Unified Genotyper 
(McKenna et al. 2010).  
The obtained variant call format (VCF) files were recalibrated using GATK Variant Score Recalibrator to 
assign a well-calibrated probability to each variant call (McKenna et al. 2010). The average number of 
called SNPs per genome was 3,884,771 SNPs. After recalibration, the VCF files were annotated using 
VariantAnnotator (McKenna et al. 2010) and SNPeff (Cingolani et al. 2012) to get information about the 
variants including expected impact of the variants, amino acid change, encoded gene, transcript 
information and others. For storage purposes, the aligned BAM file before calibration, the recalibrated 
BAM file and the annotated VCF files were stored while the other intermediates files were deleted. The 
whole genome sequencing analysis pipeline is shown in Figure 10. 
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Figure 10. Whole genome sequencing analysis pipeline. Grey boxes shows the input and output files from each step, while orange boxes shows 
tools used in each step. 
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2.8.1.3.2 Quality Control of WGS Data 
Three major QC steps were performed on the WGS data to ensure good quality of data before using 
them in downstream analysis to draw biological conclusions.  
The first QC was carried out at the Fastq level using FastQC, which is a java application available at 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). FastQC was used to investigate the 
Phred scores across all bases for each of my study subjects, using the Fastq files as input. All samples 
had good overall Phred scores. An example of the plots generated by FastQC to assess Phred scores is 
provided in Figure 11. In addition, FastQC was used to check the guanine-cytosine (GC) content of the 
sequenced genomes since the deviation from the expected average of around 40% can be indicative of 
sample sequencing failure. All of the samples had GC distribution close to the theoretical distribution. 
Figure 12 shows that the GC distribution for one of my study subjects, as an example. 
The second QC step was performed at the Bam files level, using QPLOT (Li et al. 2013), to assess the 
quality of sequencing and alignment data. QPLOT software is developed using C++ language (available at 
http://genome.sph.umich.edu/wiki/QPLOT#Where_to_Find_It) and generates a series of diagnostic 
metrics for run quality and produces graphical summaries for these metrics. As illustrated in Figure 13, 
the distribution of Phred scores has improved after bam file recalibration. 
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Figure 11. Phred scores across all bases for one sample (QO_F9_01). X-axis shows position of base in 
the sequencing reads. Y-axis determines the Phred score. The yellow boxes represent the inter-quartile 
range (25-75%) of Phred scores, the central red lines represent the median scores, the upper and lower 
whiskers represent the 10% and 90% points and the blue line represents the mean scores. 
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Figure 12. GC distribution over all sequences for one sample (QO_F9_01). Red line represents the 
distribution of GC count per read while the blue line represents the theoretical GC distribution. Little 
shift from the theoretical distribution is observed due to systematic bias. The peak shows the overall GC 
content which is about 38 to 39%. 
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Figure 13. Improvement in reported Phred scores after performing BAM file recalibration, for one 
sample (QO_F9_01). The purple line shows the empirical Phred scores through sequencing runs. 
Reported Phred scores after recalibration (red line) are closer to the empirical Phred scores than before 
recalibration (black line). Also, the distribution of Phred scores for sequenced bases after recalibration 
(dashed red line) peaked around 30, while it was more scattered before recalibration (dashed black 
line).     
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The third QC was to estimate the concordance between the genotyping calls obtained from the 
HumanOmni2.5-8 arrays and the genotypes obtained from WGS for my study subjects. For the array 
genotyping data, genotypes with a GenCall score ≥0.15 were used for the concordance test. The GenCall 
score is a quality score calculated for each genotype in GenomeStudio and it ranges between 0 to 1 with 
a lower value indicating further deviation of a sample from its genotyping cluster (Illumina 2014). I used 
the concordance (calculated as a percentage of matching number of genotypes out of the total number 
of genotypes for each subject) to estimate the overall percentage of concordance per chromosome, as 
shown in Figure 14. The high percentage of concordance obtained reflects the accuracy of the WGS 
pipeline and the genotypes obtained using these two genotyping methods that are used in the 
downstream analyses of this study.  
 
 
Figure 14. High concordance between the genotypes obtained from SNP-array genotyping and WGS. 
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2.8.1.3.3 Ingenuity Variant Analysis 
Ingenuity variant analysis (IVA) (Ingenuity® Systems, www.ingenuity.com) was used to facilitate the 
search for potential rare obesity variants with large effect on the development of obesity. IVA is a 
commercially available web-based application that allows interactive filtering of variants detected 
through WGS or WES to subsets of most compelling variants in order to be further studied. IVA 
incorporates evidence from Ingenuity Knowledge Base, which integrates information about biological 
interactions at various levels including proteins, genes, cells, drugs and diseases. IVA also integrates 
some external analytical tools such as Sorting intolerant from tolerant (SIFT) (Ng and Henikoff 2003) and 
Polymorphism Phenotyping (POLYPHEN-2) (Adzhubei et al. 2010). Both tools predict the effect of 
nonsynonymous variants based on the degree of sequence homology and amino acid conservation cross 
species. POLYPHEN2 also combines three dimensions structural feature of proteins when available. The 
predictions given by these tools can help prioritizing variants of interest.   
As discussed in Section 2.8.1.3, VCFs were generated through the mutli-sample GATK calling pipeline. A 
single multi-sample VCF was then created using VCFtools (available at http://vcftools.sourceforge.net/ ) 
and uploaded into IVA. The samples were classified as cases (n=34) and controls (n=17), and the 
pedigree information of the samples were also uploaded. IVA automatically used NCBI37/hg19 as the 
reference genome since the variants in the VCF were derived from aligned sequence reads to this 
reference genome. A total of 16,470,959 variants present in the VCF were annotated in IVA.  
Four major filters were applied on the 16,470,959 variants (present in 21,999) to narrow them down to 
the most promising potential variants. The first filter was the confidence filter, by which variants that 
have at least a Phred score of 20 in at least one case or control were only considered. By applying this 
default setting, none of the variants were dropped off. The second filter was a frequency-based filter to 
keep only rare variants that have MAF <1% in the 1000 Genome project, the public Complete Genomics 
genomes or the NHLBIESP exomes, or variants that are not available in these datasets, using the built-in 
frequency filter in IVA. A total of 6,786,327 variants in 20,966 genes remained after applying this filter. 
Although the frequency of the variants in these datasets might not necessarily reflect their frequency in 
the Qatari population, I used these figures due to the small sample size and the family structure in my 
dataset.  The third filter was the predicted deleterious filter, which was applied to keep variants that are 
expected to have phenotypic effect, or associated with gain of function of a gene, or associated with loss 
of function of a gene including missense, frameshift, in-frame indel, and start/stop codon. These filtering 
steps gave a total of 2,699 variants in 1,877 genes. These variants were further prioritized using the 
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“biological context” filter, which allows the identification of variants that affect genes relevant to a 
particular phenotype or disease such as obesity. In IVA, the list for obesity relevant genes contains 719 
genes so far. Applying this filter gave 89 variants in 53 obesity-relevant genes.  
These 89 variants were further analysed using two approaches to identify variant of potential interest. 
The first approach was to focus on variants in known monogenic obesity genes, which are LEP, LEPR, 
POMC, MC4R, SIM1 and PCSK1. While, the second approach was to focus on variants located within the 
candidate obesity regions identified, including: 1) overlapping regions between linkage and ROH, 2) 
linkage regions, and 3) ROH regions. The number of cases and controls with a particular variant, the 
gene function and the relevant literature were used to prioritize most promising variants.  
2.8.1.3.4 PCR-based Validation of Candidate Obesity Variants 
2.8.1.3.4.1 Primer Design 
Primers for polymerase chain reaction (PCR) were designed using Primer3 (Rozen and Skaletsky 2000) 
(available at http://bioinfo.ut.ee/primer3-0.4.0/), to validate four candidate obesity variants. The 
default primer design parameters were used, with primer size between 18 and 23bp, the annealing 
temperature (Tm) between 57 and 62°C, and GC content of 30-70%. Primers were checked for specificity 
the UCSC In-Silico PCR (available at http://genome.ucsc.edu/cgi-bin/hgPcr). Primers were ordered from 
Integrated DNA Technologies (IDT) and suspended in sterile ddH2O to make 100uM stock primers. PCR 
primers are shown in Table 6 and PCR reagents mix is given in Table 7. 
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Gene Primer ID Primer sequence (5’ to 3’) Product size (bp) Annealing temperature (°C) Family 
PCSK1 PCSK1_F CAGATACCAGGAATGGGCTTA 420 59 3 
PCSK1_R TGCCATTATAATTTTATGGAAAGAAA 
NMUR2 NMUR2_F CTACGTGGCCATCCTACACC 235 60 9 
NMUR2_R GAAGGAGGTGACCTGGATGA 
CLOCK CLOCK_F TTTGCTTGAAAATAATGTTCTGATCT 500 60 7 
CLOCK_R CAGAGCAGCTATGACCAAATC 
RESTSAT RETSAT_F GCCTCTGGGCAGTTTTCTTA  396 60 4 
RETSAT_R ACTCTGGGTCCTCAGCATGT 
Table 6. Primers used for PCR-based validation of candidate obesity variants. 
 
 
Reagent Volume per reaction (ul) 
 
Forward primer (10 uM) (Integrated DNA Technologies) 
 
 
0.5 
 
 
Reverse primer (10 uM) (Integrated DNA Technologies) 0.5 
AmpliTaq Gold (Applied Biosystems, cat no: 4398881) 
 
12.5 
DNA sample 1ul (of 200ng) 
 
Sterile ddH2O 10.5 
 
Table 7. PCR reagents mix for the validation of candidate obesity variants. 
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2.8.1.3.4.2 Touchdown PCR 
When performing PCR-based validation of the candidate variants, touchdown PCR was used in order to 
avoid non-specific PCR amplifications. The basic idea of touch down PCR is to have two rounds of PCR 
cycles (Korbie and Mattick 2008). The first round has a high Tm (10°C degrees above the initial primers 
Tm) that is decreased by 1°C in each subsequent cycle (n= 10 cycles). This round will ensure the specific 
binding of the primers at highest temperature and thus the amplification of the target of interest. The 
second round of PCR cycles has a lower temperature, which is equal to the initial primers Tm. This will 
allow further amplifications (n= 35 cycles) of the PCR products generated during the first round.  
Touchdown thermo-cycler program: 
The 95 °C for 15 minutes 
95 °C for 45 seconds 
Tm+10 °C for 45 seconds -1 °C /cycle 
72 °C for 1 minute 
Go to 2 for 45 seconds 
95 °C for 45 seconds 
Tm for 45 seconds 
72 °C for 1 minute 
Go to 6 for 29 cycles 
72 °C for 10 minutes 
4 °C Hold 
2.8.1.3.4.3 Gel Electrophoresis 
The success of the PCR reactions was assessed using gel electrophoresis. 1% agarose gel was prepared 
with 1% tris-acetate EDTA (TAE) and 0.1ng/ul of ethidium bromide. 8ul of PCR product mixed with 2ul of 
loading dye (New England Biolabs, cat:B7024S) were loaded on the gel along with 7ul of 100bp DNA 
ladder (New England Biolabs, cat: N3231S) to assist determining the size of the PCR product. The gel was 
run for 45 minutes to 1 hour at a voltage of 90, and was then examined using a gel documentation 
device (Bio-Rad, France). 
2.8.1.3.4.4 Sanger Sequencing 
Before performing Sanger sequencing, PCR products were cleaned-up using an enzymatic reaction that 
eliminates unincorporated primers and Deoxynucleotide Triphosphate (dNTPs). This was done by adding 
6ul of ExoSAP-IT (Affymetrix, cat: 78200) to 15ul of PCR product, followed by thermo-cycler incubation 
at 37°C for 15 minutes and at 80°C for 15 minutes. For each variant, sequencing was performed in both 
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forward and reverse directions. Samples were prepared by adding 4ul of cleaned PCR product, and 1ul 
of 25uM primer (forward or reverse). The samples were submitted to the sequencing facility at WCMC-
Q. The sequencing was performed using an ABI 373 automated sequencer, and the sequencing data file 
(*.ab1) were analysed using mutation surveyor software (available at 
http://www.softgenetics.com/mutationSurveyor.html ) to validate the candidate variants.  
2.8.2 Identification of Common and Rare Obesity CNVs 
The HumanOmni2.5-8 SNP genotyping data that were used for linkage and ROH were also utilized for 
performing CNV analyses. CNV prediction was carried out using PennCNV (Wang et al. 2007) (available 
at http://www.openbioinformatics.org/penncnv/) as will be described below. All CNV analyses were 
limited to autosomes. 
2.8.2.1 CNV Prediction using PennCNV 
PennCNV (Wang et al. 2007) is a free software tool that employs a Hidden Markov Model (HMM) to 
predict CNVs from genome-wide SNP genotyping data at kilobase resolution. This program integrates 
information on LRR and BAF at each SNP, the distance between neighbouring SNPs, frequency of SNPs 
and optionally family information to generate CNV calls.  This section will describe the various steps for 
CNV prediction using PennCNV, which are summarized in Figure 15. 
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Figure 15. CNV analysis workflow for the identification of common and rare obesity CNVs. 
Include SNP probes in CNV regions ≥ 1 
kb, encompassing ≥ 25 SNPs , and that 
had a copy number change  in >10% of 
the samples. 
1442 CNVs remained 
5759 CNVs in 63 samples were 
detected in the 22 autosomes 
 
None of the samples were 
excluded 
5621 CNVs were detected  
59 samples with 4481 CNVs 
remained 
Extraction of intensity data using 
Genome Studio (63 samples) 
Exclusion of samples with LRR_SD > 
0.35  
CNV calling using PennCNV 
Merging adjacent CNVs 
Removing outlier samples with CNVs 
>2SD above the mean 
 
Focus on SNPs with significant 
association (FDR 10%) 
 
Prioritization of candidate CNVs (based on visualization, 
genes function, no. of cases vs controls, and existence in 
other CNV datasets) 
 Keep CNVs encompassing  
> 20 SNPs 
Prioritization of large CNVs (>500kb) 
Generation of LRR and B allele  
frequency plots  
Exclusion of centromeric CNVs 
Include SNP markers with status <> 2 
for >10% of the samples & if regions of 
such markers are >10kb 
2,236 SNPs 
corresponding 
to 555 CNVs in 
39 CNV regions 
remained 
24 large CNVs detected  
16 CNVs remained 
Association of common CNVs with 
BMI 
Investigation of rare obesity CNVs 
Include SNP probes in CNV regions ≥ 1 
kb, encompassing ≥ 20 SNPs , and that 
had a copy number change  in >10% of 
the samples. 
7 SNPs 
corresponding 
to 1 CNV locus 
remained 
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2.8.2.1.1 Extraction of SNP-arrays Intensity Data 
The Genotyping Module of GenomeStudio was used to generate and export the intensity file required 
for performing CNV analyses in PennCNV. This intensity file contained SNP ID, chromosome number, 
position, genotype, B-allele frequency (BAF) and log R ratio (LRR) information for all samples. LRR is a 
measure proportional to the total signal intensity, while the BAF is a measure of the relative 
contribution of the B allele to the total signal intensity. Therefore, LRR reflects the copy number at a 
particular position while BAF reflects the allelic composition at each SNP. LRR and BAF are measured in 
GenomeStudio using the formulas: LRR= log2 (X+Y), and BAF= Y/ (X+Y), where X = signal from the allele A, 
and Y=signal from allele B. SNP probes within normal copy number states are expected to have an LRR 
of zero and a BAF of 0, 0.5 or 1, corresponding to the three possible genotypes at each SNP. Analysis of 
these measures for the probes across the genome is used to identify CNVs (Peiffer et al. 2006). 
2.8.2.1.2 CNV Calling 
Prior to CNV calling, the intensity file exported from GenomeStudio was split using kcolumn.pl script 
available in PennCNV package in order to obtain a separate intensity file for each sample, and a signal 
list file containing the names of the 63 separate intensity files obtained. In addition, a Population 
Frequency of B allele (PFB) file was generated for the sample set using compile_pfb.pl script available in 
PennCNV. These files together with the HMM file available in PennCNV, which provides the program 
with information on the expected signal intensity values for different copy number states, were used for 
CNV calling.  
The calling was performed with a Perl script (detect_cnv.pl) available in PennCNV, which calculates the 
frequencies of loss and gain of each genetic marker and counts the total number of copies at each 
marker assuming two copies as the normal state. The calling step generated a report of the raw CNVs 
(deletions and duplications) detected in the 22 autosomal chromosomes of the samples. Copy number 
(CN) was presented as CN=0 for homozygous deletion, CN=1 for heterozygous deletion, CN=3 for 
heterozygous duplication and CN=4 for homozygous duplication. Two copies (CN=2) were assumed for 
each marker as the normal state and were not included in the CNV report.  The total number of raw 
CNVs detected in the 63 subjects was 5,759 CNVs. 
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2.8.2.1.3 Quality Controls and Filtering Steps 
The first quality control step performed on the raw CNV calls was to check the LRR_SD for each subject 
in order to identify and exclude low quality samples. According to PennCNV, the LRR threshold applied 
can be set to 0.24, 0.30 or 0.35 based on the user preference. In my dataset, the LRR_SD ranged 
between 0.127 and 0.315. The threshold applied was 0.35, therefore, none of the samples (n=63) were 
excluded based on this QC step. Figure 16 shows the standard deviation of LRR for each of the samples.  
 
Figure 16. The LRR standard deviation for each of the study samples 
 
Second, the perl script clean_cnv.pl was applied to the called CNVs in order to merge large adjacent 
CNVs (>500kb) that tend to be split automatically by PennCNV into smaller CNVs (ranged between 100-
150kb). I applied the default merging threshold which merges CNVs if the gap between them is less than 
20% of the total CNV length. CNV merging gave a total of 5,621 CNVs from the 5,759 CNVs that were 
originally called.  
Third, outlier samples were identified based on the total number of CNVs detected. The number of CNVs 
detected in each of the samples is shown in Figure 17. The average number of detected CNVs per 
sample was 89.2 and the standard deviation was 61. Outliers were defined as samples carrying total 
number of CNVs more than 2SD above the mean. A total of four outliers were detected from the 63 
samples and were excluded from further analyses, giving a total of 59 samples with 4,481 CNVs. 
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Figure 17. Number of CNVs detected in each of the study samples. 
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2.8.2.1.4 Identification of Genes Overlapping CNVs 
RefGene annotation was used to identify which genes encompassed the detected CNVs. This was done 
using the scan_region.pl script from PennCNV package and the RefGene annotation files refGene.txt and 
refLink.txt for build hg19 of the human genome reference, which are available at the University of 
California, Santa Cruz (UCSC) genome browser 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/). 
2.8.2.1.5 Visualization of CNVs 
The script visualize_cnv.pl in PennCNV was used to generate LRR and BAF plots of the CNVs. These plots 
allowed the visual examination of CNV calls for candidate CNVs (at later stages of the analysis) to judge 
whether these candidate CNVs were reliable or not.  
2.8.2.2 Analysis of the 4,481 CNVs Remained after Quality Control 
The remaining 4,481 CNVs were analysed further using two approaches as will be discussed below. The 
first approach was applied for the identification of common CNVs associated with BMI. While, the 
second approach was to identify potential large rare obesity CNVs, as was summarized by the workflow 
given in Figure 15. 
2.8.2.2.1 Association of Common CNVs with BMI 
The first approach was to focus on the identification of common obesity CNVs. SNP probes included in 
CNV regions ≥ 1kb and encompassing a minimum of 25 SNPs were retained for further analysis. This 
gave a total of 19,939 SNP markers corresponding to a total of 1,098 CNVs detected in the 59 samples. I 
then selected SNP markers that that had copy number change (i.e with CN status <>2) in more than 10% 
of the samples. This filter gave a total of 2,236 SNPs that correspond to 555 CNVs (and 39 CNV regions) 
detected in the 59 samples. The CNV states of these 2,236 SNP probes were tested for association with 
BMI. Since PennCNV does not handle extended pedigrees and cannot test for the association of CNVs 
with quantitative traits, I tested the association between the CNV calls generated by PennCNV and BMI 
using a linear mixed model that partitions the total phenotypic variance into polygenic and 
environmental variance. A matrix of the expected proportion of alleles shared IBD across the genome 
between each pair of individuals in the sample set was used to model the phenotypic 
variance/covariance. Copy number state was modelled as fixed effect whilst the polygenic effect 
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between family members was modelled as random effect. Covariates (age and gender) were also 
included in the model as fixed effects. 
A likelihood ratio test was used to calculate significance of association. The test compares the likelihood 
of the described full model and the likelihood of a null model where the effect of CNVs is constrained to 
zero. The obtained P-values were then corrected using False Discovery Rate (FDR), which is a widely 
used statistical method that corrects for Type I error when performing an analysis that involves multiple 
testing or comparisons (Benjamini et al. 2001; Storey 2002). I applied FDR of 5% as the significance 
threshold and significant associations were then further investigated. 
2.8.2.2.2 Investigation of Rare Obesity CNVs 
The second approach was to investigate rare CNVs, CNVs that are present in less than 1% of the 
population and are more than 500kb in size, for the purpose of identifying rare obesity CNVs. Due to 
small size of samples (n=63) in my study, I could not assess the rarity of the predicted CNVs in the Qatari 
population based on the observed frequencies. Therefore, I prioritized CNVs based on the number of 
SNPs they encompass and their sizes. CNVs that encompass less than 20 SNPs were excluded and this 
gave a total of 1,442 remaining CNVs. Performing this step can help reducing false positive CNVs in 
downstream steps and is likely to also retain larger CNVs. After that, large CNVs with a minimum size of 
500kb were prioritized, as they are more likely to represent rare CNVs, since large CNVs are likely to 
affect many genes and thus can be intolerated. A total of 24 large CNVs were detected, and eight of 
them that were located in centromeric regions were excluded (according to the centromeric coordinates 
of each chromosome). Centromeric CNVs were excluded because of the very low coverage of SNP 
probes in the centromeres, due to their highly repetitive DNA sequence, which means that CNVs called 
in these regions are likely to be false positives. After applying this step, a total of 16 large non-
centromeric CNVs remained. 
These CNVs were visually examined using their LRR and B allele frequency plots to investigate how 
reliable they are and were checked in other CNV datasets, including the childhood obesity (CHO) data 
and the adulthood obesity (ADO) data, the Saudi obesity and Mental retardation data and the 108 
Qatari genome data, which were described in Section 2.7, to select potential candidate obesity CNVs.  
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2.8.2.2.3 Validation of the 16p11.2 deletion using Multiplex Ligation-Dependent Probe Amplification 
Multiplex ligation-dependent probe amplification (MLPA) is a widely used technology for the validation 
of CNVs. The basic idea of MLPA is shown in Figure 18. Briefly, multiple probes are designed to target 
the sequence overlapping with the CNV region of interest.  Each primer consists of two halves, a left and 
a right half, each carrying a different universal primer sequence (X and Y), that is fluorescently labelled. 
The right half also contains a stuffer sequence with a unique size for each probe. After denaturation, the 
two halves of the probe hybridise to immediately adjacent genomic segments, and a ligation reaction is 
carried out to join the two halves of the probe. Then, the ligated probes are amplified using the 
universal pair of primers and subjected to fragment separation by capillary electrophoresis. The signal 
intensities are then normalised against a group of control probes outside the CNV region to infer the 
copy number state at the region of interest. 
In this study, MLPA was carried out to validate the presence/absence of the 16p11.2 deletion in Family 1 
members. This was done using the SALSA MLPA P343-B1 Autism-1 probemix kit (MRC Holland, cat: 
P343-050R), which is designed to target three chromosomal regions at the 15q11-q13, 16p11 and 
22q13. The probemix contains 49 probes including 11 test probes that target the 16p11.2 region and 
nine control probes that target non-copy number regions, given in Table 8. MLPA was conducted 
according to the MRC Holland protocol. Briefly, DNA Samples were diluted at a concentration of 20ng/ul 
using TE0.1. Then, 5ul of DNA were used in the MLPA reaction starting with DNA denaturation followed 
by hybridisation, ligation, PCR amplification and fragment analysis, as described in Table 9. 
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Figure 18. Schematic representation of the Multiplex Ligation-dependent Probe Amplification (MLPA) 
technology. The figure is modified from MRC Holland website with permission (see Appendix 2.4). 
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Probe ID Length 
(bp) 
Target 
gene 
5' half of the primer 3' half of the primer Start  (hg18) End (hg18) 
16p11.2 probes 
11677-L12448 481 LAT CCAAGCTGTGTCTCCTTTAC
CAGTTTGTAT 
CCAAGGGGCATCCAGTTCAAAC
GGCCTCGTGAGTACAAGG 
28,904,653 28,904,722 
11672-L12443 364 SPN CAACCTACCAGGAAGTTTC
CATCAAGATGT 
CATCAGTGCCCCAGGAAACCCC
TCATGCAAC 
29,582,828 29,582,888 
11669-L12440 238 MAZ CAATAGGCTTCACCACGGC
AGCAT 
ACCTGCGCATCCACGCGGTGAA
GGACCACGG 
29,728,356 29,728,410 
11673-L12444 418 MAZ CCAGAAGGAAAGGAGGAA
GAAATGTTT 
TCTTAGGGGAATTCGCTAGGTT
TTAACGATTTGTTTCTCCTGC 
29,729,166 29,729,235 
00550-L22423 344 MVP CGGGAAGTGGAGGTCGTG
GAGATC 
ATTCAGGCCACCATCATCAGGC
AGAACCAGGC 
29,752,775 29,752,829 
11668-L12439 208 SEZ6L2 GGAGGAAAGGTGGCAGCC
AGATTA 
CTTAGAGAGGCACAGAGGAGA
GAGATCGGGGTGAGTC 
29,817,845 29,817,905 
11674-L12445 454 HIRIP3 CCAAAGAGGAGAATCCAA
GGCGAGCCTCAA 
AGGCAGTTGAGGAGAGCAGTG
ATGAGGAACGGCAGAGGGA 
29,913,518 29,913,587 
11667-L14670 172 HIRIP3 GTGGATGAAGCCGCTTCCA
GGGAAGACA 
AACTGGACCTTACCAAGAAGG
GCAAGAGGCCTCCCAC 
29,913,975 29,914,038 
13162-L12447 226 DOC2A CCTACGTCAAGCTGCACTT
GCTGCCT 
GGAGCCTGTAAGGTAACAGCC
TCCTCTCGCCC 
29,928,004 29,928,061 
11675-L12446 465 MAPK3 CCTGGCAAGCACTACCTGG
ATCAGCTC 
AACCACATTCTGGGTGAGGGA
GGCCCGGCTG 
30,036,474 30,036,531 
11671-L12442 337 CD2BP2 CAGGAGGAGATGGAGGAA
GGCCACTT 
TGATGCCGATGGCAACTACTTC
CTGAACCGGGATG 
30,272,761 30,272,821 
Control probes 
09176-L09350 124 TRAF4 TGCCAAGGTGAGTCCACAC
TGCCAGGA 
AGAAGCCCAAGCACAGTCTGTT
GCCCTTGGA 
24,098,394 24,098,460 
09979-L10438 190 SMARCA4 TGGCGGCATTGTCCAAGG
GTGAGA 
AGCTTCCCAACTGGATGGGGT
GGGCAGGTGG 
10,998,005 10,998,059 
07208-L06858 409 GHRHR CCATAGCATCTCTATTGTA
GCCCTCTTCGT 
GGCCATCACCATCCTGGTTGCT
CTCAGGTTTGTCATC 
30,977,299 30,977,367 
09431-L09680 154 RBM14 TGCCACCTTCGACTACCAG
CAGGCTTT 
TGGCAACAGCACTGGTGGCTTT
GATGGGCAA 
66,148,469 66,148,526 
05297-L04685 328 PROS1 CAGGAGATTTTGAATGTGA
ATGCCCC 
GAAGGCTACAGATATAATCTCA
AATCAAAGTCTTGTGAAGGTAG
GAT 
95,102,326 95,102,403 
02658-L02125 250 ATM CTATATGTAGAGGCTGTTG
GAAGCTGCTT 
GGGAGAAGTGGGTCCTATAGA
TTTCTCTACCATAGCTATACAAC
ATA 
107,675,640 107,675,716 
09727-L10077 130 NOS1 TTGTAAGCGCGGACAGAC
ACTGCTGAACCT 
TTCCTCTGGGACCCCCTGTGGC
CCTCGCTCT 
116,137,405 116,137,465 
10243-L02149 265 SH3BP5L GCTGCACAACGCTGCTCGA
GAAATGGTGT 
TTGTGGCTGAGCAGGGCGTCA
TGGCTGACAAGAACCGACTGG
A 
247,075,309 247,075,380 
Table 8. The 16p11.2 probes and the control probes of the SALSA MLPA P343 Autism-1 probemix kit. 
Information source: MRC Holland, SALSA MLPA P343 Autism-1 probemix product description. 
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 Reaction (X1) 
 
Thermo-cycler condition 
Denaturation  5ul of DNA (at 20ng/ul) 95°C for 5 minutes 
25°C – pause 
Hybridisation  Hybridisation mix: 
1.5ul of SALSA MLPA buffer 
1.5ul of SALSA MLPA Probemix 
95°C for 1 minute  
60°C – pause 
Ligation Ligation mix: 
25ul ddH2O 
3ul of Ligase buffer A 
3ul Ligase buffer B  
1ul SALA Ligase-65  
45°C –pause 
Add 32ul of ligation mix 
54°C for 15 minutes 
98°C  for 5 minutes 
20°C – pause 
PCR 
amplification 
PCR mix: 
7.5 ddH2O 
2ul of SALSA PCR primer mix 
0.5 ul SALSA Polymerase  
35 cycles of: 
95°C for 30 seconds 
60°C for 30 seconds 
72°C for 60 seconds 
72°C for 20 minutes 
15°C – pause 
Fragment 
analysis 
Sample: 
0.7ul of PCR product (undiluted products and diluted 
products of  1:4, 1:8 and 1:16 dilutions)  
0.3 ul of Rox 500 
10 ul of HiDi fromamide 
Incubate for 3 min at 86°C, cool for 2 min at 
4°C. 
Injection voltage:1.6 kV 
Injection time: 15 seconds 
Run voltage: 15 kV 
Run time: 1800 seconds 
Oven temperature: 60°C  
Table 9. MLPA reaction mix and thermo-cycler conditions 
 
Fragment analysis was performed by the Genomic Core Facility in the faculty of medicine at Imperial 
College. The samples were run on an ABI 3730xl capillary electrophoresis instrument (Applied 
Biosystems) that uses DS-30 as the standard dye set. The analysis of the MLPA data was performed using 
Coffalyser.Net (available at http://coffalyser.wordpress.com/ ) by following the instructions given in 
their manual. Briefly, the default parameters for the capillary system ABI 3730xl were selected and the 
filter set, which defines the fluorescent dye which the machine recognizes, was set to ‘D’ since in the 
experiment a FAM label was used for probe labelling and ROX500 as size marker (GS500-250). The 
experiment type was set to “DNA-MLPA” analysis and the Coffalyser work sheet for the SALSA MLPA 
P343-B1 Autism-1 probemix kit, which contains the probes information, was selected.   Then, the 
fragment data traces files (*.fsa), which contain the raw signal data, were imported and the sample type 
was defined either as sample (for five test samples), reference sample (for three samples expected to 
have normal copy number state), or no DNA (for three no DNA samples that were processed to ensure 
that no reagents were contaminated). Thereupon, the fragment analysis was run using the default 
“auto-bin” as the probe recognition method. This method creates a common probe length reference 
vector across the samples based on the predicted probe product lengths, and matches each peak to 
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probe ID. Comparative analysis was then carried-out involving two normalisation steps: 1) intra-
individual normalisation by dividing the peak height of each of the test probes by the mean peak height 
of the nine control probes. This step is important to control for probe bias due to probe properties, and 
2) inter-individual normalisation by dividing the normalised peak heights (from step 1) by the mean of 
the corresponding probes in the reference samples. The final ratios for each test sample were visualized 
to facilitate the detection of the presence or absence of the 16p11.2 deletion.   
2.8.3 Identification of Differentially Methylated Sites with BMI 
As discussed in Section 2.6.3, genome-wide methylation profiling data was generated for 96 subjects 
using the Infinium HumanMethylation450 Beadchip. My DNA methylation data was analysed together 
with another DNA methylation dataset on Qatari families that was generated by my colleague Wadha Al 
Muftah, as described Section 2.7.4.  The combined dataset consists of a total of 123 subjects from 16 
Qatari families. The methylation data was extracted, quality controlled and then analysed for differential 
methylation with BMI, as described below. 
2.8.3.1 Extraction of DNA Methylation Data 
First, the methylation module of GenomeStudio (Illumina) was used to pre-process the raw DNA 
methylation intensity data, according the manufacturer’s recommendations. The total number of 
subjects was initially 123 and total number of methylation probes was 485,577 (including 482,421 CpG 
probes, 3091 CpH probes (H = A/C/T) and 65 SNP genotyping probes). 
For each interrogated CpG site, GenomeStudio assigns a beta-value (b-value), which is a widely used 
quantitative measure for DNA methylation levels calculated as the ratio of the methylated probe 
intensity to the total intensity. B-values range between 0 and 1, where 0 shows absence of methylation 
and 1 shows complete methylation (Du et al. 2010; Marabita et al. 2013). Another method for 
measuring methylation levels is using the M-value which is simply the logit transform of the b-value (Du 
et al. 2010). The range of M-values may vary across different datasets and they exhibit bimodal 
distribution, where the positive mode represents the methylated status and the negative mode 
represents the unmethylated status (Du et al. 2010). Both methods can be used interchangeably in 
methylation studies (Du et al. 2010). 
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2.8.3.2 Quality Control of DNA Methylation Data 
Quality control (QC) was carried out on the extracted DNA methylation data in order to reduce technical 
variability before performing differential methylation analysis and drawing biological conclusions. The 
QC steps were performed based on the lumi: quantile normalisation (QN) + beta mixture quantile 
dilation (BMIQ) normalisation pipeline. This pipeline was selected as the most optimal pipeline for pre-
processing of Infinium HumanMethylation450 Beadchip data by Marabita et al. based on their 
evaluation of six different analysis pipelines (Marabita et al. 2013). 
2.8.3.2.1 Sample Filtering 
The first quality step aimed to exclude samples with low percentage of detected sites or with abnormal 
distributions of intensities and/or b-values. All samples had high percentage of detected sites with an 
average of 99.5% (with P-value <0.01) and followed the expected data distributions. Therefore, no 
samples were excluded based on these criteria. 
2.8.3.2.2 Probe Filtering 
The methylation dataset contained a total of 11,135 probes on the X chromosome and 416 probes on 
the Y chromosome. These probes were filtered out from the dataset to avoid any potential bias in the 
downstream differential methylation analysis that may arise due to differences in the proportion of 
males and females in the dataset. Therefore, the total number of remaining probes became 470,870 
probes. 
After that, the detection P-value for each probe was calculated in GenomeStudio by comparing the 
intensity of the probe to the average intensity of the negative control probes (600 probes), as an 
estimate of the strength of DNA hybridisation over the background. Probes with high detection P-value 
of >0.01 in more than 5% of samples were discarded as the values obtained from those probes appeared 
not reliable. A total of 2,398 probes were excluded leaving 468,472 probes. 
The existence of SNPs within the query site or probe region has a potential risk of interference with DNA 
methylation measurements. Since the Infinium assay is based on the quantitative genotyping of C/T 
SNPs at the CpG query sites after bisulfite conversion, the presence of a C/T polymorphism at the query 
site may confound methylation measurements (Dedeurwaerder et al. 2014). This means that in the case 
of a fully methylated site, for example, methylation measurement can approach 1 in subjects carrying 
C/C genotypes while it will be close to 0 in subjects with T/T genotype and will be around 0.5 in subjects 
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with C/T genotype (Dedeurwaerder et al. 2014). Thus, the methylation measure is not a true reflection 
of methylation status of the query site but rather the genotype. SNPs within probe regions might also 
affect methylation measurements by interfering with probe binding. Therefore, in the Human Infinium 
HumanMethylation450 Beadchip assay design, Illumina avoided assays that included known SNPs 
positions (from dbSNP). In 65 instances, regions of interest were covered by assays that included SNP 
positions and were described in Illumina manifest. These probes were excluded from my dataset giving a 
total of 468,407 remaining probes. Since WGS data were also available in my study, the methylation 
values were set to missing if a genetic variant was present within ±110 base pairs of the CpG query sites 
to avoid potential bias due to SNP existence, and these represented 0.5% of the methylation sites. 
2.8.3.2.3 Colour-Bias Adjustment 
As discussed in Section 2.6.3, Infinium HumanMethylation450 Beadchip contains two different types of 
assays. Infinium I assay has two bead types (methylated and unmethylated) for each CpG site and the 
signals generated are reported by the same colour channel. Infinium I assay represent 30% of the 450k 
array probes (20% are reported via the red channel and 10% via the green channel). On the other hand, 
Infinuim II assay has single bead type per CpG locus and the signals are reported by two different colour 
channels depending on the label colour of the nucleotide added at the final extension step (A or T 
nucleotides measured on the red channel while C or G nucleotides on the green channel) (Bibikova et al. 
2011). Differences in labelling and scanning properties of the two colour channels may result in some 
inconsistencies in the intensities measured especially in the case of Infinium II assay (Marabita et al. 
2013). To correct for this potential colour-bias, a normalisation step of the two colours was performed 
on the intensity data using the smoothQuantileNormalisation method available in the R package lumi 
(Du, Kibbe, Lin 2008). Figure 19 shows the reduction in colour-bias between the two channels after 
performing the colour-bias adjustment step. 
2.8.3.2.4 Quantile Normalisation (QN) 
Variations in intensity measurements between samples might arise from technical issues such probe 
type and sample position on the slide. Quantile normalisation (QN), which is available in the lumi 
package (Du, Kibbe, Lin 2008), was applied to normalise the intensities after colour-bias adjustment, 
assuming that the distribution of intensities is similar across samples. Figure 20 shows the reduction in 
between-sample variation after quantile normalisation. 
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Figure 19. Boxplots of CpG sites intensities for the two colour channels per sample. A) Before colour-bias adjustment, and B) After colour-bias 
adjustment. The circles represent outliers, and the red and green boxes represent the red colour channel and the green colour channel 
respectively. 
2. Materials and Methods 
108 
 
 
Figure 20. Boxplots of the colour adjusted CpG sites intensities per sample after quantile normalisation. The circles represent outliers, and the 
red and green boxes represent the red colour channel and the green colour channel, respectively. 
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2.8.3.2.5 Beta Mixture Quantile Dilation (BMIQ) Normalisation 
Due to their different chemistries, Infinium I and Infinium II assays exhibit distinct distributions of b-
values. In general, the peak of Infinium I assay at the extreme ends of methylation are usually further 
out compared to Infinium II, showing that Infinium I assay has an extended dynamic range of measured 
methylation b-values compared to Infinium II assay. This is due to the fact that Infinium I assay is more 
likely to be the assay of choice for targeting CpG islands (Zaghlool et al. 2015). 
Based on previous experience (Marabita et al. 2013), assay type bias does not sufficiently reduce with 
quantile normalisation. Therefore, beta mixture quantile dilation (BMIQ) normalisation was applied on 
the b-values of the quantile-normalised intensity data in order to match the distribution of the two 
assay types, especially at the extreme ends (Teschendorff et al. 2013). BMIQ is a quantile normalisation-
based method that decomposes the density profile of Infinium I and Infinium II assays into two groups of 
three b-value distributions; unmethylated (close to 0), methylated (close to 1) and hemi-methylated 
(close to 0.5), and then it applies quantile normalisation to fit each of the b-value distributions of 
Infinium II to its corresponding b-value distribution of the Infinium I (Dedeurwaerder et al. 2014; 
Teschendorff et al. 2013).  Figure 21 shows the effect of BMIQ normalisation on the b-values 
distribution. 
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Figure 21. Histograms of DNA methylation profiles (b-values) for one of the study subjects (QO_F7_09) 
showing the effect of BMIQ normalisation. A) Before BMIQ normalisation, and B) after BMIQ 
normalisation. The extra peak in A) is due to the probe bias. Figure is reproduced from Zaglool et al. 
(Zaghlool et al. 2015). 
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2.8.3.2.6 Adjustment for Cellular Heterogeneity 
Whole blood is composed of a cocktail of different cell subtypes in uneven fractions, and these subtypes 
carry unique DNA methylation profiles (Houseman et al. 2012; Reinius et al. 2012). This means that 
differential methylation at some CpG sites between cases and controls might not reflect real differences 
in DNA methylation patterns but rather reflects changes in the proportion of these subtypes as a 
consequence of disease for example. 
Due to the fact that the methylation profiles in this study were generated from whole blood-DNA, it was 
necessary to take the potential confounding effect of cellular heterogeneity into account (Michels et al. 
2013). One way of quantifying cell type composition is using flow cytometry approach. However, it was 
difficult to implement this approach in the study since it requires large volumes of fresh blood sample, 
labour-intensive antibody tagging and timely cell analysis (Zaghlool et al. 2015). Housman et al. 
(Houseman et al. 2012) have recently developed and validated a statistical method called 
MethylSpectrum implemented in the MethylSpectrum software that permits the estimation of cell type 
composition at data level rather than blood sample level. This method uses reference information on 
unique DNA methylation signatures for each of the principle immune components in blood (monocytes, 
granulocytes, NK-cells, B-cells, CD8+-T-cells, and CD4+-T-cells) to estimate the cell-type distribution in 
study samples using their individual genome-wide methylation profiles.  
Liu et al. applied the MethylSpectrum method in their methylation study on rheumatoid arthritis to 
obtain cell type information (cell type coefficients) from the HumanMethylation450 array data derived 
from whole blood-DNA (Liu et al. 2013). They showed that adjusting for cell type information in 
differential methylation analysis has a notable reduction in the association signals obtained, showing the 
importance of such adjustment in removing false positive signals. Therefore, I applied the 
MethylSpectrum method, using the MethylSpectrum software (version 2.0), to the methylation data and 
included the cell type coefficients calculated as covariates in the association model between DNA 
methylation and BMI. 
2.8.3.3 Association of DNA methylation with BMI 
Association of DNA methylation levels with BMI was performed using a Java package called Population 
and Pedigree Association Testing of the Epigenome (PopPANTE), available at FIXME 
(https://sites.google.com/site/populationgenomics/poppante). PopPANTE uses the DNA methylation 
data in a variance component framework to model the resemblance among family members. The 
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association between the phenotypic traits of interest (BMI) and DNA methylation levels was evaluated 
using linear mixed model, where DNA methylation level was modelled as a fixed effect while the 
phenotypic variance (environmental and polygenic variance) was modelled as a random effect. A matrix 
of the expected proportion of alleles shared IBD across the genome between each pair of individuals in 
the sample set was used to model the phenotypic variance/covariance. 
The association model can also be extended to include covariates as fixed effects. In my study age, 
gender, T2D status and the six cell type coefficients were included as covariates.  A likelihood ratio test 
between the full model and the null model where the effect of DNA methylation values is constrained to 
zero, was used to evaluate the significance of association. The differentially methylated CpGs were then 
annotated using the IlluminaHumanMethylation450k.db package in R. Quantile-Quantile (QQ) plot was 
generated to ensure that the association statistics were not inflated. 
2.8.3.4 Selection of CpG Associations with BMI for Replication 
I aimed to replicate the major associations from two large EWASs that were published at the time of this 
study (Dick et al. 2014; Sun.D. et al. 2014). This includes three CpG sites at ATP-binding cassette, sub-
family G (WHITE), member 1 (ABCG1), carnitine palmitoyltransferase 1A (CPT1A) and  ring finger protein 
145 (RNF145) that were reported by Sun et al. (Sun.D. et al. 2014), and three CpG sites at the hypoxia 
inducible factor 3, alpha subunit (HIF3A), clustered mitochondria (cluA/CLU1) homolog (CLUH), Kruppel-
like factor 13 (KLF13) that were reported by Dick et al. (Dick et al. 2014). I attempted to replicate the 
strongest association for each reported locus. I did not carry out the association only at the selected 
probes in order to avoid missing any potential inflation of the association statistics that might be due to 
the limited size of the sample set. Instead, I first performed an EWAS and assessed inflation through QQ-
plot and calculation of the lambda inflation coefficient of the EWAS. To correct for multiple testing, 
associations were considered replicated if the association P-value was below 8.33x10-3 (0.05/6).  
2.8.3.5 Association of DNA Methylation with BMI in the TwinsUK Cohort 
The association of two CpG sites at ABCG1 and CPT1A with BMI was performed on the TwinsUK data. 
This was carried out by my supervisor Dr Mario Falchi and my colleague Dr Alessia Visconti, who are 
currently working at Kings College, and have access to the data. For this analysis, probes with detection 
P-value >0.05 or missing values were removed and blood cell type coefficients were estimated from the 
methylation data using the Houseman method (Houseman et al. 2012). The association was then 
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assessed with a linear mixed effect model using also PopPANTE to correct for family and zygosity in the 
TwinsUK cohort. 
Similar to the association model in the Qatari data, the model included DNA methylation level as fixed 
effect and the phenotypic variance as random effect. A matrix of the expected proportion of alleles 
shared IBD across the genome between each pair of individuals in the sample set was created using the 
R package kinship2 (Therneau et al. 2014) to model the phenotypic variance/covariance. The covariates 
T2D status and the blood cell types coefficients for monocytes, granulocytes, NK-cells, B-cells, CD8+-T-
cells, and CD4+-T-cells were included as fixed effects. 
2.8.3.6 Meta-analysis of the DNA Methylation association studies with BMI using the Qatari and the 
TwinsUK data 
A meta-analysis between the Qatari and the TwinsUK sample sets was performed for the associations of 
the two CpG sites at ABCG1 and at CPT1A with BMI. This was carried out using the GWAMA (Genome-
Wide Association Meta-Analysis) software (Magi and Morris 2010). The regression coefficients with their 
standard errors form the Qatar and the UK studies were combined using a fixed-effect model with 
inverse variance, and the heterogeneity between the two studies was estimated using the Cochran’s Q 
test and by measuring the proportion of variability that is explained by between-trial heterogeneity both 
implemented in GWAMA. 
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3. Identification of Rare Obesity Mutations 
As introduced in Section 1.7.2, there is a growing evidence that rare variants play a role in the 
susceptibility of obesity and other complex diseases (Blakemore et al. 2009; Bodmer and Bonilla 2008; 
Creemers et al. 2012; Ichimura et al. 2012; Nejentsev et al. 2009; Pearce et al. 2013; Pritchard 2001; 
Schork et al. 2009). Therefore, one of the aims of this study was to identify rare obesity mutations that 
may confer susceptibility to obesity in my sample set.  
As discussed in Section 1.7.1, family-based designs offer an opportunity for enrichment of rare disease 
variants with increased locus specific heritability, which can facilitate the detection of rare disease 
variants. The strategy I applied was to perform whole genome sequencing in families with multiple 
affected individuals from the Qatari population and to combine linkage and ROH evidence in these 
families to narrow down the regions and thus variants of interest.  
The linkage and ROH analyses were performed using the SNP genotyping data available for a total of 63 
subjects (34 obese, 17 lean and 12 overweight). These subjects are indicated by the “GSM” label in their 
pedigrees which are given in Figure 2 in Section 2.4. I then selected potential obesity variants based on 
variant prioritization analyses through Ingenuity Variant Analysis, gene functions and the available 
relevant literature using the WGS data for the 34 obese and 17 lean subjects. In addition, I validated the 
candidate variants in the families in whom they were detected using Sanger, and attempted to replicate 
the identified variants in a population-based cohort from Qatar that is described in Section 2.7.1. 
Methods that are relevant to this chapter are given Section 2.8.1 while the results and discussion are 
presented below. 
3.1 Identification of Candidate Obesity Regions 
3.1.1 SNP-Array Genotyping and Quality Control 
SNP array genotyping was performed using the HumanOmni2.5-8 SNP array for 63 samples (34 obese, 
17 lean and 12 overweight). The genotypes were extracted from the raw intensities using 
GenomeStudio (Illumina). All samples had genotyping call rates > 95% and inferred gender was 
consistent with clinical information. The genotyping data were subjected to a group of quality control 
steps using Plink (Purcell et al. 2007), Pedstats (Abecasis and Wigginton 2005), Pedwipe and Merlin 
(Abecasis et al. 2002), for the purpose of identifying candidate obesity regions through linkage and ROH 
analyses. 
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3.1.2 Linkage Analysis 
As discussed in Section 2.8.1.1, linkage analysis was conducted with 20,872 SNP markers selected using 
Method A, which is based on markers informativeness and LD pruning, since they provided higher 
information content (IC) (average IC= 0.80) and higher marker’s density (average genetic distance 
between markers= 0.13cM) compared to Method B, which was based on Illumina’s V panel linkage 
marker set (average IC= 0.72, and average genetic distance 1.7cM).  
For the purpose of the NPL for obesity as adiscrete trait, the obese (n=34) and the lean (n=18) subjects 
were considered while the overweight subjects were set as unknowns (n=11). For the VC analysis for 
obesity-related traits, all 63 subjects were considered. The results of NPL VC linkage were expressed as 
LOD scores. LOD scores ≥3.3 are usually considered as significant linkage signals while LOD scores ≥1.9 
as suggestive (Lander and Kruglyak 1995), though these criteria may be too strict for this small sample 
size. None of the signals detected for NPL and VC showed significant linkage. The highest signal for NPL 
was on 3p14.1 with a LOD score of 1.4. For the variance component analyses, two suggestive signals 
were obtained at same position on 16p12.3 with a LOD score of 2.3 and 2.1 for muscle mass percentage 
and fat-free mass (FFM) respectively. In addition, another suggestive signal with LOD score of 2.1 was 
detected on 10q23.1 with muscle mass percentage. Linkage signals with LOD scores ≥1 were considered 
as regions of linkage, and the linkage regions were defined as the region within a drop of 1 LOD score on 
both sides of the obtained linkage signals, as shown in Table 10. The NPL plots are given in Figure 22, 
and the VC linkage plots for the signals with LOD scores ≥1.5 are given in Figure 23. NPL and VC linkage 
plots for all of the 22 autosomes are shown in Appendices 1.4 and 1.5 respectively.  
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Chr. Trait Peak SNP Peak SNP 
position (cM) 
 
Peak SNP position 
(bp) 
LOD 
score 
Region start 
position (bp) 
Region end 
position (bp) 
Region cytoband Empirical 
P-value 
 
Most contributing  
family 
 
LOD of most 
contributing family 
Nonparametric linkage 
3 Obesity rs9809725 92.866 69,541,799 1.4 54,807,240 76,126,167 p14.3-p12.3 6.3X10
-
3
 
6 0.4 
13 Obesity rs259730 51.79 46,845,976 1.3 41,820,714 67,752,445 q14.11-q21.32 6.7X10
-
3
 
4  0.6 
14 Obesity rs11623206 77.50 76750175 1.1 91,871,744 80,182,967 q22.2-q31.1 1.2X10
-
2
 
9  0.9 
Variance component linkage 
16 Muscle mass rs1457907 38.034 17,346,236 2.3 13,616,086 25,248,442 p13.12-p12.1 5.6X10
-4
 7  1.4 
16 FFM rs1457907 38.034 17,346,236 2.1 13,616,086 25,248,442 p13.12-p12.1 9.8X10
-4
 7  1.2 
16 Bone mass rs1457907 37.793 17,346,236 1.8 13,364,121 26,564,980 p13.12-p12.1 1.8X10
-3
 1  1.2 
16 BMR rs1457907 37.793 17,346,236 1.3 740,466 49,767,921 p13.12-q12.1 7.6X10
-3
 7  0.9 
10 Muscle mass % rs5029676 107.377 87,189,235 2.1 77,379,512 93,347,297 q22.2-q23.32 1.0X10
-
2
 
9  1.2 
10 Waist 
circumference  
 
rs1655155 170.916 87,189,235 1.6 13,074,4348 134,316,622 q26.3-q26.3 3.8X10
-
3
 
1  0.7 
10 FFM% rs2286741 131.279 115,388,588 1.4 105,517,583 118,359,548 q24.33-q25.3 5.6X10
-3
 1 0.8 
10 FFM% rs7086375 61.307 35,246,612 1.4 27,851,166 37,066,341 p12.1-p11.21 6.1X10
-3
 7  0.8 
10 Bone mass rs2817683 117.44 98,838,694 1.0 63,043,987 121,922,699 q21.2-q26.12 1.5X10
-2
 1  0.6 
10 BMR rs902467 117.739 98,923,531 1.0 63,043,987 121,480,161 q21.2-q26.11 1.5X10
-2
 1  0.6 
13 Waist 
circumference  
 
rs9550629 51.79 20,881,255 1.4 34,637,818 63,816,136 q32.33-q11.2 5X10
-3
 1  0.8 
14 FFM% rs10131138 13.193 21,061,167 1.5 107,287,663 23,244,138 q32.33-q11.2 4.4X10
-3
 1  1.0 
14 Fat mass rs1766142 40.346 36,696,327 1.3 33,442,259 56,418,830 q13.1-q22.3 7.8X10
-3
 9  1.1 
14 FFM% rs3736824 14.753 21,821,821 1.2 107,287,663 23,244,138 q32.33-q11.2 1.0X10
-2
 1  1.0 
14 Fat% rs1766142 40.346 36,696,327 1.1 33,442,259 54,081,493 q13.1-q22.1 1.2X10
-2
 9  1.5 
5 FFM% rs1175072 156.841 150,887,925 1.3 140,372,222 158,131,574 q31.3-q33.3 7.8X10
-3
 9  0.8 
5 Bone mass rs6556877 108.369 94,952,136 1.1 81,710,048 123,449,266 q14.2-q23.2 1.2X10
-2
 1  0.7 
5 FFM% rs349682 146.803 143,849,358 1.1 134,769,827 162,600,918 q31.1-q 34 1.3X10
-2
 9  1.0 
18 FFM% rs6506399 22.387 6,489,772 1.1 4,318,407 33,015,239 p11.31-q12.2 1.2X10
-2
 9  0.6 
18 Muscle mass % rs4362456 25.144 7,416,263 1.1 4,318,407 33,015,239 p11.31-q13.33 1.2X10
-2
 9  0.9 
20 FFM% rs6015458 100.463 57,807,095 1.1 52,677,959 59,491,673 q13.2-q13.33 1.1X10
-2
 1  0.7 
20 Bone mass rs2427386 113.273 61,323,883 1.0 55,555,203 217,281 q13.31-p13 1.6X10
-2
 1  0.4 
Table 10. Summary of the signals with LOD score of ≥1 for NPL and VC linkage. Coordinates are according to GRCh37/hg19 genome assembly.
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Figure 22. The NPL signals with LOD scores ≥1.0 on chromosomes 3, 13 and 14. 
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Figure 23. The VC linkage signals with LOD ≥1.5 on chromosomes 16, 10 and 14. 
Muscle mass Fat-free mass 
Bone mass Muscle mass percentage 
Fat-free mass percentage Waist circumference 
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3.1.3 Run of Homozygosity Analysis 
As discussed in Section 2.8.1.2, ROH analysis was performed for the 63 samples (34 obese, 17 lean and 
12 overweight) using the SNP array genotyping data after the exclusion of SNPs with: >5% missing 
genotypes, MAF<0.05, deviation from HWE and Mendelian errors. Overlapping ROH regions detected in 
the samples were given by Plink as ROH pools.  When considering ROH regions of all subjects in the 
dataset (34 obese, 17 lean and 12 overweight), 279 ROH pools were identified in the 22 autosomal 
chromosomes. When considering the ROH regions of the obese and lean subjects only, a total of 248 
ROH pools were identified. Out of these 248 ROH pools, 168 pools contained more obese than lean 
subjects with enrichment >1. Enrichment was calculated as (number of cases with ROH * number of 
controls without ROH)/ (number of cases without ROH * number of controls with ROH). These pools 
were considered as candidate regions and were checked for overlap with candidate linkage regions.  A 
total of 47 ROH pools were overlapping with 14 candidate linkage regions, as given in Table 11.  
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Chr. Linkage trait Linkage region start 
(hg19) 
Linkage region end 
(hg19) 
ROH pools overlapping with linkage 
regions (number of subjects showing 
overlap) 
3 Obesity 54,807,240 73,964,127 S1 (6), S4 (2), S5 (3) 
5 FFM % 140,372,222 158,131,574 S12 (2), S13 (2) 
5 Bone mass 82,904,528 123,449,266 S6 (2), S7 (2), S8 (1), S9 (1), S17 (2), S20 (2), 
S35 (1) 
5 FFM% 134,769,827 162,385,429 S12 (2), S13 (2) 
10 Muscle mass % 77,379,512 93,347,297 S1 (5), S35 (3) 
10 Waist circumference  130,744,348 133,198,982 S5 (3), S11 (3) 
10 FFM % 105,727,659 117,718,290 S20 (1), S1 (5), S35 (3), S14 (2), S20 (1) 
10 BMR 63,043,987 121,480,161 S1 (5), S35 (3), S14 (1), S20 (5) 
13 Waist circumference  34,637,818 61,201,257 S8 (5) 
14 Obesity 54,221,757 78,870,408 S1 (4), S2 (1) 
18 FFM % 4,468,352 33,015,239 S35 (3), S14 (1) 
18 Muscle mass % 4,468,352 33,015,239 S35 (3), S14 (1) 
20 FFM% 53,647,394 58,795,536 S10 (1), S11 (3), S24 (2) 
20 Bone mass 217,281 56,511,689 S1 (4), S2 (4), S3 (4), S4 (4), S7 (3), S8 (3), S9 
(2), S10 (1), S11 (2), S24 (2) 
Table 11. Summary of overlapping regions between linkage and ROH regions. Column 5 of the table 
provides the IDs of the ROH pools that overlap with the linkage region and the number of subjects 
within the pool that show the overlap with the linkage region is given between brackets. Expanded table 
providing lists of all genes located within these regions is provided in the Appendix 1.6.
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3.2 Identification of Candidate Obesity Variants 
3.2.1 Whole Genome Sequencing and Quality Control 
Whole genome sequencing was performed for 63 subjects (34 obese, 17 lean and 12 overweight) with 
the Illumina’s HiSeq 2500 platform. As discussed in Section 2.8.1.3, the data were analysed using the 
pipeline implemented at WCMC-Q shown in Figure 10. All samples had good overall Phred scores and 
had average GC content close to the expected (about 40%).  The average depth of sequencing across the 
samples was 39.5 and the average number of sequencing reads was 659,841,529. The average number 
of called SNPs per genome (using GATK multi-sample calling) was 3,884,771 SNPs. In addition, high 
concordance was observed between the genotyping calls obtained from the HumanOmni2.5-8 
genotyping arrays and the WGS pipeline, which demonstrated the accuracy of these two genotyping 
methods that were used in this study. 
3.2.2 Ingenuity Variant Analysis (IVA) 
A multi-sample VCF containing the variants information for the obese (n=34) and the lean (n=17) 
subjects was uploaded into IVA for the purpose of identifying potential rare obesity variants in the 
dataset. A total of 16,470,959 SNP variants present in the VCF were annotated in IVA. Table 12 provides 
an overview on these variants. 
Four major filters were applied on the 16,470,959 variants that were identified in the 51 genomes, 
including confidence filter, frequency based filter, predicted-deleterious filter, and biological context 
filter in order to obtain a short list of potential obesity-relevant variants. This gave a total of 89 variants 
in 53 genes (see Section 3.22 for details). These variants were analysed further using two approaches.  
The first approach was to prioritize variants within the known monogenic obesity genes (LEP, LEPR, 
POMC, MC4R, SIM1 and PCSK1). While, the second approach for studying the 89 variants was to focus 
on variants located within the candidate obesity regions identified, including 1) overlapping regions 
between linkage and ROH, 2) linkage regions, and 3) ROH regions, as summarized by the workflow in 
Figure 24. These analyses gave four candidate variants given in Table 13. 
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Total number of variants 16,470,959 
Total number of genes 21,999 
Rare variants (MAF < 1%)* 
Total number of variants 
Non-synonymous variants 
Synonymous variants 
Noncoding variants 
Variants present in dbSNP 
Variants not present in dbSNP 
  
8,564,188 variants  
19,164 variants  
2,123 variants  
8,542,910 variants  
6,918,484 variants 
1645,704 variants  
Common variants (MAF ≥ 0.5%)* 
Total number of variants 
Non-synonymous variants 
Synonymous variants 
Noncoding variants 
Variants present in dbSNP 
Variants not present in dbSNP 
  
6,384,161 variants  
14,709 variants 
451 variants  
6,369,010 variants  
6,370,757 variants 
13,404 variants 
Table 12. Overview of the variants uploaded into IVA. 
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Figure 24. Variant prioritization workflow for the identification of potential rare obesity variants. 
Green boxes show the major filtering steps performed in IVA while blue boxes how the focused analysis 
within the monogenic obesity genes and the candidate obesity regions.  
All SNPs in 51 subjects 
(16,470,959 SNPs in 21,999 genes) 
Confidence filter  
(no SNPs were filtered out) 
Frequency-based filter  
(6,786,327 SNPs in 20,966 genes 
remained) 
Predicted-deleterious filter 
(2,699 SNPs in 1,877 genes 
remained) 
Interesting 
candidates 
Type of 
analysis   
A) Variants within 
monogenic genes 
(2 variants in 2 
genes) 
A variant in PCSK1 
Overlapping linkage & 
ROH regions 
(3 variants in 2 genes) 
Linkage regions 
(8 SNPs in 7 genes) 
ROH regions 
(39 variants in 26 
genes) 
A variant in NMUR2 No promising variants 
Two variants in: 
CLOCK 
RETSAT 
 
B) Focused analysis on 
variants within candidate 
regions 
(50 SNPs in 35 genes) 
Biological context filter 
(89 SNPs in 53 genes remained)  
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Chr. 
 
Position 
 
Ref 
allele 
Alt 
allele 
dbSNP ID 
 
Region 
 
Gene 
symbol 
Protein 
variant 
Cases 
 
Controls 
 
Impact 
 
SIFT 
prediction 
SIFT score 
 
PolyPhen-2 
prediction 
 
Conservation 
phyloP P-value 
 
Family 
5 95,764,963 C T rs1799904 Exonic PCSK1 p.R80Q; 
p.R33Q 
1 0 Missense Tolerated 0.12 Possibly 
damaging 
1.74X10
-4
 3 
5 151,784,043 C T - Exonic NMUR2 p.W211* 2 0 Stop gain - - - 1.46X10
-6
 9 
4 56,348,952 T C - Exonic CLOCK p.M1V 2 1 Start loss Damaging 0 Benign - 7 
2 85,578,069 A C - Exonic RETSAT p.L144R 2 0 Missense Damaging 0 Probably 
damaging 
1.60X10
-5
 4 
Table 13. Candidate obesity variants identified in this study. Coordinates are given according to the GRCh36/hg18 genome assembly and allele 
coding based on the positive strand.  
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3.2.3.1 The Rare Variants in LEPR and PCSK1 Genes 
The analysis of variants within the monogenic obesity genes gave two variants only; one in leptin 
receptor (LEPR) and the other in proprotein convertase subtilisin/kexin type 1 (PCSK1). The LEPR variant 
was a heterozygous missense mutation (p.S1007C) that has been previously reported in dbSNP 
(rs145651189) with a frequency of 0.09% in the 1000 genome project data and 0.04% in the NHLBIESP 
exomes data. The variant was present in 1 case and two controls in my study, and was predicted to be 
tolerated and benign by SIFT (SIFT score > 0.05) and polyphen-2, respectively. Thus, this variant did not 
seem promising.   
The variant in PCSK1 was a heterozygous missense variant (p.R80Q) that has been previously reported in 
dbSNP (rs1799904) with a frequency of 0.87% in the 1000 genome projecdataset. This rare variant was 
detected in one case only in my study (BMI=30.1kg/m2) who was also diabetic. The variant was 
predicted to be tolerated by SIFT but possible damaging by Polyphen-2. Therefore, the variant seemed 
to be of potential interest. Sanger sequencing confirmed the presence of the PCSK1 variant in the 
subject in whom it has been detected and also confirmed its absence in the other family 3 members, as 
illustrated in Figures 25 and 26. 
3.2.3.2 The Rare Variant in NMUR2 Gene 
The most promising variant within the overlapping regions between linkage and ROH was a novel stop 
gain variant (p.W211*) in neuromedin U receptor 2 (NMUR2). The overlapping region was on 
chr5:141,912,239-155,615,071 (build: hg19). The linkage region was identified on chr5:134,769,827-
162,385,429 (build: hg19) with fat free mass percentage (FFM %), and the most contributing family to 
the signal was family 9. The ROH was identified in two cases, one from family 9 and one from family 8. 
The variant was detected in two cases from family 9. In one case (QO_F9_02, BMI= 46.1kg/m2), the 
variant was in homozygous state (and it is one of the cases in whom the ROH has been detected), while 
in the other case (QO_F9_08, BMI= 30.2kg/m2), the variant was seen in heterozygous state. The variant 
was not present in any of the controls, and was not also seen in data from the 1000 Genome project, the 
public Complete Genomics genomes or the NHLBIESP exomes.  
Sanger sequencing was performed to confirm the presence of the variant in the two cases and also to 
check the genotypes of all Family 9 members with available DNA samples (n=17) including the 
overweight subjects, in order to obtain more information about the segregation of the variant in the 
family. As illustrated in Figures 25 and 26, Sanger sequencing has shown that the NMUR2 variant is 
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present in a total of 3 cases (1 homozygous and 2 heterozygotes) out of 10 cases, and in 4 overweight 
subjects (1 homozygous and 3 heterozygous) out of 6 overweight subjects. None of the four controls in 
the family had the variant.  
3.2.3.3 The Rare Variant in CLOCK Gene 
One of the candidate obesity variants is the novel missense variant (p.M1V) in the circadian locomotor 
output cycles kaput (CLOCK) gene, detected in a candidate ROH region. The ROH region was identified in 
2 cases (from family 1 and 9) and 1 control from family 1.  While the variant was detected in two cases 
from family 7 as compound heterozygous with a G>A substitution on the 3’UTR of the gene 
(chr4:56,295,141; hg19) and in one control also from family 7 in heterozygous state. Clock consists of 
846 amino acids and the mutation identified (p.M1V) result in loss of the translation start site, therefore 
the variant was considered as a potential candidate, despite the fact that the ROH was not detected in 
family 7 members. Sanger sequencing confirmed the presence of the variant in these subjects in 
addition to one overweight subject that was not analysed in IVA, as illustrated in as illustrated in Figures 
25 and 26. 
3.2.3.4 The Rare Variant in RETSAT Gene 
Another candidate obesity variant is the novel missense variant (p.L144R) in retinol saturase (RETSAT) 
gene, detected in an ROH region. The ROH region was seen in three cases from family 6, family 8 and 
family 3. The variant was seen in two cases from family 4 (compound heterozygous) and none of the 
controls. Interestingly, the variant was predicted to be damaging and probably damaging by SIFT and 
Polyphen2, respectively. Therefore, the variant was considered as a potential candidate although the 
ROH and the variants were seen in different families. Sanger sequencing was performed on family 4 
members for validation. Sanger sequencing confirmed the presence of the variants in the two cases as 
well as an additional overweight subject, as illustrated in Figures 25 and 26. No control was available 
from this family.  
3.2.4 Replication of the Candidate Rare Obesity Variants 
I checked the candidate variants in the WGS of the 108 Qatari genomes, which are described in Section 
2.7.1, using an internal web application at WCMC-Q called Jbrowse. I aimed to find out whether any of 
the four potential candidate variants identified in my study is present in cases and/or controls from this 
population-based cohort consisting of 108 Qatari genomes. None of the four candidate variants were 
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seen in the 108 Qatari genomes data. Although 108 is not a large number of samples, the absence of 
these variants may support the rarity of theses variants in the Qatari population.
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Figure 25. 1% agarose gel for PCR amplification products and Sanger sequencing traces for candidate variants in: A) PCSK1, B) NMUR2, C) 
CLOCK and D) RETSAT. Lane L shows 100bp DNA ladder (New England Biolabs) followed by test samples, and lane “–ve” for a negative control. 
Sanger sequencing trace is shown for heterozygous carriers for each of the variants with base change position indicated by the arrows. 
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Figure 26. The genotypes of the candidate variants in the families in which they were detected. Obese subjects are shown in black, overweight 
in blue, normal in white and unknowns in grey. Probands are indicated with arrows. Sample ID, age and BMI are given below the individual 
symbol, respectively. The GSM label beside some individuals indicates the availability of genotyping, sequencing and methylation data for these 
subjects, while the M label indicates the availability of methylation data only. The reference allele is shown in blue while the alternative allele is 
shown in red.  
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3.3 Discussion 
3.3.1 Candidate Obesity Regions 
As SNPs are the most abundant source of genetic variations, it was not surprising to obtain about four 
million SNPs, including both frequent and rare SNPs, per genome through whole genome sequencing. 
This makes the identification of causative disease loci challenging especially for a common disease like 
obesity. Therefore, I applied a family-based strategy that combines linkage and ROH analyses with WGS 
to facilitate my search for rare obesity variants. 
The linkage signals were generally low both in the NPL and the VC linkage analyses, and no significant 
linkage peak (LOD≥3.3) was obtained. However, the results obtained were somewhat expected for a 
common disease like obesity, where even families with highly penetrant rare variants show imperfect 
co-segregation (Hinney et al. 2006; Stutzmann et al. 2008). In addition, the modest sample size of my 
study resulted in lack of statistical power for linkage detection. Some inconsistency has been observed 
between NPL and VC linkage signals, as well as between the signals obtained for different quantitative 
traits using VC linkage analysis particularly for key obesity traits like BMI. This has also been seen in 
other genome-wide linkage scans for obesity and obesity-related traits (Saunders et al. 2007). A likely 
explanation for such inconsistency is the high locus heterogeneity underlying obesity and obesity-
related traits. This corresponds with the fact that BMI values may not always represent adiposity 
consistently and may be influenced by other body composition traits like muscle mass and bone mass.  
Some of the overlapping linkage regions identified across different traits seemed interesting. For 
example, four linkage signals were observed at the same position on 16p12.3 for four quantitative traits 
(muscle mass, fat free mass (FFM), bone mass and basal metabolic rate (BMR). The region identified for 
these four traits encompass G protein-coupled receptor class C group 5 member B (GPRC5B) gene, 
which encodes a G protein couples receptor that has unknown function, and a SNP located near this 
gene has been reported in a large meta-analysis of GWASs with BMI (Speliotes et al. 2010). The region 
identified with BMR also extends further and includes SH2B adapter protein 1 (SH2B1) gene, which 
encodes for an adaptor protein involved in leptin signalling, close to which a SNP has been identified in 
association  with BMI (Thorleifsson et al. 2009; Willer et al. 2009). In addition, the signal identified on 
13q14.13 has been observed in both NPL (LOD=1.3) and VC linkage with waist circumference (LOD=1.4). 
The overlapping region is about 22 megabases in size and it overlaps with 156 annotated genes.  
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It is not easy to prioritize linkage regions (and variants) based on the genes they overlap or based on the 
previously published linkage studies since a large number of linkage scans has been performed and they 
identified a large number of linkage regions for obesity and obesity-related traits, which are usually of 
megabases in size and may overlap hundreds of genes. Therefore, my strategy was to consider linkage 
regions with a LOD score of ≥1 for further analysis, and to also combine ROH information and WGS data 
for variant prioritization analyses (through Ingenuity Variant Analysis as well as gene functions and the 
available relevant literature) to facilitate the search for potential obesity variants. However, the success 
in finding rare obesity risk variants can be dependent on the nature of the variants in terms of frequency 
and functional recognisability. 
My assumption was that as an inbreed population; the obesity risk variants might be present in 
homozygous state. Therefore, ROH analysis was applied to help prioritizing candidate linkage regions 
and to identify ROH regions that are enriched in case versus controls, however the sample size may have 
been too small for a robust enrichment analysis. Therefore, I investigated the linkage regions for 
harbouring rare obesity variants even if they did not overlap with ROH region, and also because the 
obesity variants are not necessarily present in homozygous state.   
3.3.2 Whole Genome Sequencing 
One of the strengths of my study is that WGS (with 40x coverage) were generated, which can provide a 
picture of the variants present within a genome. Whole exome sequencing (WES) provides information 
on the coding genomic regions, which represent only about 1% of the human genome, therefore it is 
widely used as an alternative to WGS to avoid the high cost, storage need as well as complexity of data 
interpretation in WGS. However, WES has some drawbacks including the bias in exome capture steps, 
missing variants within noncoding elements, and difficulty in using the data for other purposes like the 
detections of copy number variants. Therefore, WGS is the technique of choice for the future, especially 
when it becomes more affordable. The reduction in cost of WGS facilities and services is expected to 
accelerate the discovery of variants involved in complex diseases such as obesity. In addition, it will 
facilitate the routine screening for pathogenic mutations in clinical settings.   
Analysing WGS data has several challenges including the low concordance between some variant calling 
algorithms that are currently available and the lack of efficient and publicly available tools for the 
annotation of the millions of variants identified through sequencing, including variants that are not 
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present in variant databases. Therefore, different research groups are developing their own in-house 
WGS pipelines using a combination of different softwares and tools.   
I applied the WGS pipelines implemented at WCMC-Q for performing quality control (using FastQC, 
QPLOT and others), sequence reads alignment (using Bowtie2) and SNP variant calling (using GATK). The 
genotypes obtained using this pipeline showed high concordance with the genotypes obtained from SNP 
genotyping arrays. In addition, the genotypes of the four candidate variants that were validated with 
Sanger sequencing were concordant with the genotype calls given by the WGS pipeline, which reflects 
the high quality of the WGS data and analysis pipeline applied.  
3.3.3 Candidate Rare Obesity Variants 
In this study four potential rare obesity variants were identified through the filtration and prioritization 
steps in IVA and focusing on variants within monogenic obesity genes and candidate obesity regions 
identified through linkage and ROH. These rare variants were in PCSK1, NMUR2, CLOCK and RETSAT. 
3.3.3.1 The Rare Variant in PCSK1 Gene 
By prioritizing variants within known monogenic obesity genes, I identified a candidate variant in PCSK1. 
PCSK1 is a very interesting gene in relation to obesity due to the fact that a number of homozygous, 
compound heterozygous or heterozygous mutations in the gene can cause monogenic obesity (Farooqi 
et al. 2007; Jackson et al. 1997; Philippe et al. 2015; Zhu et al. 2002) and heterozygous mutations 
causing partial PC1 deficiency result in increased risk for obesity development (Creemers et al. 2012). In 
addition, frequent variants that modestly impair the function of PC1/3 were also found to increase the 
risk for common obesity (Benzinou et al. 2008; Creemers et al. 2012; Villalobos-Comparan et al. 2012). 
Such wide spectrum of PCSK1 variants contributing to obesity underscores the critical role of this gene 
and its encoded enzyme in the regulation of energy metabolism.  
Interestingly, the rare PCSK1 variant (p.R80Q, rs1799904), which I detected in one obese subject of my 
samples, has been functionally studied in vitro by Pickett et al. (Pickett et al. 2013). They selected this 
rare variant for studying from the 1000 Genome project since it is comparatively more frequent (MAF 
0.87%) in the 1000 genome project than other PCSK1 variants and because it is predicted to be possibly 
damaging by Polyphen. The study showed that this variant, which is located within the secondary 
cleavage site of the prodomain of the enzyme, had significantly adverse effects on the maturation and 
catalytic function of the enzyme compared to wild type. Moreover, they illustrated that effect observed 
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of this rare variant was even greater than the effect observed for other previously described common 
obesity risk SNPs in PCSK1 (Benzinou et al. 2008; Pickett et al. 2013). This finding supports the role of the 
PCSK1 variant identified in this study to obesity susceptibility, and also highlights the potential role of 
rare variants in PCSK1 as contributors to obesity risk in the general population. 
3.3.3.2 The Rare Variant in NMUR2 Gene 
By prioritizing variants within overlapping regions between linkage and ROH, a promising candidate 
obesity variant in NMUR2 (p.W211*) was identified. NMUR2 encodes a G-protein coupled receptor 
widely expressed in the central nervous system and in the paraventricular nucleus (PVN) of the 
hypothalamus (Howard et al. 2000). NMUR2 functions as a receptor for neuromedin U, neuropeptide 
that is widely distributed in the gut and central nervous system and modulate appetite and energy 
homeostasis (Howard et al. 2000).  Knock-out mice for Nmu are hyperphagic and obese whereas mice 
overexpressing Nmu are hypophagic and lean, suggesting that NMU is involved in energy regulation in 
humans. The acute central administration of NMU results in reduced food intake and increased physical 
activity in mice (Peier et al. 2009). However, such anorexigenic effect of NMU is not seen in Nmu2 
knock-out mice (Peier et al. 2009). Moreover, common variants in NMU were reported in association 
with overweight and obesity (Hainerova et al. 2006). The functional importance of NMUR2 encouraged 
Bhattacharyya et al. to screen the coding region of NMUR2 in 96 subjects with severe early onset 
obesity to look for potential rare obesity causing variants in order to confirm the contribution of NMUR2 
to obesity in man (Bhattacharyya et al. 2004). However, no rare missense variants were detected in any 
of their study subjects. 
In a recent study conducted by Benzon et al. (Benzon et al. 2014), viral-mediated RNAi was used to 
knock down NMUR2 gene expression in the PVN in rats brains. When the rats were fed a standard chow 
(15% fat), nmur2 knockdown produced no significant effect on food intake or body weight compared to 
wild type rats. However, when the same rats were fed a high-fat diet (45% fat), they consumed 
significantly more food (with preference for higher-fat food) and gained more body weight compared to 
wild type rats (Benzon et al. 2014). Therefore, I would expect that variants in NMUR2 may have variable 
obesity outcomes depending on environmental effects like food type. 
NMUR2 consists of 412 amino acids with seven transmembrane domains. The novel stop codon variant 
identified in this study is located within the third extracellular topological domain of the receptor. This 
means that this stop codon variant will result in a truncated receptor that lacks the C-terminus signalling 
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domain. Collectively, NMUR2 studies supports the idea that the novel NMUR2 variant detected in this 
study is of potential interest and that it deserves further follow-up studies to confirm its functional 
consequences on obesity, especially since it was present in homozygous state in two of the study 
subjects. 
3.3.3.3 The Rare Variant in CLOCK Gene 
In addition, a candidate variant was identified (p.M1V) in CLOCK gene. This gene encodes for the clock 
transcription factor which is a key component of the circadian clock system in mammals that allows a 
cell to perceive the time of the day (Gamble et al. 2014). Animal studies have demonstrated that 
homozygous Clock mutant mice have a greatly attenuated diurnal feeding rhythm in addition to obesity, 
hyperphagia and metabolic syndromes including hyperleptinemia, hyperlipidemia, hyperglycemia and 
hypoinsulinemia (Turek et al. 2005). Feeding these mice with high-fat diet accelerated the development 
of the obesity phenotype.  
The variant identified in this study results in loss of the translation start site, therefore it might result in 
reduction of CLOCK protein levels. However, further investigations are needed to investigate the 
potential effect of this variant on circadian clock impairment and obesity before reaching a conclusion 
about this potential effect of this variant, especially since no obesity causing mutations have been 
previously identified within CLOCK in humans. 
3.3.3.4 The Rare Variant in RETSAT Gene 
Another potential candidate variant was detected in RETSAT gene. This gene encodes for the enzyme 
retinol saturase that catalyses the saturation of vitamin A, all-trans-retinol, to produce all-trans-13,14-
dihydroretinol (Moise et al. 2010). Vitamin A metabolites play a role in the regulation of fat stores and in 
the differentiation of adipocytes. In addition, administration of vitamin A supplementation was shown 
to delay the onset of obesity in obesity rat models (Jeyakumar, Vajreswari, Giridharan 2006). Animal 
studies on retsat have shown that retsat knockout mice have similar weight gain and food intake rates 
compared to wild type littermates. However, they are characterized with increased adiposity and 
increased expression of adipogenic markers while maintained on high-fat diet (Moise et al. 2010). This 
shows an example of gene-environment interaction in modulating obesity. The variant I detected in 
RETSAT is a potential obesity candidate, and it might confer obesity risk under certain environmental 
conditions. However, these arguments are modest at this stage and more work is needed before 
drawing a valid conclusion. 
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3.3.4 Limitations 
The complexity of obesity is one of the features that make the search for rare obesity variants difficult 
even when using family-based study designs. Such complexity arises from several factors including the 
high heterogeneity of obesity, the fact that obesity is not monogenic in several cases even if causal 
variants are within key obesity genes, the variable penetrance of obesity variants in age and gender-
dependent manners which was even seen for rare monogenic obesity variants like some variants in 
MC4R (Hinney et al. 2006; Stutzmann et al. 2008), and the gene-environment interactions that play a 
role in determining the effect of  some risk variants as in the case of variants near FTO for example. Such 
complexity may explain why there was no clear co-segregation or association evidence for the variant 
identified in this study. Therefore, further investigations are necessary in order to obtain valid 
conclusions about the role of the identified candidate variants in relation to obesity. 
In addition, having WGS data with coverage of 40x can be a limiting factor when searching for rare 
disease variants as many rare SNPs are expected to be missed out, therefore, deeper coverage of about 
100x is usually desired for such study purpose. Another limitation of the study is the difficulty in 
inferring the frequency of the identified variants in the general population due to the small sample size 
and the familial structure of the dataset, thus affecting my selection of rare SNPs. Therefore, I selected 
the rare obesity variants based on the frequencies observed in the 1000 Genome project, the public 
Complete Genomics genomes or the NHLBIESP exomes despite the fact they may not reflect the 
frequencies on such variants in the Qatari population. 
As discussed in Section 3.2.4, none of the candidate variants were detected in the available replication 
dataset of the 108 Qatari genomes. The rarity of the identified candidate variants and their existence as 
family-specific suggests that large sample sets are in need in order to increase the chance for replicating 
such variants. The lack of other available datasets from Qatar or other Arab countries to be used for 
replication purposes is one of the study limitations at the current stage, which will be hopefully 
addressed in the future with the advancement in the genetic research projects in the Arab world.  
3.3.5 Future Directions 
The current study combined linkage (using Merlin), ROH (using Plink) and variant prediction from WGS 
data (using IVA) to identify candidate obesity variants. One of the future plans of this study is to apply 
another tool for that purpose, called the Pedigree Variant Annotation, Analysis, and Search Tool 
(pVAAST) (Hu et al. 2014). Unlike IVA, pVAAST is freely available at 
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http://www.hufflab.org/software/pvaast/. pVAAST is designed for the identification of disease genes 
from high throughput sequencing data in pedigrees. The tool performs linkage analysis and integrates 
functional prediction and case-control association features in a unified statistical framework. This 
approach was found to be applicable and robust for monogenic to polygenic phenotypes. It will be 
interesting to see whether the candidates I obtained will also be identified as disease variants using 
pVAAST.  
Another direction for future research is to sequence the candidate genes identified in this study in large 
population-based cohorts in order to see whether variants in these genes are enriched in obese cases 
compared to controls. This can be done through collaborative efforts with Qatar Biobank and or other 
research institutions in the Arabian Gulf.   
In addition, the possible effects of the candidate variants identified in this study can be assessed 
functionally, which was beyond the scope of this thesis. This would be particularly interesting for the 
NMUR2 as it is the most promising candidate among the four candidates. Variants of interest can be 
studied in vitro by expressing them in adipose cell lines for example and measuring their effect on 
adiposity, mRNA levels and/or protein levels compared to wild type littermates.  Other experiments may 
also involve the use of reporter genes to study the effect of the variant on protein localization. Different 
experimental designs can be applied to different candidate variants based on the variant and gene 
properties.   
3.4 Conclusions 
In conclusion, this chapter presents four potential obesity variants. For the PCSK1, it is likely that this 
variant contributes to obesity susceptibility since the effect of this particular variant on obesity has 
already been established functionally. The other candidate variants in NMUR2, CLOCK and RETSAT 
present very interesting obesity candidates based on gene function. However, further replication and/or 
functional evidence on these variants are necessary to confirm their functional role as contributors to 
obesity susceptibility. 
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4. Identification of Common and Rare Obesity CNVs 
As discussed in Section 1.8.3 of this thesis, several common (Falchi et al. 2014; Jarick et al. 2011; Sha et 
al. 2009; Speliotes et al. 2010; Willer et al. 2009) and rare CNVs (Bochukova et al. 2010; Glessner et al. 
2010; Walters et al. 2013; Wang et al. 2010a; Yu et al. 2011) have been associated with obesity in global 
populations. Our knowledge about obesity-related CNVs mainly came from studies on samples from 
European descents. Arabs are understudied in this research field despite the increasing incidence of 
obesity among Arabs.  
In this chapter, I present and discuss the CNV analyses I performed on my sample set using the intensity 
data obtained from the HumanOmni2.5-8 SNP genotyping data for the purpose of identifying common 
and rare CNVs possibly contributing to obesity risk in the Qatari population. The CNV analyses were 
performed using the SNP genotyping data available for a total of 63 subjects (34 obese, 17 lean and 12 
overweight). These subjects are indicated by the “GSM” label in their pedigrees which are given in 
Figure 2 in Section 2.4. CNV prediction was performed for the 63 sample using PennCNV (Wang et al. 
2007), and the obtained CNVs were subjected to quality control checks and then analysed in order to 
identify common and rare obesity CNVs. Description of the methods is given in Chapter 2 in Section 
2.8.3 while the results and discussion are given below. 
4.1 CNV Prediction 
The LRR and BAF information was exported form GenomeStudio (Illumina) and used for CNV detection 
in PennCNV (Wang et al. 2007). The initial CNV calling gave a total of 5,759 CNVs in 63 subjects (34 
obese, 12 overweight and 17 lean). As quality control, CNV merging was applied to merge large (≥500kb) 
adjacent CNVs that tend to split automatically by PennCNV, which gave a total of 5,621 CNVs in the 63 
samples. None of the samples had LRR_SD above the quality control threshold of 0.350 (samples LRR_SD 
ranged between 0.127 and 0.315). In addition, four outlier samples (3 obese and 1 overweight), that had 
a total number of predicted CNVs >2SD above the mean, were excluded from the study. A total of 4,481 
CNVs in 59 subjects (31 obese, 11 overweigh and 17 lean) remained after quality control.  
The most frequent type of CNVs within the 4,481 remaining CNVs was the heterozygous deletions (with 
55.2%), the heterozygous duplications (with 33.1%), the homozygous deletions (with 11.6%) and the 
homozygous duplication (with 0.1%) respectively, as shown in Figure 27. Within each CNV state 
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category, there was no significant difference between the number of CNVs detected in the obese, 
overweight and lean subjects. 
Two different approaches were applied for analysing these 4,481 CNVs for the purpose of identifying 
common and rare obesity CNVs (as summarized in the CNV analysis workflow given in Figure 15 in 
Section 2.8.2.1). 
 
Figure 27. The frequency of the different CNV states detected in the obese, overweight and lean 
subjects. Number of CNVs was corrected for the number of subjects within the obese (n=34), 
overweight (n=11) and lean (n=17) categories. 
 
4.2 Association of Common CNVs with BMI 
To perform the common CNV association with BMI, I included SNP probes that were within inferred CNV 
regions of ≥1kb in size, encompassing at least 25 SNPs, and that had a copy number change in more than 
10% of the samples. This gave a total of 2,236 SNP probes that correspond to 555 CNVs (detected in the 
59 subjects) within 39 CNV regions. These 39 CNVs regions are summarized in Table 14. The CNV states 
at the 2,236 SNP probes were tested for association with BMI in a variance component framework. 
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Chr. Start position (bp) Start SNP End position (bp) End SNP Size (kb) 
  
# of SNPs # of CNVs 
  
Copy number state 
1 798,959 rs11240777 915,543 kgp15845210 116.584 35 11 Het duplication 
1 1,119,858 kgp2944849 1,425,700 kgp8416131 305.842 32 8 Het duplication 
1 187,899,551 kgp15159942 188,339,497 kgp15729292 439.946 260 7 Het deletion 
2 89,978,069 kgp22790915 90,275,455 kgp22747169 297.386 37 9 Het deletion/Het duplication 
2 242,819,535 kgp14410578 243,068,869 kgp14601317 249.334 163 11 Het deletion/Het duplication 
3 65,189,366 kgp7986924 65,214,685 rs1479940 25.319 29 15 Het deletion 
3 75,419,736 rs2091866 75,682,933 kgp22757643 263.197 64 15 Het deletion/ Hom deletion 
4 942,439 rs10516158 999,255 kgp22755893 56.816 20 7 Het duplication 
4 25,557,047 rs7686265 25,578,269 kgp10702045 21.222 35 12 Het duplication 
4 69,374,369 kgp20682437 69,601,154 kgp1629687 226.785 30 19 Het deletion/ Hom deletion 
4 73,816,871 kgp6857414 74,059,396 kgp20702777 242.525 39 6 Het duplication 
5 8,703,085 rs17289138 8,748,627 kgp8401171 45.542 34 6 Het duplication 
5 9,902,340 kgp5416696 9,928,862 rs1035961 26.522 40 15 Het deletion 
6 29,853,641 rs2394231 29,899,389 rs9259910 45.748 95 24 Het deletion/ Hom deletion 
6 67,011,900 kgp1762263 67,048,885 kgp17083576 36.985 59 12 Het deletion 
6 78,972,930 rs818248 79,035,739 kgp1698345 62.809 32 23 Het deletion/ Hom deletion 
7 41,421 kgp7844626 79,243 kgp2138630 37.822 37 6 Het duplication 
7 111,010,389 kgp13620239 111,020,216 kgp8817054 9.827 6 6 Het deletion 
8 2,131,125 rs11989864 2,184,115 kgp6516407 52.99 39 6 Het deletion/ Hom deletion 
8 39,232,581 kgp7704339 43,791,691 rs10958798 4559.11 75 38 Het deletion/ Hom deletion/Het duplication 
8 144,894,496 rs4875060 145,025,515 kgp20103881 131.019 43 22 Het duplication 
11 50,677,929 kgp1850048 51,373,124 kgp12658484 695.195 46 6 Het deletion 
11 55,365,761 rs4459320 55,451,045 rs12789430 85.284 40 34 Het deletion/ Hom deletion 
11 129,864,983 kgp10349003 129,959,902 kgp2634961 94.919 33 8 Het duplication 
14 22,770,738 kgp331668 22,955,890 kgp37081 185.152 105 21 Het deletion 
14 106,103,358 rs7492390 106,949,307 rs12590146 845.949 68 53 Het duplication 
15 22,299,434 rs2605929 22,585,470 kgp8159039 286.036 28 6 Het duplication 
15 34,720,794 kgp22810994 34,814,869 kgp4635701 94.075 40 9 Het deletion/ Hom deletion 
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Table 14. The 39 CNV regions overlapping the 2,236 SNP probes that were included for the common CNV association analysis with BMI. 
 
 
 
Chr. Start position (bp) Start SNP End position (bp) End SNP Size (kb) 
  
# of SNPs # of CNVs 
  
Copy number state 
16 568,748 kgp11405027 847,469 kgp16358310 278.721 41 7 Het duplication 
16 1,916,103 rs453494 2,263,836 kgp10861734 347.733 38 6 Het duplication 
16 32,363,472 kgp16212574 32,649,736 kgp16279043 286.264 40 13 Het deletion 
19 797,032 kgp5849680 1,526,931 kgp5590298 729.899 124 37 Het duplication 
19 2,422,177 rs735911 2,478,753 kgp4884420 56.576 31 7 Het duplication 
19 20,601,006 kgp3163698 20,717,536 kgp578458 116.53 62 13 Het deletion 
19 43,370,213 kgp5660821 53,552,296 rs12151194 10182.08 60 13 Het duplication 
20 25,828,885 kgp5800882 25,896,760 kgp19273570 67.875 27 10 Het deletion 
21 10,766,457 kgp242945 10,874,452 kgp13171982 107.995 47 8 Het duplication 
21 38,347,199 kgp8090543 44,854,995 rs162365 6507.796 65 19 Het duplication 
22 25,663,994 kgp7778013 25,985,070 kgp4381032 321.076 137 7 Het duplication 
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As shown in Table 15, seven probes showed significant association with BMI at FDR 5%. These seven 
probes were located at 19p13.3 (chr19:812,172-817,783; hg19). The minimum P-value (1.0X10-4) 
observed was at the SNP probes: kgp21514629, kgp6465525, kgp6806336 and kgp7302446. This size of 
the duplication at the 19p13.3 region was ~5.6kb and it was associated with higher BMI. This duplication 
overlaps with two annotated genes: the lipid phosphatase-related protein type 3 (LPPR3) and 
polypyrimidine tract binding protein 1 (PTBP1).  
I investigated the CNV on 19p13.3 in the database of genomic variations (DGV), which is a database that 
aims to provide a comprehensive summary of the structural variation in the human genome using CNV 
information from healthy controls. The database currently consists of 55 published CNV studies 
(MacDonald et al. 2014). The duplication on 19p13.3 which I identified in this study seems to be 
infrequent in the database since only three CNV variants (seen in 5 subjects) were overlapping with this 
duplication (Conrad et al. 2010; Park et al. 2010), as shown in Table 16. The studies that reported these 
variants did not investigate or relate these variants to any obesity phenotype; therefore, they don’t 
provide any insight about the identified 19p13.3 CNV in relevance to obesity. 
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Marker 
 
Chr. 
 
Position (hg19) 
 
P-value 
 
Q-value 
 
Beta 
 
kgp21514629 19 816,065 1.0X10
-4
 0.04 10.1 
kgp6465525 19 817,708 1.0X10
-4
 0.04 10.1 
kgp6806336 19 817,783 1.0X10
-4
 0.04 10.1 
kgp7302446 19 815,086 1.0X10
-4
 0.04 10.1 
kgp21389405 19 812,309 2.0X10
-4
 0.05 10.3 
kgp4757336 19 814,680 2.0X10
-4
 0.05 10.3 
kgp590383 19 812,172 2.0X10
-4
 0.05 10.3 
Table 15. SNP probes associated with BMI at FDR 5% 
 
Variant ID Position (hg19) Size (kb) Frequency Reference 
 
nsv828354 
 
chr19:796,933-815,173 
 
18.2 1 in 31 (Park et al. 2010) 
dgv566n67 chr19:805,448-814,402 
 
9.0 2 in 31 (Park et al. 2010) 
esv26343 chr19:811,335-812,583 
 
12.5 1 in 40 (Conrad et al. 2010) 
Table 16. CNV duplications in the database of genetic variants overlapping with the 19p13.3 
duplication detected in my study. 
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4.3 Investigation of Rare Obesity CNVs 
For the identification of rare obesity CNVs, I investigated large CNVs that are ≥ 500kb in size in order to 
find out whether any of the obese subjects in the sample set carry a CNV that may explain the 
phenotype. 24 large CNVs were detected in the dataset, as given in Appendix 1.7, and after excluding 
those that are located within centromeric regions, 16 CNVs remained. Visual examination of the log R 
ratio and B allele frequency plots, which were generated using a script in PennCNV, showed that seven 
of the large non-centromeric CNVs were reliable, as given in Table 17 and Figure 28. Reliable deletions 
are supposed to be reflected by the decrease in LRR and the loss of heterozygosity demonstrated by BAF 
while duplications are supposed to be reflected by the increase in LRR and the allelic imbalance 
demonstrated BAF. The change in LRR is usually more apparent in the case of homozygous deletions and 
duplications compared to heterozygous deletions and duplications. 
These seven reliable CNVs were detected in seven individuals (5 obese and 2 overweight). The CNVs 
were located on 2p11.2, 6q21, 14q12 and 16p11.2. I checked these CNVs in other obesity CNV datasets 
to see whether they exist in any cases or controls, which will help prioritizing most potential obesity 
CNVs. These datasets including the childhood obesity cohort (CHO), the adulthood obesity cohort (ADO) 
from Imperial College London, the Saudi obesity and mental retardation (MR) cohort from Kings Faisal 
Hospital and the 108 Qatari genomes from WCMC-Q, which were all described in Section 2.7. As shown 
in Table 17, the large CNVs detected on 2p11.2 were present in controls from the other CNV studies. 
Whereas, the CNVs detected on 6q21, 14q12 and 16p11.2 were not seen in any controls across these 
different studies, which makes them the most promising obesity CNVs. 
In addition, the large CNVs detected were examined in UCSC genome browser 
(http://genome.ucsc.edu/). The script visulaize_cnv.pl available in PennCNV was used to convert the 
PennCNV output to BED format. This was done to explore these CNV by visualizing them alongside with 
other genomic features like the overlapping RefSeq genes, SNPs and CNVs from CNV databases such as 
DGV (MacDonald et al. 2014) and the Database of Chromosomal Imbalance and Phenotype in Humans 
Using Ensembl Resources (DECIPHER) (Firth et al. 2009), as given in Appendix 1.8. 
I also investigated the large CNVs detected in my samples in the DECIPHER, which catalogues 
information about rare CNVs in patients with rare disorders based on information obtained from more 
than 200 academic departments of clinical genetics centres (Firth et al. 2009), to check whether any of 
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these large CNVs detected in my study were previously reported to cause obesity, as shown in Table 17. 
The only CNV reported in patients with severe obesity was the 16p11.2 deletion. 
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Chr Start End Size 
(kb) 
Number 
of SNPs 
Cytoband CN state Subject ID Age 
(y) 
Family 
ID 
BMI 
(kg/m
2
)
 
Overlapping genes COB/AOB 
data 
Saudi 
obesity 
and MR 
data 
108 
Qatari 
genomes 
data 
2 
 
873,92,157 
 
87,995,393 
 
603.2 
 
36 
 
p11.2 Het 
deletion 
DMF5S1 56 
 
4 32.9 
 
LINC00152, MIR4435-1 
and MIR4435-2 
1 COB 
control 
 
4 
controls 
- 
2 
 
87,392,157 
 
87,995,393 
 
603.2 
 
36 
 
Het 
deletion 
DMF5S2 53 
 
28.1 
 
2 
 
87,392,157 
 
87,972,393 
 
580.2 
 
35 
 
Het 
deletion 
DMF5S5 41 
 
33.6 
 
6 
 
110,883,633 
 
111,591,037 
 
707.4 
 
401 
 
q21 Het 
duplication 
DMF3S1 
 
51 
 
3 35.4 
 
AMD1, CDK19, 
GSTM2P1,GTF3C6, 
KIAA1919, RPF2 and 
SLC16A10 
- 
 
- - 
6 
 
110,887,169 
 
111,591,037 
 
703.9 
 
396 
 
Het 
duplication 
DMF3S2 
 
54 
 
28.7 
 
14 25,099,980 25,612,838 512.9 
 
469 
 
q12 Het 
duplication 
QO_F5_05 20 5 39.9 GZMB and STXBP6 - - 1 case 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29,581,764 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30,199,579 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
617.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
300 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p11.2 
 
Het 
deletion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QO_F4_02 
 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 51.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALDOA, ASPHD1, 
C16orf54, C16orf92, 
CDIPT, CDIPTAS1, 
CORO1A, DOC2A, 
FAM57B, GDPD3, 
HIRIP3, INO80E, 
KCTD13, KIF22, MAPK3, 
MAZ, MVP, PAGR1, 
PPP4C, PRRT2, QPRT, 
SEZ6L2, SLC7A5P1, SPN, 
TAOK2, TBX6, 
TMEM219, YPEL3 and 
ZG16 
Observed 
in 4 COB 
cases and 4 
AOB cases 
 
1 case - 
Table 17.  Large (≥500kb) rare non-centromeric CNVs detected in seven study subjects, and validated by visual examination of LRR and BAF 
plots. Coordinates are given according to the GRCh37/hg19 genome assembly. Het stands for heterozygous. 
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Figure 28. LRR and BAF plots of the seven large non-centromeric CNVs detected in seven study subjects. A, B and C show the heterozygous 
deletions observed on 2p11.2 in DMF5S1, DMF5S2 and DMF5S5, respectively. D and E show the heterozygous duplication observed on 6q21 in 
DMF3S1 and DMF3S2, respectively. F and G show the heterozygous duplication observed on 14q12 in QO_F5_05 and the heterozygous deletion 
observed on 16p11.2 in QO_F4_02, respectively. Heterozygous deletions are reflected by the decrease in LRR and the loss of heterozygosity 
demonstrated by BAF, which support the deletion of one allele. Heterozygous duplications are reflected by the increase in LRR and the gain of 
heterozygosity demonstrated by BAF, which support the gain of one allele. 
F) G) 
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Chr 
 
Query CNV 
state 
Patient 
ID 
 
CNV start-end Phenotype Size (kb) 
2 
 
Deletion 252352 84,470,510-89,026,775 Abnormality of dental morphology, broad thumb, 
delayed speech and language development, long 
toe, macrotia, muscular hypotonia, narrow 
palate, sandal gap, short philtrum, thin lower lip 
vermilion, thin upper lip vermilion, widely spaced 
teeth 
4,556.3 
307922 87,374,062-88,297,268 Constipation, EEG abnormality, epicanthus, 
expressive language delay, high-arched palate 
923.2 
256076 87,376,107-87,832,122 Autism, cognitive impairment 456.0 
274865 87,771,617-89,050,417 No available phenotypes 1,278.8 
6 
 
Duplication 266259 401,016-170,888,348 Arrhythmia, depressed nasal bridge 170,487.3 
4145 105,704,971-113,968,447 Brachycephaly, epicanthus, intellectual disability, 
intrauterine growth retardation, muscular 
hypotonia, ptosis 
8,263.5 
252054 110,967,228-111,260,923 Delayed speech and language development, high 
palate, intellectual disability, microcephaly, 
micrognathia, muscular hypotonia, short stature 
293.7 
287630 111,100,244-111,321,676 Behavioural/psychiatric abnormality, global 
developmental delay 
221.4 
258535 111,250,449-111,651,155 No available phenotypes 400.7 
254935 111,583,447-111,620,386 No available phenotypes 36.9 
14 
 
Duplication 301147 20,253,739-41,764,477 No available phenotypes 21,510.7 
253272 20,295,211-29,615,149 No available phenotypes 9,319.9 
283651 20,472,548-31,139,579 Generalized hypotonia, seizures, severe global 
developmental delay, short stature 
10,667.0 
262903 20,608,216-29,238,842 Intellectual disability 8,630.6 
249644  
 
 
25,478,462-28,626,135 Deeply set eye, frontal upsweep of hair, 
hypertelorism, hypoplasia of the corpus callosum, 
pointed chin, prominent ears, prominent 
fingertip pads, short philtrum, spasticity, thick 
lower lip vermilion, thick upper lip vermilion 
3147.7 
16 Deletion In about 
260 
patients 
Vary in different patients Intellectual disability, obesity, global 
developmental delay, delayed speech and 
language development, autism spectrum 
disorders, muscular hypotonia, seizures and 
others. 
~600kb 
Table 18. CNVs in the DECIPHER that overlap with the large rare CNVs detected in my study. 
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4.4 Confirmation of the 16p11.2 Deletion 
I decided to independently investigate the 16p11.2 deletion since previous reports have associated this 
CNV to obesity (Bochukova et al. 2010; Walters et al. 2010). The CNV detected on 16p11.2 was a 
heterozygous deletion (chr16:29,581,764-30,199,579; hg19), as illustrated by the LRR and the BAF plots 
given in Figure 28 (G). The presence or absence of the deletion in the carrier (QO_F4_02) and the other 
family members (Family 1) was examined through Multiplex Ligation-Dependent Probe Amplification 
(MLPA), using the SALSA MLPA P343 Autism-1 probemix kit available by MRC-Holland (as was described 
in Section 2.8.2.2.3). The deletion was confirmed in the deletion carrier but was not detected in any 
other family members (Figure 29). The absence of the deletion in both parents of the deletion carrier 
suggests that it occurred de novo. Interestingly, this subject was the most extremely obese subject in the 
family and also in the whole sample set with a BMI of 51.8kg/m2. In addition to the extreme obesity 
phenotype, this subject had speech delay and learning disabilities, consistent with a diagnosis of 
developmental delay. Interestingly, this subject had two siblings only and they were both obese (BMI= 
42.4 and 37.8kg/m2) but they were not affected with developmental delay and were not carrying the 
16p11.2 deletion. In addition to the MLPA analysis, I investigated the deletion using the available WGS 
data. In the case of a heterozygous deletion, I would expect a drop in the sequencing read depth within 
the deletion region of about half the average genomic read depth of 40x.  As shown in Figure 30, the 
WGS data also confirmed the presence of the 16p11.2 in the deletion carrier. 
 
 
 
 
 
 
 
 
A) 
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Figure 29. The normalised ratios of peak heights of the MLPA probes for: A) the 16p11.2 deletion 
carrier and B) a sibling that does not carry the deletion. The x-axis shows the chromosomal position of 
the probes, and probe IDs are given on the top of the plots.  Boxes represent the 95% confidence 
interval of peak height ratios of reference samples (blue boxes are for test probes while green boxes are 
for control probes). The yellow “x” symbol shows the average ratios of three reference samples. Blue 
and red lines represent upper and lower arbitrary borders of the ratios. Circles represent ratios in test 
samples and error bars indicate their confidence range (black circles = normal ratio, yellow = ambiguous 
increase, pink = ambiguous decrease, and red = significant decrease).   
 
B) 
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Figure 30. Read depth across the 16p11.2 deletion region (chr16:29,581,764-30,199,579 ± 100kb; hg19).  A) Shows read depth in the 16p11.2 
deletion carrier (QO_F4_02), where the rapid drop in read depth across the deletion region compared to the neighbouring regions supports the 
deletion of one allele. B) Shows read depth in a sibling that does not carry the deletion (QO_F4_03), where the observed normal read depth 
across the deletion region supports the presence of two alleles. 
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4.5 Discussion 
4.5.1 Association of Common CNVs with BMI 
Despite the alarming figures of obesity in the Arab world and the Gulf Arabian countries in particular, 
the genetics of obesity remain understudied in Arabs. To the best of my knowledge, this is the first 
genome-wide CNV association study with BMI in Arabs. At 5% FDR (Benjamini et al. 2001), I identified a 
common CNV located on 19p13.3 that associates with higher BMI. This CNV is a duplication of ~5.6kb in 
size and it overlaps two annotated genes, which are the lipid phosphatase-related protein type 3 
(LPPR3) and the polypyrimidine tract binding protein 1 (PTBP1).  LPPR3 belongs to the lipid phosphate 
phosphatase (LPP) protein family, which consists of integral membrane proteins that play a role in the 
modulation of bioactive lipid phosphates including phosphatidate, lysophosphatidate, and sphingosine-
1-phosphate. PTBP1 is part of the heterogeneous nuclear ribonucleoproteins (hnRNPs) protein family, 
which are RNA-binding proteins involved in pre-mRNA splicing, transport and metabolism. PTBP1 might 
have some obesity and obesity-related metabolic actions through affecting the expression of 
adiponectin receptor 1 (AdipoR1), needed to mediate the pleiotropic effects of adiponectin (Lustig et al. 
2014; Yamauchi et al. 2007). However, the identified duplication on the 19p13.3 only overlaps with the 
sequence of last exon of PTBP1, which lowers the potential of this CNV for altering the dosage of the 
gene. 
4.5.2 Candidate Rare Obesity CNVs 
In regard to rare CNVs, I investigated large (≥500kb) rare CNVs to identify potential obesity causing 
CNVs. I confirmed the contribution of the 16p11.2 deletion to severe obesity beyond European 
populations. The short arm of chromosome 16 is enriched with large segmental duplications which 
facilitates the occurrence of non-allelic homologous recombination, resulting in recurrent copy number 
changes at this locus.  As was discussed in Section 1.8.3, Bochukova et al. (Bochukova et al. 2010) has 
previously reported a rare deletion of ~220kb at the 16p11.2 region (chr16:28,731,428-28,951,376; 
hg18) in association with extreme obesity in European children. In addition, my group at Imperial 
College London has identified a separate deletion of ~593kb in size at the 16p11.2 region 
(chr16:29,421,854-30,014,587; hg19) that was associated with severe obesity in European adults 
(Walters et al. 2010). Interestingly, reciprocal duplication at the same region was found to confer an 
increased risk for underweight (Jacquemont et al. 2011). 
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In this study, I detected a heterozygous de novo deletion of 617kb at the 16p11.2 region in the most 
obese subject in my samples with a BMI of 51.8 kg/m2 who was also affected with developmental delay. 
The similarity between the deletion I identified in my study and the 16p11.2 deletion previously 
reported to cause a highly penetrant form of obesity in European adults (Walters et al. 2010) in terms of 
deletion state (heterozygous), position (29,581,764-30,199,579 vs 29,421,854-30,014,857; hg19), size 
(617kb vs 593kb), the genes they encompass (same 29 annotated genes which are given in Table 17), 
and the clinical phenotype (severe obesity with developmental delay) supports the causality of the 
deletion in the deletion carrier in my study. To the best of my knowledge, this is the first report of the 
16p11.2 deletion in obese subjects from a non-European population.  
Another interesting observation regarding the 16p11.2 deletion detected in this study is that the 
deletion carrier had two siblings who were obese but they were not carrying the deletion and were not 
affected with developmental delay. Such observation shows that even within the same family, obesity 
may result from different genetic causes or be non-genetic, and can also be associated with different 
phenotypic features, which highlights the genetic and phenotypic heterogeneity of such devastating 
health condition.  
In addition to the 16p11.2 deletion, I identified other large CNV loci. The CNV on the 6q21 locus, which 
was detected in two siblings (1 obese and 1 overweight) from Family 3, seems to be of potential 
interest. This duplication was ~700kb in size and it overlaps with seven annotated genes: 
adenosylmethionine decarboxylase 1 (AMD1), cyclin-dependent kinase 19 (CDK19), glutathione-
transferase mu 2 (muscle) pseudogene 1 (GSTM2P1), general transcription factor IIIC, polypeptide 6 
(GTF3C6), ribosome production factor 2 homolog (S. cerevisiae) (RPF2), solute carrier family 16 
(aromatic amino acid transporter), member 10 (SLC16A10) and KIAA1919. A study conducted by 
Tabassum et al. (Tabassum et al. 2012) has shown that a SNP (rs2796749) in AMD1 gene, which encodes 
an enzyme involved in polyamine biosynthesis essential for cellular proliferation, is associated with 
childhood obesity, BMI, other measures of adiposity, and plasma leptin levels. The same study 
investigated the effect of rs2796749 on BMI in adults using the data available from the GIANT 
consortium meta-analysis (Speliotes et al. 2010). They found that rs2796749 showed consistency in 
association with BMI although it did not reach statistical significance. 
Moreover, I detected two additional CNV loci located at 2p11.2 and 14q12. The CNV on 2p11.2 was a 
recurrent deletion observed in two obese and one overweight siblings form Family 4 with average size 
of ~596kb. The deletion overlaps with three non-protein coding RNA genes: long intergenic non-protein 
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coding RNA 152 (LINC00152), microRNA 4435-1 (MIR4435-1), and microRNA 4435-2 (MIR4435-2). The 
deletion was also detected in 1 control from the CHO cohort and 4 controls from the Saudi obesity and 
MR cohort (Table 17), which does not support the causality of the deletion. 
The CNV on 14q12 was a ~513kb duplication detected in an obese subject from Family 5, and it overlaps 
granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) (GZMB) gene and 
syntaxin binding protein 6 (amisyn) (STXBP6) gene. The duplication carrier had a high BMI of 39.9 kg/m2 
and the CNV was seen in another case from the 108 Qatari genomes dataset (Table 17). This gives 
potential importance to this duplication in relation to obesity, however further work is needed to 
investigate and confirm such potential effect, especially since the genes overlapping the duplication 
have not been previously implicated genetically or functionally in obesity. 
4.5.3 Limitations 
The small sample size of the study is considered one of the study limitations because PennCNV can 
generate better CNV calls (less false-positive calls) when larger sample size is available and also the 
larger the sample size the more robust the association analysis can be. Moreover, the small sample size 
makes it difficult to infer the frequency of the identified CNVs in the general population and thus 
affecting the selection of both common and rare CNVs.  
Studies with large sample size have previously illustrated the rarity and the large effect size of the 
16p11.2 deletion. This means that the 16p11.2 deletion has a large predictive value at the individual 
level for obesity and thus it can be used for clinical prediction of obesity (El-Sayed Moustafa and Froguel 
2013). This is in fact important for a deletion like the 16p11.2 because it can be inherited from parents 
to children in an autosomal dominant fashion, and is associated with developmental delay as well. 
Another limitation of the current study, which can be generalized to other CNV studies, is the limited 
ability for defining the functionally relevant gene(s) within a CNV in relevance to the disease or 
phenotype of interest. This is particularly an issue in the case of large CNVs that contain multiple 
potential disease genes. Therefore, it is vital to follow findings from CNV studies with functional work in 
order to understand and define the genes and mechanisms underlying the disease of interest, especially 
since CNVs may lead to increasing or decreasing effects on gene expression even when they are lying 
outside DNA coding regions (de Smith et al. 2008). 
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Golzio et al. (de Smith et al. 2008; Golzio et al. 2012) conducted a functional study on the 16p11.2 to 
study the macrocephalic phenotype associated with the 16p11.2 deletion reported by Walters et al. 
(Walters et al. 2013). They overexpressed and suppressed the expression of each of the 29 genes in 
zebrafish. They found that the suppression of potassium channel tetramerization domain containing 13 
(KCTD13) expressions can solely induce the macrocephalic phenotype associated with the 16p11.2 
deletion while its overexpression induced the macrocephalic phenotype associated with the 16p11.2 
duplication. However, they could not draw a conclusion about the gene responsible for the obesity 
phenotypes, due to the limitation of zebrafish as animal model for studying obesity. Another study 
(Blaker-Lee et al. 2012) also performed on zebrafish, has investigated the role of the 16p11.2 deletion 
on brain development, and found that the majority of the genes within the deletion region affect brain 
development. For the kinesin family member 22 (KIF22) and aldolase A, fructose-bisphosphate (ALDOA) 
genes, a reduction of 50% in gene expression resulted in the development of abnormal brains and body 
shapes. While for most of the other genes, a reduction of at least 75% in gene expression was needed to 
observe such effects. Performing similar kind of studies but in mice models can help determining the 
obesity causing gene within the 16p11.2 deletion. 
4.4.4 Future Directions 
In this thesis, the CNV analysis was performed using the high-density SNP genotyping data. One of the 
future directions of the current study is to perform the CNV analysis using the available WGS data. This 
will allow the prediction of a wider spectrum of CNVs and at a higher resolution. In addition, it can 
facilitate the determination of the CNV breakpoint with a better accuracy.  
In addition, since the CNVs detected on 6q21 and 14q12 seem to be of potential interest, follow-up 
investigations can be performed to confirm their possible impact on obesity. Overexpression and 
silencing experiments of the genes within these CNVs in animal models of obesity can be one of the 
approaches to achieve this aim. 
4.6 Conclusions 
In conclusion, this is the first CNV study on obesity in an Arab population. I conducted a genome-wide 
CNV association analysis with BMI and identified a common CNV at 19p13.3 that associates with higher 
BMI. In addition, I confirmed the contribution of deletions at 16p11.2 to severe obesity beyond 
European populations, and under different environmental pressures, which makes this study the first 
identifying any genetic cause of obesity in the Qatari population. Moreover, I found rare CNVs at 6q21 
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and 14q12 with potential contribution to obesity risk in this population, which merits further 
investigations. This work demonstrates the importance of common and rare CNVs in the susceptibility to 
common diseases like obesity. Also, it encourages researchers to study and/or extend their current 
genetic studies to accommodate samples from understudied populations such as the Gulf Arabs in order 
to better understand the genetic causes of obesity in such populations. 
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5. Identification of Differentially Methylated Sites with BMI 
As introduced in Section 1.9 of this thesis, variation in DNA methylation might provide a link between 
environmental exposures and phenotypes, and thus play a role in determining the susceptibility to 
complex diseases including obesity. The DNA methylation studies on obesity published so far (Almen et 
al. 2012; Almen et al. 2014; Feinberg et al. 2010; Godfrey et al. 2011; Groom et al. 2012; Kuehnen et al. 
2012; Relton et al. 2012; Souren et al. 2011; Stepanow et al. 2011; Sun.D. et al. 2014; Wang et al. 2010b; 
Zhao, Goldberg, Vaccarino 2013) were summarized in Table 5 in Section 1.9.3.2. Given the early state of 
the epigenome-wide technologies for DNA methylation profiling, there is a small number of published 
EWASs with obesity and obesity-related traits. To date, no epigenetic study on obesity was performed 
on Arabs, therefore in this study I attempted to replicate previously reported DNA methylation 
associations from large EWASs with BMI (Dick et al. 2014; Sun.D. et al. 2014) in the Qatari population. 
To achieve this aim, genome-wide methylation profiling was performed for 96 subjects of my samples 
using the Infinium HumanMethylation450 BeadChip, including 49 obese, 21 overweight and 26 lean 
subjects. These subjects are indicated by the “GSM” and the “M” labels in their pedigrees which are 
given in Figure 2 in Section 2.4. In addition, I combined the methylation data for additional 27 subjects 
from a datast of Qatari families with T2D, described in Section 2.7.4, giving a total of 123 subjects for the 
methylation analysis. The analysis was carried out for BMI as a continuous trait. Details the experimental 
and analytical aspects relevant to this chapter are given in Section 2.8.3. Here, I present the results and 
discussions related to the analyses performed.  
5.1 Replication of Known Associations between DNA Methylation and BMI in the Qatari Samples 
After extensive quality control steps that included sample and probe filtering, colour bias adjustment, 
quantile normalisation, BMIQ normalisation and estimation of the blood cell types coefficients, data on 
b-values for 468,472 CpG sites for 123 subjects were used to carry out an epigenome-wide association 
analysis with BMI. The association was evaluated using a linear mixed effect model in which DNA 
methylation levels as well as the covariates including age, gender, T2D status and the coefficients for the 
six blood cell components (monocytes, granulocytes, NK-cells, B-cells, CD8+-T-cells, and CD4+-T-cells) 
were used as fixed effects, while polygenic and environmental effects were modelled as random 
components, as discussed in Section 2.8.3.3. 
5. Identification of Differentially Methylated Sites with BMI 
162 
 
My aim was to replicate the associations of six selected CpG sites with BMI that were reported in large 
EWASs published by the time this study was conducted (Dick et al. 2014; Sun.D. et al. 2014). These CpG 
sites are at ABCG1 (cg06500161), CPT1A (cg00574958), RNF145 (cg26403843), HIF3A (cg22891070), 
cluA/CLU1 (cg09664445) and KLF13 (cg07814318). I did not carry out the association only at the selected 
probes in order to avoid missing any potential inflation of the association statistics that might be due to 
the limited size of my sample set. Instead, I first performed an EWAS and assessed inflation through QQ-
plot and calculation of the lambda inflation coefficient of the EWAS. As shown in Figure 31, the QQ-plot 
showed negligible inflation of the association statistics (lambda=1.09) possibly due to hidden 
confounders. Therefore, no correction for inflation was applied. 
 
 
Figure 31. QQ-plot for the association between BMI and methylation sites. The blue line shows the 
expected P-values and the red is an interpolation of the P-values through the second and third quartile 
of the data. Here, the inflation coefficient is negligible (lambda= 1.0932). 
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I replicated the association between BMI and the CpG site cg06500161 in ABCG1 (P-value=6.3X10-3) and 
the CpG site cg00574958 in CPT1A (P-value=8.7X10-5), as shown in Table 19. For every increase of BMI 
by a unit of 1, there is a corresponding increase by 0.0134 in the DNA methylation b-value at 
cg06500161 (in ABCG1) and a decrease by 0.0073 at cg00574958 (in CPT1A). The distributions of the 
DNA methylation b-values for these two CpG sites are shown in Figure 32, and scatterplots of their 
associations with BMI are given in Figure 33. 
The most significant association in my dataset was detected with the CpG site cg17501210 at the 
Ribosomal protein S6 kinase, 90kDa, polypeptide 2 (RPS6KA2) gene (P-value=8.2X10-7) which did not 
reach genome-wide significance after Bonferroni correction (Bland and Altman 1995). The top ten 
associated CpG sites are given in Table 20 while the top 100 associated sites are given in Appendix 1.9. 
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Probe Chromosome Position (hg19) Gene 
symbol 
Gene name Reported   
P-value 
 P-value in my 
study 
Beta in my 
study 
Reference 
cg00574958 11 68,607,622 CPT1A Carnitine palmitoyltransferase 1A  1.1X10
−9
 8.7X10
-5
 -136.92 (Sun.D. et al. 
2014) 
cg06500161 21 43,656,587 ABCG1 ATP-binding cassette, sub-family G 
(WHITE), member 1 
2.2X10
−9
 6.2 X 10
-3
 74.52 
cg26403843 5 158,634,085 RNF145 Ring finger protein 145 4.0X10
−3
 0.02 24.07 
cg07814318 15 31,624,584 KLF13 Kruppel-like factor 13 4.6X10
−7
 0.10 28.18 (Dick et al. 
2014) 
cg22891070 19 46,801,642 HIF3A Hypoxia inducible factor 3, alpha subunit 4·0X10
−8 
0.14 10.40 
cg09664445 17 2,612,406 CLUH Clustered mitochondria (cluA/CLU1) 
homolog 
2.3X10
−7
 0.87 -6.10 
Table 19. Known CpG sites associations with BMI that were attempted using my Qatari sample set. Replicated associations with BMI in my 
dataset are shown in bold. Replicated associations are those with P-value less than (0.05/6=8.33310−8).
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Figure 32. Histograms of the methylation b-values distribution for (A) cg06500161 at ABCG1 and (B) 
cg00574958 at CPT1A. 
 
 
Figure 33. Scatterplots of methylation b-values against BMI for (A) cg06500161 at ABCG1 and (B) 
cg00574958 at CPT1A. Red lines indicate the slopes of the regression models (Beta = 74.5 and -136.9, 
respectively). 
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Probe Chromosome Position (hg19) Gene symbol Gene name 
 
P-value 
cg17501210 6 166,970,252 RPS6KA2 Ribosomal protein S6 kinase, 90kDa, polypeptide 2 
 
8.2X10
−7
 
cg18181703 17 76,354,621 SOCS3 Suppressor of cytokine signalling 3 
 
1.7X10
−6
 
cg23943013 5 79,551,904 SERINC5 Serine incorporator 5 
 
2.9X10
−8
 
cg05864010 11 85,376,948 CREBZF CREB/ATF bZIP transcription factor 
 
4.6X10
−6
 
cg06183831 1 9,883,466 CLSTN1 Calsyntenin 1 
 
7.4X10
−6
 
cg14551938 8 49,173,274 NA NA 
 
8.7X10
−6
 
cg07146912 3 73,671,377 PDZRN3 PDZ domain containing ring finger 3 
 
8.9X10
−6
 
cg13057167 14 103,750,565 NA NA 
 
1.1X10
−5
 
cg03717755 6 16,136,539 MYLIP Myosin regulatory light chain interacting protein 
 
1.1X10
−5
 
cg25499461 19 46,389,574 IRF2BP1 Interferon regulatory factor 2 binding protein 1 
 
1.1X10
−5
 
Table 20. The top ten associated CpG sites with BMI in my Qatari data. 
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5.2 Association of DNA Methylation at ABCG1 and CPT1A with BMI in the TwinsUK Cohort 
As epigenetic patterns are strongly influenced by environmental factors, I compared in collaboration 
with my colleague Dr Alessia Visconti and my supervisor Dr Mario Falchi the effects of the associations I 
observed at ABCG1 and CPT1A with BMI in my Qatari dataset to the effects they observed in the 
TwinsUK cohort (which is described in Section 2.7.5). Such comparison will address the question of 
whether the associations observed are homogeneous between these two populations and thus may give 
an indication of whether they are independent from variations due to differing genetic backgrounds and 
lifestyles. 
The association between DNA methylation levels of the two probes at ABCG1 and CPT1A with BMI in the 
TwinsUK cohort was assessed by a linear mixed effect model using also PopPANTE. The association 
model included DNA methylation levels and the covariates T2D status and the blood cell types 
coefficients for monocytes, granulocytes, NK-cells, B-cells, CD8+-T-cells, and CD4+-T-cells as fixed effects, 
while polygenic and environmental effects were modelled as random components. The analysis in the 
TwinsUK cohort confirmed significant association between BMI and the probes at ABCG1 (P-
value=1.3X10-11) and CPT1A (P-value=7.1X10-12). 
5.3 Meta-analysis of the DNA Methylation Association Studies with BMI using the Qatari and TwinsUK 
Data 
A meta-analysis was carried out combining the effects I observed for the associations between DNA 
methylation level with BMI at ABCG1 (cg06500161) and CPT1A (cg00574958) probes using my Qatari 
samples data together with those observed using the TwinsUK data. The meta-analysis showed low to 
moderate heterogeneity between the two studies (I2 =11.7% and 41.7%, for ABCG1 and CPT1A, 
respectively; Cochran's heterogeneity P-value > 0.05). It also increased the associations at ABCG1 (P-
value=2.5x10-13) and CPT1A (P-value=1.9x10-15). 1 
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5.4 Discussion 
Since the prevalence of obesity is high in Arab countries including Qatar, it is essential to initiate genetic 
and epigenetic research on obesity in this under-studied region of the world. To the best of my 
knowledge, this study is the first epigenetic study on obesity in an Arab population.  As I did not have 
the power the carry out a full EWAS, I aimed to replicate in the Qatari population known associations 
with BMI from large EWASs that were mainly carried out in Caucasian populations.  
5.4.1 Replicated Associations between DNA Methylation Levels and BMI 
I attempted to replicate six CpG sites at ABCG1, CPT1A, RNF145, HIF31A, CLUH and KLF13 and I 
successfully replicated the association of cg06500161 at ABCG1 and cg00574958 at CPT1A (Table 19). 
The link between DNA methylation levels at ABCG1 and CPT1A to obesity is not fully established yet. 
However, these genes can be functionally linked to obesity-related phenotypes.  
ABCG1 encodes for ATP-binding cassette transporter that acts as a facilitator of cholesterol and 
phospholipid transportation in macrophages and other cell types including pancreatic beta-cells. In 
agreement with ABCG1 function, a recent EWAS has reported higher levels of DNA methylation at 
cg06500161 in ABCG1 with increased levels of chylomicrons and VLDL-cholesterol (Petersen et al. 2014), 
which supports the importance of the epigenetic regulation of ABCG1 in relation to obesity. Animal 
studies on mice have shown that the disruption of abcg1 leads to reduced granule cholesterol, altered 
granule morphology, impaired insulin secretion and glucose intolerance (Kruit et al. 2012). In addition, 
T2D patients have been characterized with reduced ABCG1 mRNA and protein levels, which leads to 
altered cholesterol efflux, increased intracellular cholesterol accumulation and vascular complications 
(Mauldin et al. 2008). 
Very recently, an EWAS on T2D carried out by Chambers et al. (Chambers et al. 2015) have reported 
association between DNA methylation levels at cg06500161 in peripheral blood with incident T2D in 
Indian Asians and Europeans. Interestingly, cg06500161 showed also significant association with BMI, 
waist-hip ratio, glucose concentrations, and other metabolic measures of insulin resistance (Chambers 
et al. 2015). Another study carried out by Kulkarni et al. (Kulkarni et al. 2015) has also recently reported 
association between cg06500161 methylation levels and T2D in Mexican American families. In 
concordance to Sun et al. (Sun.D. et al. 2014) and the recent Chambers’s paper (Chambers et al. 2015), 
higher levels of DNA methylation at cg06500161 were associated with higher BMI in my study. Such 
increase in methylation levels at this site might be one of the mechanisms that mediates the reduction 
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of ABCG1 expression and its consequences on lipid homeostasis and insulin resistance. Further work is 
needed to confirm such an effect and the underlying mechanisms, especially since ABCG1 can provide a 
link between obesity, insulin resistance and T2D. 
In addition, I replicated the association of cg00574958 at CPT1A, where lower levels of methylation were 
associated with higher BMI. CPT1A encodes for hepatic lipid oxidation enzyme called carnitine 
palmitoyltransferase 1A that catalyses the transfer of the acyl group of long-chain fatty acids into 
carnitine. This reaction is essential for the transportation of long-chain fatty acids into the mitochondria 
for beta-oxidation. Interestingly, a study conducted by Lemas et al. (Lemas et al. 2012) reported 
associations between genetic variants in CPT1A with obesity and fasting lipid traits. In addition, Sanchez 
et al. (Sanchez et al. 2012) found that lower levels of CPT1A mRNA levels in peripheral blood are 
protective against increased plasma triglycerides, cholesterol, BMI and also against insulin resistance. In 
addition to the reported association of cg00574958 with BMI (Dick et al. 2014), combined analysis of the 
methylation levels of CpG sites at CPT1A has recently revealed its association with T2D (Kulkarni et al. 
2015). 
The probes at ABCG1 and CPT1A replicated in the Qatari samples (P-values of 6.3X10-3 and 8.7X10-5 for 
ABCG1 and CPT1A, respectively) were also significantly associated with BMI in the TwinsUK samples (P-
values of 1.3X10-11 and 7.1X10-12 for ABCG1 and CPT1A, respectively) with similar direction and 
magnitude of association effect. These findings from my study as well as those from the epigenetic 
studies discussed above might underscore the role of these two CpG sites in relevance to obesity 
independently form differing genetic backgrounds and environmental pressures between different 
populations. It might also mean that the methylation patterns at these loci are consequences of obesity 
instead of cause (i.e. reverse causation) in which external environment might play a small role. These 
replicated CpG sites (and their relative genes) merit further investigations to better understand their 
role in relevance to obesity risk.  
One of the most functionally interesting CpGs sites that was not attempted for replication at the 
beginning of this study but showed association with BMI was the CpG site cg18181703 at SOCS3 
(P=1.7X10-6), which was ranked the second top associated site (Table 20). SOCS3 is part of the SOCS 
protein family that is usually induced by cytokines, and functions as inhibitors of several cytokine 
signalling pathways. Interestingly, SOCS3 acts as a negative regulator of leptin (Bjorbaek et al. 1998; 
Bjorbaek et al. 1999) and insulin signalling (Emanuelli et al. 2000; Rui et al. 2002; Shi et al. 2004), and 
SNPs located close to SOCS3 were associated with BMI and other obesity related traits as well as glucose 
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homeostasis (Talbert et al. 2009; Tang et al. 2011). In addition, a study conducted by Mori et al. (Mori et 
al. 2004) has shown that socs3 deficiency in the brains of mice models results in enhanced leptin-
induced hypothalamic Stat3 tyrosine phosphorylation which consequently leads to loss in body weight 
and reduction in food intake compared to their wild type littermates. In addition, these mice showed 
resistance to high fat-induced weight gain and hyperleptinemia.  
Chambers et al. (Chambers et al. 2015) have recently reported cg18181703 at SOCS3 in association with 
T2D, BMI, waist-hip ratio, glucose concentrations, and other metabolic measures of insulin resistance. 
This means that my study replicates the association between cg18181703 at SOCS3 and BMI, although 
this probe was not selected for replication at the start of my study since the Chamber’s paper 
(Chambers et al. 2015) has just been published. In addition, methylation levels of CpG sites at SOCS3, in 
a combined analysis, has revealed association with T2D liability in Mexican American families (Kulkarni 
et al. 2015). Similar to ABCG1 and CPT1A, SOCS3 merits further investigations to better understand the 
epigenetic mechanism underlying its effects on obesity and its associated metabolic abnormalities. 
5.4.2 Challenges of DNA Methylation Studies 
Performing DNA methylation studies especially at the genome-wide level has many challenges. One of 
these is applying a proper quality control pipeline that is essential to minimize bias in methylation 
measures due to technical variations, and help focusing the downstream analysis to answer the 
biological question. For example, these technical issues includes the potential bias in methylation 
measures due to variation between the two colour channels in the Infinium HumanMethylation450K 
arrays, which I corrected for through a normalisation step in the quality control pipeline, and the 
potential bias due to variation in probe types and samples positions on the array, which we corrected 
for using quantile normalisation and BMIQ normalisation. Therefore, applying a proper quality control 
pipeline is crucial for obtaining clean data set before drawing biological conclusions (Section 2.8.3.2). 
In addition to the technical issues of methylation, the instable nature of DNA methylation patterns over 
time and also between different cell and tissue types, and in response to environmental changes adds 
further complexity to the analysis of DNA methylation patterns (Sandholt, Hansen, Pedersen 2012). Such 
instability means that the association analysis can be confounded by many factors including age, tissue 
type and disease conditions. Therefore, age, gender, coefficients of blood cell types and T2D status were 
included in the association analysis. In addition to these factors, the degree of relatedness and thus the 
underlying genetic similarity between study subjects may bias the association analysis especially in 
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family-based studies. Therefore, we used a family-based approach for performing the association 
analysis. The availability of advanced technologies for DNA methylation profiling at the genome-wide 
level together with the required computational tools for addressing the related technical and analytical 
issues is expected to accelerate the number of epigenetic studies in the field of obesity and other 
complex diseases.  However, a major problem with DNA methylation association studies is the lack of 
evidence for causality, which means that associations of DNA methylation levels at a particular CpG site 
with a disease does not necessarily mean that the methylation is responsible for causing the disease but 
it might reflect the effect of obesity on methylation patterns, and this could also be the basis for the low 
heterogeneity observed between the associations observed in the Qatari samples and the TwinsUK 
cohort for ABCG1 and/or CPT1A. 
5.4.3 Limitations 
There are some limitations of this study that I’m aware off. One of these limitations is the small sample 
size that limited the study power from performing a full EWAS. Therefore, I focused on replicating 
known associations with BMI that were reported in large EWASs. Future studies with larger sample size 
are likely to detect associations that were not observed in the current study due to power limitations.  
Another limitation of this study is that DNA methylation profiling was performed using the Infinium 
HumanMethylation450K arrays. These arrays can target a number of CpG sites across the genome, and 
therefore can provide limited methylation information to the targeted sites. On the other hand, the use 
of some other available whole genome sequencing-based methylation technologies can provide a more 
complete and comprehensive view of the methylation levels across the genome. 
Moreover, the methylation measures obtained from array-based technologies can be biased in the case 
of the presence of SNPs within probe binding sites. Therefore, in most studies probes that contain 
known SNPs, based on the annotations given in the Illumina manifest, are excluded to address this 
problem. However, there is a chance for the existence of other unknown SNPs within the study samples, 
especially if they are non-Caucasian samples, since these annotations are mainly based on SNP array 
genotyping studies performed on Caucasian genomes. However, one of the strengths of this study is 
that I also have whole genome sequencing data with 40x coverage for my study subjects, which allowed 
the removal of such potentially confounding genetic effect. 
Furthermore, DNA methylation was measured using whole-blood DNA since it was the only accessible 
type of sample as blood samples can be easily obtained compared to other kinds of samples. DNA 
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methylation measures on blood might not be representative of more disease-relevant tissues such as 
adipose tissues due to the existence of tissues-specific methylation patterns. In addition, as discussed in 
Section 2.8.3.2.6, blood is made of a cocktail of cellular subtypes in variable proportions and these 
subtypes carry variable methylation signatures, which may bias methylation estimates from whole 
blood. This problem was addressed here by estimating the cell type coefficients from the methylation 
data using the MethylSpectrum software (Houseman et al. 2012) and taking them into account in the 
association analysis with BMI, as discussed in Section 2.8.3.3. 
Furthermore, it is usually common to independently validate the methylation profiles obtained using 
array-based methods for the candidate CpG sites of interest, like those at ABCG1 and CPT1A in my study, 
using other technologies. However, I have not performed such experiments since the CpG sites at 
ABCG1 and CPT1A were already included in the validation experiments performed by Petersen et al. 
(Petersen et al. 2014) using the EpiTYPER system.  In addition, Illumina has reported high correlation 
between the DNA methylation profiles obtained using the HumanMethylation 450K array and whole 
genome bisulfite sequencing-based methods (Illumina 2012a).  
5.4.4 Future Directions 
As the association between BMI and the CpG site at SOCS3 was significantly replicated in the Qatari 
samples, it will be interesting to also investigate such association in the TwinsUK cohort. Another 
interesting future directions on the methylation work presented in this chapter is to investigate the 
heritability of DNA methylation patterns especially at ABCG1, CPT1A and SOCS3. Such study is possible 
due to the family structure in the dataset that is considered a quite unique feature. This could help the 
determination of CpG sites with heritable patterns of methylation, and such CpG sites can be prioritized 
as potential obesity causative candidates from other differentially methylated sites with BMI that might 
be due to reverse causation.  
Performing genome-wide expression analysis on the sample set, using array or sequencing-based 
technologies, can help understanding the consequences of the methylation patterns at ABCG1 and 
CPT1A, and SOCS3 on gene expression. It is possible to conduct such experiments since I have collected 
additional blood samples from my study participants in PAXgene Blood RNA tubes that stabilize 
intracellular RNA at the point of collection (PreAnalytiX, cat: 762165 (BD)) for downstream RNA 
extractions and profiling experiments.  
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5.5 Conclusions 
This study is the first epigenetic study on obesity performed on samples from an Arab Gulf population. I 
replicated the previously associations of CpG sites at ABCG1 and CPT1A in the Qatari samples and also in 
the TwinsUK samples, and also the association of a CpG site at SOCS3 in the Qatari samples. Such finding 
supports the role of these CpG sites to obesity independently from variations due to differing genetic 
backgrounds and environmental pressures between different populations. 
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6. Conclusions 
Obesity is a complex disease that results from interactions between genetic and environmental factors. 
Although there has been a significant progress in understanding the genetic contribution to the 
susceptibility to obesity, much remain to be revealed. Most of the success in the field of obesity genetics 
came from studying monogenic forms of obesity whilst, the identification and understanding of the 
genetic contributors to common obesity has proven to be more challenging.  Rare genomic variants 
including SNPs and CNVs have gained a lot of attention as contributors to the missing heritability of 
obesity. In addition, the role of DNA methylation in complex diseases has recently become a hot 
research topic. Therefore, I decided to initiate through my PhD work the first genetic and epigenetic 
study on obesity in Qatar.  
In chapter three of this thesis, I identified four rare candidate obesity mutations at PCSK1, NMUR2, 
CLOCK and RETSAT. Among these, the most interesting candidate was the NMUR2 mutation and this was 
based on supporting evidence for its obesity-related function from the available literature. In chapter 
four, I identified a common CNV on 19p13.3 in associated with higher BMI, and I detected and validated 
a rare deletion at 16p11.2 in the most extremely obese adult in my samples, which confirmed the 
contribution of the 16p11.2 deletions to obesity beyond European populations.  Moreover, I detected 
rare candidate obesity CNVs at 6q21 and 14q12. Further replication and/or functional investigation of 
the candidate mutations (from chapter three) and CNVs (from chapter four) are needed to confirm their 
potential effect on obesity. In chapter five, I replicated previously reported associations between BMI 
and DNA methylation levels at two CpG sites at ABCG1 and CPT1A in both the Qatari samples and the 
TwinsUK cohort, and I also replicated the association at SOCS3 in the Qatari samples. Replicating such 
associations in populations with differing genetic and environmental background supports the role of 
these genes in obesity and encourages further research on this topic. 
There are some limitations and strengths of the work presented in this thesis that I’m aware off. One of 
these limitations is the small sample size of the discovery cohort, due to time and cost reasons, which 
limited the detection power of the study. In addition, the lack of large Arab cohorts or databases with 
sequencing, CNV and/or methylation data has limited my ability to replicate findings from this study in 
Arabs. However, there are some research projects in the Arab region that will help addressing such 
limitation in the future. One of these projects is the Saudi Human Genome Project by the Saudi Arabian 
national science agency, which aims to identify genetic basis of disease in the Saudi population by 
6. Conclusions 
176 
 
sequencing the ~100,000 Saudi genomes representing normal and disease conditions. Similar research 
project is also planned in Qatar by the Qatar Biobank in collaboration with Hamad Medical Corporation 
and Sidra Medical and Research Centre. 
The Qatar Biobank project has been established in Qatar and they have recruited about 2,000 Qatari 
subjects so far. Such project offers a great opportunity for researcher to access various types of samples 
based on their study designs, which will save the time, cost and effort needed for sample recruitment 
and study initiation. 
The Biobank can also address another limitation that I encountered in this study, which is the limited 
phenotypic data that can be obtained from patient through secondary health care clinics and home 
visits.  Having a wide range of phenotypic data and medical tests through the Biobank records and 
databases can facilitate the careful selection of most suitable study subjects for a particular study 
purpose. Also, it can help researchers providing links between closely related diseases such as obesity 
and T2D. 
The development in the genetics research field is highly technology-driven. In this study, I utilized the 
state of the art technologies for genetic and epigenetic profiling such as the high-density genotyping 
arrays (HumanOmni2.5 array), WGS (paired-end sequencing using Hiseq2500 platform) and high-density 
methylation arrays (Infinium HumanMethylation450 BeadChip) that allowed the performance of genetic 
and epigenetic analyses at genome-wide level. Having multi-level data such as WGS and DNA 
methylation profiling on the same study subjects is considered as one the strengths of this dataset as it 
can be utilized in the future for integrating and/or confirming study findings toward system biology 
strategies. The advantage of having WGS and methylation data was clear in this study as the availability 
of the WGS data allowed the removal of the bias in DNA methylation measures that may arise from 
genetic variations.  
One of the future strategies that can maximize the use of the current dataset is to also perform genome-
wide expression profiling using expression arrays or RNA-seq technology from the study sample set 
using the blood samples that were collected for RNA experiments. This will be particularly useful to 
establish links between DNA methylation levels and their impact on gene expression in relation to 
obesity.  
The development of analytical tools for studying the omics data is as important as the availability of the 
omics platforms. For example, analysing my WGS data required the implementation of the WGS pipeline 
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at WCMC-Q, which consisted of a number of tools for quality control, sequence alignment, and variant 
calling and annotation. High computing facilities were also needed for processing and storage of the 
large sequencing files. Similar to the WGS data, extensive quality control pipeline was applied to the 
methylation data to address the various sources of bias in methylation measures due to experimental 
factors, which also consisted of a number of tools. My study was one of the first studies at WCMC-Q that 
were utilized for the testing and implementation of these pipelines, which are currently utilized for the 
purpose of other studies at WCMC-Q. 
The conductance of genetic and epigenetic studies at genome-wide level is usually a starting point that 
helps identifying disease-related candidates. Functional studies are then usually required to better 
understand the underlying mechanisms that might link such candidates to the disease of interest, and 
that might pave the way for drug discovery and personalized therapy in the future. Conducting 
functional studies was beyond the reach of this thesis due to time limitations but can be one as one of 
the future research directions. 
The initiation of genetic and epigenetic research on obesity in Qatar was a big aim that has been 
successfully achieved by the conductance of this study as it represents the first genetic and epigenetic 
study on obesity in Arabs. In addition, it is the first study identifying any genetic cause of obesity (the 
16p11.2 deletion) in a Qatari patient. It will be interesting to witness the development of research in 
Qatar and particularly in the field of obesity research with the completion of the Biobank project and the 
official opening of the Sidra Medical and Research Centre, as well as the drop in NGS technologies that 
will facilitate the conductance of sequencing projects at a large-scale. 
This thesis encourages further research in this under-studied region of the world and also motivates 
existing projects to include samples from under-studied populations like Arabs. It is hoped that further 
follow-up of findings from this thesis will provide better understating of obesity, and might help 
providing better treatment and/or prevention options for obesity in the future. 
 
 
References 
178 
 
References 
Abecasis GR and Wigginton JE. 2005. Handling marker-marker linkage disequilibrium: Pedigree analysis 
with clustered markers. Am J Hum Genet 77(5):754-67. 
Abecasis GR, Cherny SS, Cookson WO, Cardon LR. 2002. Merlin--rapid analysis of dense genetic maps 
using sparse gene flow trees. Nat Genet 30(1):97-101. 
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 
2010. A method and server for predicting damaging missense mutations. Nat Methods 7(4):248-9. 
Almen MS, Nilsson EK, Jacobsson JA, Kalnina I, Klovins J, Fredriksson R, Schioth HB. 2014. Genome-wide 
analysis reveals DNA methylation markers that vary with both age and obesity. Gene 548(1):61-7. 
Almen MS, Jacobsson JA, Moschonis G, Benedict C, Chrousos GP, Fredriksson R, Schioth HB. 2012. 
Genome wide analysis reveals association of a FTO gene variant with epigenetic changes. Genomics 
99(3):132-7. 
Atwood LD, Heard-Costa NL, Cupples LA, Jaquish CE, Wilson PW, D'Agostino RB. 2002. Genomewide 
linkage analysis of body mass index across 28 years of the framingham heart study. Am J Hum 
Genet 71(5):1044-50. 
Baldini A. 2005. Dissecting contiguous gene defects: TBX1. Curr Opin Genet Dev 15(3):279-84. 
Barsh GS and Schwartz MW. 2002. Genetic approaches to studying energy balance: Perception and 
integration. Nat Rev Genet 3(8):589-600. 
Beckmann JS, Sharp AJ, Antonarakis SE. 2008. CNVs and genetic medicine (excitement and 
consequences of a rediscovery). Cytogenet Genome Res 123(1-4):7-16. 
Bell CG, Walley AJ, Froguel P. 2005. The genetics of human obesity. Nat Rev Genet 6(3):221-34. 
Bell JT, Tsai PC, Yang TP, Pidsley R, Nisbet J, Glass D, Mangino M, Zhai G, Zhang F, Valdes A, et al. 2012. 
Epigenome-wide scans identify differentially methylated regions for age and age-related 
phenotypes in a healthy ageing population. PLoS Genet 8(4):e1002629. 
Bener A and Alali KA. 2006. Consanguineous marriage in a newly developed country: The qatari 
population. J Biosoc Sci 38(2):239-46. 
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. 2001. Controlling the false discovery rate in behavior 
genetics research. Behav Brain Res 125(1-2):279-84. 
Benzinou M, Walley A, Lobbens S, Charles MA, Jouret B, Fumeron F, Balkau B, Meyre D, Froguel P. 2006. 
Bardet-biedl syndrome gene variants are associated with both childhood and adult common 
obesity in french caucasians. Diabetes 55(10):2876-82. 
References 
179 
 
Benzinou M, Creemers JW, Choquet H, Lobbens S, Dina C, Durand E, Guerardel A, Boutin P, Jouret B, 
Heude B, et al. 2008. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat Genet 
40(8):943-5. 
Benzon CR, Johnson SB, McCue DL, Li D, Green TA, Hommel JD. 2014. Neuromedin U receptor 2 
knockdown in the paraventricular nucleus modifies behavioral responses to obesogenic high-fat 
food and leads to increased body weight. Neuroscience 258:270-9. 
Berndt SI, Gustafsson S, Magi R, Ganna A, Wheeler E, Feitosa MF, Justice AE, Monda KL, Croteau-Chonka 
DC, Day FR, et al. 2013. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits 
and provides insights into genetic architecture. Nat Genet . 
Bhattacharyya S, Luan J, Farooqi IS, Keogh J, Montague C, Brennand J, Jorde L, Wareham NJ, O'Rahilly S. 
2004. Studies of the neuromedin U-2 receptor gene in human obesity: Evidence for the existence of 
two ancestral forms of the receptor. J Endocrinol 183(1):115-20. 
Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson KL. 2009. Genome-wide DNA 
methylation profiling using infinium(R) assay. Epigenomics 1(1):177-200. 
Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, et al. 
2011. High density DNA methylation array with single CpG site resolution. Genomics 98(4):288-95. 
Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. 1999. The role of SOCS-3 in leptin signaling and leptin 
resistance. J Biol Chem 274(42):30059-65. 
Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. 1998. Identification of SOCS-3 as a potential 
mediator of central leptin resistance. Mol Cell 1(4):619-25. 
Blakemore AI and Froguel P. 2010. Investigation of mendelian forms of obesity holds out the prospect of 
personalized medicine. Ann N Y Acad Sci 1214:180-9. 
Blakemore AI, Meyre D, Delplanque J, Vatin V, Lecoeur C, Marre M, Tichet J, Balkau B, Froguel P, Walley 
AJ. 2009. A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from 
obesity. Obesity (Silver Spring) 17(8):1549-53. 
Blaker-Lee A, Gupta S, McCammon JM, De Rienzo G, Sive H. 2012. Zebrafish homologs of genes within 
16p11.2, a genomic region associated with brain disorders, are active during brain development, 
and include two deletion dosage sensor genes. Dis Model Mech 5(6):834-51. 
Bland JM and Altman DG. 1995. Multiple significance tests: The bonferroni method. BMJ 310(6973):170. 
Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, Saeed S, Hamilton-Shield J, 
Clayton-Smith J, O'Rahilly S, et al. 2010. Large, rare chromosomal deletions associated with severe 
early-onset obesity. Nature 463(7281):666-70. 
Bodmer W and Bonilla C. 2008. Common and rare variants in multifactorial susceptibility to common 
diseases. Nat Genet 40(6):695-701. 
References 
180 
 
Bonnefond A, Raimondo A, Stutzmann F, Ghoussaini M, Ramachandrappa S, Bersten DC, Durand E, Vatin 
V, Balkau B, Lantieri O, et al. 2013. Loss-of-function mutations in SIM1 contribute to obesity and 
prader-willi-like features. J Clin Invest 123(7):3037-41. 
Bradfield JP, Taal HR, Timpson NJ, Scherag A, Lecoeur C, Warrington NM, Hypponen E, Holst C, Valcarcel 
B, Thiering E, et al. 2012. A genome-wide association meta-analysis identifies new childhood 
obesity loci. Nat Genet 44(5):526-31. 
Bruder CE, Piotrowski A, Gijsbers AA, Andersson R, Erickson S, Diaz de Stahl T, Menzel U, Sandgren J, von 
Tell D, Poplawski A, et al. 2008. Phenotypically concordant and discordant monozygotic twins 
display different DNA copy-number-variation profiles. Am J Hum Genet 82(3):763-71. 
Cai G, Cole SA, Bastarrachea RA, Maccluer JW, Blangero J, Comuzzie AG. 2004. Quantitative trait locus 
determining dietary macronutrient intakes is located on human chromosome 2p22. Am J Clin Nutr 
80(5):1410-4. 
Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. 1995. Recombinant mouse OB protein: Evidence for a 
peripheral signal linking adiposity and central neural networks. Science 269(5223):546-9. 
Carter NP. 2007. Methods and strategies for analyzing copy number variation using DNA microarrays. 
Nat Genet 39(7 Suppl):S16-21. 
Challis BG, Pritchard LE, Creemers JW, Delplanque J, Keogh JM, Luan J, Wareham NJ, Yeo GS, 
Bhattacharyya S, Froguel P, et al. 2002. A missense mutation disrupting a dibasic prohormone 
processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity 
through a novel molecular mechanism. Hum Mol Genet 11(17):1997-2004. 
Chambers JC, Elliott P, Zabaneh D, Zhang W, Li Y, Froguel P, Balding D, Scott J, Kooner JS. 2008. Common 
genetic variation near MC4R is associated with waist circumference and insulin resistance. Nat 
Genet 40(6):716-8. 
Chambers JC, Loh M, Lehne B, Drong A, Kriebel J, Motta V, Wahl S, Elliott HR, Rota F, Scott WR, et al. 
2015. Epigenome-wide association of DNA methylation markers in peripheral blood from indian 
asians and europeans with incident type 2 diabetes: A nested case-control study. Lancet Diabetes 
Endocrinol . 
Chiang DY, Getz G, Jaffe DB, O'Kelly MJ, Zhao X, Carter SL, Russ C, Nusbaum C, Meyerson M, Lander ES. 
2009. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat 
Methods 6(1):99-103. 
Chua SC,Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL. 1996. Phenotypes of mouse 
diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271(5251):994-6. 
Church C, Moir L, McMurray F, Girard C, Banks GT, Teboul L, Wells S, Bruning JC, Nolan PM, Ashcroft FM, 
et al. 2010. Overexpression of fto leads to increased food intake and results in obesity. Nat Genet 
42(12):1086-92. 
References 
181 
 
Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. 2012. A program 
for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the 
genome of drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6(2):80-92. 
Cirulli ET and Goldstein DB. 2010. Uncovering the roles of rare variants in common disease through 
whole-genome sequencing. Nat Rev Genet 11(6):415-25. 
Clarke L, Zheng-Bradley X, Smith R, Kulesha E, Xiao C, Toneva I, Vaughan B, Preuss D, Leinonen R, 
Shumway M, et al. 2012. The 1000 genomes project: Data management and community access. Nat 
Methods 9(5):459-62. 
Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte 
JM, et al. 1998. A mutation in the human leptin receptor gene causes obesity and pituitary 
dysfunction. Nature 392(6674):398-401. 
Coin LJ, Asher JE, Walters RG, Moustafa JS, de Smith AJ, Sladek R, Balding DJ, Froguel P, Blakemore AI. 
2010. cnvHap: An integrative population and haplotype-based multiplatform model of SNPs and 
CNVs. Nat Methods 7(7):541-6. 
Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. 2003. Sensitive and quantitative universal 
pyrosequencing methylation analysis of CpG sites. BioTechniques 35(1):146-50. 
Conrad DF and Hurles ME. 2007. The population genetics of structural variation. Nat Genet 39(7 
Suppl):S30-6. 
Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. 2006. A high-resolution survey of deletion 
polymorphism in the human genome. Nat Genet 38(1):75-81. 
Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts J, Andrews TD, Barnes C, Campbell P, 
et al. 2010. Origins and functional impact of copy number variation in the human genome. Nature 
464(7289):704-12. 
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, 
McKee LJ, Bauer TL. 1996. Serum immunoreactive-leptin concentrations in normal-weight and 
obese humans. N Engl J Med 334(5):292-5. 
Cooper GM, Nickerson DA, Eichler EE. 2007. Mutational and selective effects on copy-number variants in 
the human genome. Nat Genet 39(7 Suppl):S22-9. 
Cotsapas C, Speliotes EK, Hatoum IJ, Greenawalt DM, Dobrin R, Lum PY, Suver C, Chudin E, Kemp D, 
Reitman M, et al. 2009. Common body mass index-associated variants confer risk of extreme 
obesity. Hum Mol Genet 18(18):3502-7. 
Creemers JW, Choquet H, Stijnen P, Vatin V, Pigeyre M, Beckers S, Meulemans S, Than ME, Yengo L, 
Tauber M, et al. 2012. Heterozygous mutations causing partial prohormone convertase 1 deficiency 
contribute to human obesity. Diabetes 61(2):383-90. 
References 
182 
 
Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, Roumain J, Bennett PH, Knowler 
WC. 2000. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: A study 
of discordant sibships. Diabetes 49(12):2208-11. 
de Smith AJ, Walters RG, Froguel P, Blakemore AI. 2008. Human genes involved in copy number 
variation: Mechanisms of origin, functional effects and implications for disease. Cytogenet Genome 
Res 123(1-4):17-26. 
de Smith AJ, Purmann C, Walters RG, Ellis RJ, Holder SE, Van Haelst MM, Brady AF, Fairbrother UL, 
Dattani M, Keogh JM, et al. 2009. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) 
is associated with hyperphagia, obesity and hypogonadism. Hum Mol Genet 18(17):3257-65. 
Deaton AM and Bird A. 2011. CpG islands and the regulation of transcription. Genes Dev 25(10):1010-22. 
Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. 2014. A comprehensive 
overview of infinium HumanMethylation450 data processing. Brief Bioinform 15(6):929-41. 
Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. 
1998. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower 
body mass index and improved insulin sensitivity. Nat Genet 20(3):284-7. 
Deng HW, Deng H, Liu YJ, Liu YZ, Xu FH, Shen H, Conway T, Li JL, Huang QY, Davies KM, et al. 2002. A 
genomewide linkage scan for quantitative-trait loci for obesity phenotypes. Am J Hum Genet 
70(5):1138-51. 
Diamond J. 2003. The double puzzle of diabetes. Nature 423(6940):599-602. 
Dick KJ, Nelson CP, Tsaprouni L, Sandling JK, Aissi D, Wahl S, Meduri E, Morange PE, Gagnon F, Grallert H, 
et al. 2014. DNA methylation and body-mass index: A genome-wide analysis. Lancet 
383(9933):1990-8. 
Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, Carlsson LM, Kiess W, Vatin V, Lecoeur C, et 
al. 2007. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 
39(6):724-6. 
Dong C, Wang S, Li WD, Li D, Zhao H, Price RA. 2003. Interacting genetic loci on chromosomes 20 and 10 
influence extreme human obesity. Am J Hum Genet 72(1):115-24. 
Dorajoo R, Blakemore AI, Sim X, Ong RT, Ng DP, Seielstad M, Wong TY, Saw SM, Froguel P, Liu J, et al. 
2012. Replication of 13 obesity loci among singaporean chinese, malay and asian-indian 
populations. Int J Obes (Lond) 36(1):159-63. 
Drong AW, Lindgren CM, McCarthy MI. 2012. The genetic and epigenetic basis of type 2 diabetes and 
obesity. Clin Pharmacol Ther 92(6):707-15. 
Du P, Kibbe WA, Lin SM. 2008. Lumi: A pipeline for processing illumina microarray. Bioinformatics 
24(13):1547-8. 
References 
183 
 
Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM. 2010. Comparison of beta-value and M-
value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 
11:587,2105-11-587. 
Duan J, Zhang JG, Deng HW, Wang YP. 2013. Comparative studies of copy number variation detection 
methods for next-generation sequencing technologies. PLoS One 8(3):e59128. 
Dubern B, Clement K, Pelloux V, Froguel P, Girardet JP, Guy-Grand B, Tounian P. 2001. Mutational 
analysis of melanocortin-4 receptor, agouti-related protein, and alpha-melanocyte-stimulating 
hormone genes in severely obese children. J Pediatr 139(2):204-9. 
Eleftherohorinou H, Andersson-Assarsson JC, Walters RG, El-Sayed Moustafa JS, Coin L, Jacobson P, 
Carlsson LM, Blakemore AI, Froguel P, Walley AJ, et al. 2011. famCNV: Copy number variant 
association for quantitative traits in families. Bioinformatics 27(13):1873-5. 
El-Gharbawy AH, Adler-Wailes DC, Mirch MC, Theim KR, Ranzenhofer L, Tanofsky-Kraff M, Yanovski JA. 
2006. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and 
adolescents. J Clin Endocrinol Metab 91(9):3548-52. 
Elks CE, den Hoed M, Zhao JH, Sharp SJ, Wareham NJ, Loos RJ, Ong KK. 2012. Variability in the 
heritability of body mass index: A systematic review and meta-regression. Front Endocrinol 
(Lausanne) 3:29. 
El-Sayed Moustafa JS and Froguel P. 2013. From obesity genetics to the future of personalized obesity 
therapy. Nat Rev Endocrinol 9(7):402-13. 
Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. 2000. SOCS-3 is an 
insulin-induced negative regulator of insulin signaling. J Biol Chem 275(21):15985-91. 
Falchi M, El-Sayed Moustafa JS, Takousis P, Pesce F, Bonnefond A, Andersson-Assarsson JC, Sudmant PH, 
Dorajoo R, Al-Shafai MN, Bottolo L, et al. 2014. Low copy number of the salivary amylase gene 
predisposes to obesity. Nat Genet 46(5):492-7. 
Farooqi IS. 2005. Genetic and hereditary aspects of childhood obesity. Best Pract Res Clin Endocrinol 
Metab 19(3):359-74. 
Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. 2003. Clinical spectrum of obesity and 
mutations in the melanocortin 4 receptor gene. N Engl J Med 348(12):1085-95. 
Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, O'Rahilly S. 2000. Dominant 
and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J 
Clin Invest 106(2):271-9. 
Farooqi IS, Volders K, Stanhope R, Heuschkel R, White A, Lank E, Keogh J, O'Rahilly S, Creemers JW. 
2007. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in 
prohormone convertase 1/3. J Clin Endocrinol Metab 92(9):3369-73. 
References 
184 
 
Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, 
O'Rahilly S. 1999. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. 
N Engl J Med 341(12):879-84. 
Feinberg AP, Irizarry RA, Fradin D, Aryee MJ, Murakami P, Aspelund T, Eiriksdottir G, Harris TB, Launer L, 
Gudnason V, et al. 2010. Personalized epigenomic signatures that are stable over time and covary 
with body mass index. Sci Transl Med 2(49):49ra67. 
Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, Van Vooren S, Moreau Y, Pettett RM, 
Carter NP. 2009. DECIPHER: Database of chromosomal imbalance and phenotype in humans using 
ensembl resources. Am J Hum Genet 84(4):524-33. 
Fischer J, Koch L, Emmerling C, Vierkotten J, Peters T, Bruning JC, Ruther U. 2009. Inactivation of the fto 
gene protects from obesity. Nature 458(7240):894-8. 
Fox CS, Heard-Costa NL, Wilson PW, Levy D, D'Agostino RB S, Atwood LD. 2004. Genome-wide linkage to 
chromosome 6 for waist circumference in the framingham heart study. Diabetes 53(5):1399-402. 
Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, 
Rayner NW, et al. 2007. A common variant in the FTO gene is associated with body mass index and 
predisposes to childhood and adult obesity. Science 316(5826):889-94. 
Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. 2001. Relationship of childhood obesity to 
coronary heart disease risk factors in adulthood: The bogalusa heart study. Pediatrics 108(3):712-8. 
Friedman JM and Halaas JL. 1998. Leptin and the regulation of body weight in mammals. Nature 
395(6704):763-70. 
Froguel P and Blakemore AI. 2008. The power of the extreme in elucidating obesity. N Engl J Med 
359(9):891-3. 
Fujisawa T, Ikegami H, Kawaguchi Y, Ogihara T. 1998. Meta-analysis of the association of Trp64Arg 
polymorphism of beta 3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab 
83(7):2441-4. 
Gamble KL, Berry R, Frank SJ, Young ME. 2014. Circadian clock control of endocrine factors. Nat Rev 
Endocrinol 10(8):466-75. 
Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS, Yeo GS, McDonough MA, Cunliffe S, 
McNeill LA, et al. 2007. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent 
nucleic acid demethylase. Science 318(5855):1469-72. 
Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, Trussell RA. 2004. Congenital 
leptin deficiency due to homozygosity for the Delta133G mutation: Report of another case and 
evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab 89(10):4821-6. 
References 
185 
 
Glessner JT, Bradfield JP, Wang K, Takahashi N, Zhang H, Sleiman PM, Mentch FD, Kim CE, Hou C, 
Thomas KA, et al. 2010. A genome-wide study reveals copy number variants exclusive to childhood 
obesity cases. Am J Hum Genet 87(5):661-6. 
Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C, Rodford J, Slater-Jefferies JL, 
Garratt E, Crozier SR, et al. 2011. Epigenetic gene promoter methylation at birth is associated with 
child's later adiposity. Diabetes 60(5):1528-34. 
Golzio C, Willer J, Talkowski ME, Oh EC, Taniguchi Y, Jacquemont S, Reymond A, Sun M, Sawa A, Gusella 
JF, et al. 2012. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 
copy number variant. Nature 485(7398):363-7. 
Gorlova OY, Amos CI, Wang NW, Shete S, Turner ST, Boerwinkle E. 2003. Genetic linkage and imprinting 
effects on body mass index in children and young adults. Eur J Hum Genet 11(6):425-32. 
Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, Keogh JM, Yanovski JA, El Gharbawy A, Han JC, Tung YC, et al. 
2006. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with 
functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 
55(12):3366-71. 
Greer SN, Metcalf JL, Wang Y, Ohh M. 2012. The updated biology of hypoxia-inducible factor. EMBO J 
31(11):2448-60. 
Groom A, Potter C, Swan DC, Fatemifar G, Evans DM, Ring SM, Turcot V, Pearce MS, Embleton ND, Smith 
GD, et al. 2012. Postnatal growth and DNA methylation are associated with differential gene 
expression of the TACSTD2 gene and childhood fat mass. Diabetes 61(2):391-400. 
Gu H, Bock C, Mikkelsen TS, Jager N, Smith ZD, Tomazou E, Gnirke A, Lander ES, Meissner A. 2010. 
Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat 
Methods 7(2):133-6. 
Guo DF and Rahmouni K. 2011. Molecular basis of the obesity associated with bardet-biedl syndrome. 
Trends Endocrinol Metab 22(7):286-93. 
Guo Y, Lanktree MB, Taylor KC, Hakonarson H, Lange LA, Keating BJ, IBC 50K SNP array BMI Consortium. 
2013. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and 
reveal three novel signals. Hum Mol Genet 22(1):184-201. 
Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, Down TA, Surani MA. 2013. Germline DNA 
demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Science 
339(6118):448-52. 
Hager J, Dina C, Francke S, Dubois S, Houari M, Vatin V, Vaillant E, Lorentz N, Basdevant A, Clement K, et 
al. 1998. A genome-wide scan for human obesity genes reveals a major susceptibility locus on 
chromosome 10. Nat Genet 20(3):304-8. 
References 
186 
 
Hainerova I, Torekov SS, Ek J, Finkova M, Borch-Johnsen K, Jorgensen T, Madsen OD, Lebl J, Hansen T, 
Pedersen O. 2006. Association between neuromedin U gene variants and overweight and obesity. J 
Clin Endocrinol Metab 91(12):5057-63. 
Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. 
1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 
269(5223):543-6. 
Hanson RL, Ehm MG, Pettitt DJ, Prochazka M, Thompson DB, Timberlake D, Foroud T, Kobes S, Baier L, 
Burns DK, et al. 1998. An autosomal genomic scan for loci linked to type II diabetes mellitus and 
body-mass index in pima indians. Am J Hum Genet 63(4):1130-8. 
Haslam DW and James WP. 2005. Obesity. Lancet 366(9492):1197-209. 
Heard-Costa NL, Zillikens MC, Monda KL, Johansson A, Harris TB, Fu M, Haritunians T, Feitosa MF, 
Aspelund T, Eiriksdottir G, et al. 2009. NRXN3 is a novel locus for waist circumference: A genome-
wide association study from the CHARGE consortium. PLoS Genet 5(6):e1000539. 
Heinzen EL, Depondt C, Cavalleri GL, Ruzzo EK, Walley NM, Need AC, Ge D, He M, Cirulli ET, Zhao Q, et al. 
2012. Exome sequencing followed by large-scale genotyping fails to identify single rare variants of 
large effect in idiopathic generalized epilepsy. Am J Hum Genet 91(2):293-302. 
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR 
assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93(18):9821-6. 
Hinds DA, Kloek AP, Jen M, Chen X, Frazer KA. 2006. Common deletions and SNPs are in linkage 
disequilibrium in the human genome. Nat Genet 38(1):82-5. 
Hinney A, Nguyen TT, Scherag A, Friedel S, Bronner G, Muller TD, Grallert H, Illig T, Wichmann HE, Rief 
W, et al. 2007. Genome wide association (GWA) study for early onset extreme obesity supports the 
role of fat mass and obesity associated gene (FTO) variants. PLoS One 2(12):e1361. 
Hinney A, Bettecken T, Tarnow P, Brumm H, Reichwald K, Lichtner P, Scherag A, Nguyen TT, 
Schlumberger P, Rief W, et al. 2006. Prevalence, spectrum, and functional characterization of 
melanocortin-4 receptor gene mutations in a representative population-based sample and obese 
adults from germany. J Clin Endocrinol Metab 91(5):1761-9. 
Holder JL,Jr, Butte NF, Zinn AR. 2000. Profound obesity associated with a balanced translocation that 
disrupts the SIM1 gene. Hum Mol Genet 9(1):101-8. 
Holliday R and Pugh JE. 1975. DNA modification mechanisms and gene activity during development. 
Science 187(4173):226-32. 
HOTCHKISS RD. 1948. The quantitative separation of purines, pyrimidines, and nucleosides by paper 
chromatography. J Biol Chem 175(1):315-32. 
References 
187 
 
Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, Kelsey 
KT. 2012. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC 
Bioinformatics 13:86,2105-13-86. 
Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM, Zeng Z, Williams DL,Jr, Feighner SD, Nunes 
CN, et al. 2000. Identification of receptors for neuromedin U and its role in feeding. Nature 
406(6791):70-4. 
Hu H, Roach JC, Coon H, Guthery SL, Voelkerding KV, Margraf RL, Durtschi JD, Tavtigian SV, 
Shankaracharya, Wu W, et al. 2014. A unified test of linkage analysis and rare-variant association 
for analysis of pedigree sequence data. Nat Biotechnol 32(7):663-9. 
Hunt SC, Abkevich V, Hensel CH, Gutin A, Neff CD, Russell DL, Tran T, Hong X, Jammulapati S, Riley R, et 
al. 2001. Linkage of body mass index to chromosome 20 in utah pedigrees. Hum Genet 109(3):279-
85. 
Hunter-Zinck H, Musharoff S, Salit J, Al-Ali KA, Chouchane L, Gohar A, Matthews R, Butler MW, Fuller J, 
Hackett NR, et al. 2010. Population genetic structure of the people of qatar. Am J Hum Genet 
87(1):17-25. 
Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, 
Boston BA, Cone RD, et al. 1997. Targeted disruption of the melanocortin-4 receptor results in 
obesity in mice. Cell 88(1):131-41. 
Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C. 2004. Detection of 
large-scale variation in the human genome. Nat Genet 36(9):949-51. 
Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, Kimura I, Leloire A, Liu N, 
Iida K, et al. 2012. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. 
Nature 483(7389):350-4. 
Illumina. BeadArray Microarray Technology [Internet]; c2015 [cited 2014 11/12]. Available from: 
http://technology.illumina.com/technology/beadarray-technology.html . 
Illumina. Infinium Genotyping Data Analysis (Technical Note: Genotyping) [Internet]; c2014 [cited 2014 
January 20]. Available from: 
http://res.illumina.com/documents/products/technotes/technote_infinium_genotyping_data_anal
ysis.pdf . 
Illumina. HumanOmni2.5-8 BeadChips (Data Sheet) [Internet]; c2013 [cited 2013 February 17]. Available 
from: http://www.illumina.com/content/dam/illumina-
marketing/documents/products/datasheets/datasheet_human_omni2.5.pdf . 
Illumina. Infinium HumanMethylation450 BeadChip (Data Sheet: Epigenetics) [Internet]; c2012a [cited 
2014 September 20]. Available from: 
http://www.illumina.com/Documents/products/datasheets/datasheet_humanmethylation450.pdf 
. 
References 
188 
 
Illumina. HumanMethylation450 BeadChip Achieves Breadth of Coverage Using Two Infinium® 
Chemistries (Technical Note) [Internet]; c2012b [cited 2012 January 20]. Available from: 
http://www.illumina.com/documents/products/technotes/technote_hm450_data_analysis_optimi
zation.pdf . 
Illumina. HumanLinkage Panels for Infinium and GoldenGate SNP Genotyping (Data Sheet) [Internet]; 
c2007 [cited 2012 . Available from: 
http://supportres.illumina.com/documents/products/datasheets/datasheet_goldengate_infinium_
linkage_panels.pdf . 
Ingalls AM, Dickie MM, Snell GD. 1950. Obese, a new mutation in the house mouse. J Hered 41(12):317-
8. 
International HapMap Consortium. 2005. A haplotype map of the human genome. Nature 
437(7063):1299-320. 
International HapMap Consortium. 2003. The international HapMap project. Nature 426(6968):789-96. 
International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, 
Belmont JW, Boudreau A, Hardenbol P, et al. 2007. A second generation human haplotype map of 
over 3.1 million SNPs. Nature 449(7164):851-61. 
Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O'Rahilly S. 
1997. Obesity and impaired prohormone processing associated with mutations in the human 
prohormone convertase 1 gene. Nat Genet 16(3):303-6. 
Jacquemont S, Reymond A, Zufferey F, Harewood L, Walters RG, Kutalik Z, Martinet D, Shen Y, Valsesia 
A, Beckmann ND, et al. 2011. Mirror extreme BMI phenotypes associated with gene dosage at the 
chromosome 16p11.2 locus. Nature 478(7367):97-102. 
Jaenisch R and Bird A. 2003. Epigenetic regulation of gene expression: How the genome integrates 
intrinsic and environmental signals. Nat Genet 33 Suppl:245-54. 
Jamshidi Y, Snieder H, Ge D, Spector TD, O'Dell SD. 2007. The SH2B gene is associated with serum leptin 
and body fat in normal female twins. Obesity (Silver Spring) 15(1):5-9. 
Jarick I, Vogel CI, Scherag S, Schafer H, Hebebrand J, Hinney A, Scherag A. 2011. Novel common copy 
number variation for early onset extreme obesity on chromosome 11q11 identified by a genome-
wide analysis. Hum Mol Genet 20(4):840-52. 
Jeyakumar SM, Vajreswari A, Giridharan NV. 2006. Chronic dietary vitamin A supplementation regulates 
obesity in an obese mutant WNIN/ob rat model. Obesity (Silver Spring) 14(1):52-9. 
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. 1992. Comparative 
genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258(5083):818-
21. 
References 
189 
 
Karimi M, Johansson S, Stach D, Corcoran M, Grander D, Schalling M, Bakalkin G, Lyko F, Larsson C, 
Ekstrom TJ. 2006. LUMA (LUminometric methylation assay)--a high throughput method to the 
analysis of genomic DNA methylation. Exp Cell Res 312(11):1989-95. 
Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ, Walley AJ, Kyrieleis O, 
Khan A, et al. 2007. A mal functional variant is associated with protection against invasive 
pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39(4):523-8. 
Kilpelainen TO, Zillikens MC, Stancakova A, Finucane FM, Ried JS, Langenberg C, Zhang W, Beckmann JS, 
Luan J, Vandenput L, et al. 2011. Genetic variation near IRS1 associates with reduced adiposity and 
an impaired metabolic profile. Nat Genet 43(8):753-60. 
Kirin M, McQuillan R, Franklin CS, Campbell H, McKeigue PM, Wilson JF. 2010. Genomic runs of 
homozygosity record population history and consanguinity. PLoS One 5(11):e13996. 
Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, 
Jacob HJ, Weber J, et al. 2000. Quantitative trait loci on chromosomes 3 and 17 influence 
phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A 97(26):14478-83. 
Klose RJ and Bird AP. 2006. Genomic DNA methylation: The mark and its mediators. Trends Biochem Sci 
31(2):89-97. 
Knowler WC, Pettitt DJ, Saad MF, Bennett PH. 1990. Diabetes mellitus in the pima indians: Incidence, 
risk factors and pathogenesis. Diabetes Metab Rev 6(1):1-27. 
Kohno D, Gao HZ, Muroya S, Kikuyama S, Yada T. 2003. Ghrelin directly interacts with neuropeptide-Y-
containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type 
channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 52(4):948-56. 
Kondo T, Hayakawa T, Shibata T, Sato Y, Toda Y. 1988. Serum levels of pancreatic enzymes in lean and 
obese subjects. Int J Pancreatol 3(4):241-8. 
Korbel JO, Urban AE, Affourtit JP, Godwin B, Grubert F, Simons JF, Kim PM, Palejev D, Carriero NJ, Du L, 
et al. 2007. Paired-end mapping reveals extensive structural variation in the human genome. 
Science 318(5849):420-6. 
Korbie DJ and Mattick JS. 2008. Touchdown PCR for increased specificity and sensitivity in PCR 
amplification. Nat Protoc 3(9):1452-6. 
Krude H and Gruters A. 2000. Implications of proopiomelanocortin (POMC) mutations in humans: The 
POMC deficiency syndrome. Trends Endocrinol Metab 11(1):15-22. 
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. 1998. Severe early-onset obesity, adrenal 
insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 
19(2):155-7. 
Kruglyak L. 1997. The use of a genetic map of biallelic markers in linkage studies. Nat Genet 17(1):21-4. 
References 
190 
 
Kruit JK, Wijesekara N, Westwell-Roper C, Vanmierlo T, de Haan W, Bhattacharjee A, Tang R, Wellington 
CL, LutJohann D, Johnson JD, et al. 2012. Loss of both ABCA1 and ABCG1 results in increased 
disturbances in islet sterol homeostasis, inflammation, and impaired beta-cell function. Diabetes 
61(3):659-64. 
Ku CS, Loy EY, Pawitan Y, Chia KS. 2010. The pursuit of genome-wide association studies: Where are we 
now? J Hum Genet 55(4):195-206. 
Kublaoui BM, Holder JL,Jr, Gemelli T, Zinn AR. 2006. Sim1 haploinsufficiency impairs melanocortin-
mediated anorexia and activation of paraventricular nucleus neurons. Mol Endocrinol 20(10):2483-
92. 
Kuehnen P, Mischke M, Wiegand S, Sers C, Horsthemke B, Lau S, Keil T, Lee YA, Grueters A, Krude H. 
2012. An alu element-associated hypermethylation variant of the POMC gene is associated with 
childhood obesity. PLoS Genet 8(3):e1002543. 
Kulkarni H, Kos MZ, Neary J, Dyer TD, Harald HH, Cole SA, Comuzzie AG, Almasy L, Mahaney MC, Curran 
JE, et al. Novel epigenetic determinants of type 2 diabetes in Mexican American families [Internet]; 
c2015 [cited 2015 June 24]. Available from: 
http://hmg.oxfordjournals.org/content/early/2015/06/21/hmg.ddv232.abstract . 
Kumar P, Al-Shafai M, Al Muftah WA, Chalhoub N, Elsaid MF, Aleem AA, Suhre K. 2014. Evaluation of 
SNP calling using single and multiple-sample calling algorithms by validation against array base 
genotyping and mendelian inheritance. BMC Res Notes 7:747,0500-7-747. 
Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, Badner JA, Gilliam TC, Nowak NJ, Cook EH,Jr, 
Dobyns WB, et al. 2008. Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet 17(4):628-38. 
Kurokawa N, Young EH, Oka Y, Satoh H, Wareham NJ, Sandhu MS, Loos RJ. 2008. The ADRB3 Trp64Arg 
variant and BMI: A meta-analysis of 44 833 individuals. Int J Obes (Lond) 32(8):1240-9. 
Ladd-Acosta C, Aryee MJ, Ordway JM, Feinberg AP. 2010. Comprehensive high-throughput arrays for 
relative methylation (CHARM). Curr Protoc Hum Genet Chapter 20:Unit 20.1.1-19. 
Lan X, Adams C, Landers M, Dudas M, Krissinger D, Marnellos G, Bonneville R, Xu M, Wang J, Huang TH, 
et al. 2011. High resolution detection and analysis of CpG dinucleotides methylation using MBD-seq 
technology. PLoS One 6(7):e22226. 
Lander E and Kruglyak L. 1995. Genetic dissection of complex traits: Guidelines for interpreting and 
reporting linkage results. Nat Genet 11(3):241-7. 
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh 
W, et al. 2001. Initial sequencing and analysis of the human genome. Nature 409(6822):860-921. 
Langmead B and Salzberg SL. 2012. Fast gapped-read alignment with bowtie 2. Nat Methods 9(4):357-9. 
References 
191 
 
Lee JH, Reed DR, Li WD, Xu W, Joo EJ, Kilker RL, Nanthakumar E, North M, Sakul H, Bell C, et al. 1999. 
Genome scan for human obesity and linkage to markers in 20q13. Am J Hum Genet 64(1):196-209. 
Lemas DJ, Wiener HW, O'Brien DM, Hopkins S, Stanhope KL, Havel PJ, Allison DB, Fernandez JR, Tiwari 
HK, Boyer BB. 2012. Genetic polymorphisms in carnitine palmitoyltransferase 1A gene are 
associated with variation in body composition and fasting lipid traits in yup'ik eskimos. J Lipid Res 
53(1):175-84. 
Li B, Zhan X, Wing MK, Anderson P, Kang HM, Abecasis GR. 2013. QPLOT: A quality assessment tool for 
next generation sequencing data. Biomed Res Int 2013:865181. 
Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, et al. 
2009. Human DNA methylomes at base resolution show widespread epigenomic differences. 
Nature 462(7271):315-22. 
Liu J, Morgan M, Hutchison K, Calhoun VD. 2010. A study of the influence of sex on genome wide 
methylation. PLoS One 5(4):e10028. 
Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, Reinius L, Acevedo N, Taub M, 
Ronninger M, et al. 2013. Epigenome-wide association data implicate DNA methylation as an 
intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 31(2):142-7. 
Liu YJ, Rocha-Sanchez SM, Liu PY, Long JR, Lu Y, Elze L, Recker RR, Deng HW. 2004a. Tests of linkage 
and/or association of the LEPR gene polymorphisms with obesity phenotypes in caucasian nuclear 
families. Physiol Genomics 17(2):101-6. 
Liu YJ, Xu FH, Shen H, Liu YZ, Deng HY, Zhao LJ, Huang QY, Dvornyk V, Conway T, Davies KM, et al. 2004b. 
A follow-up linkage study for quantitative trait loci contributing to obesity-related phenotypes. J 
Clin Endocrinol Metab 89(2):875-82. 
Lloyd DJ, Bohan S, Gekakis N. 2006. Obesity, hyperphagia and increased metabolic efficiency in Pc1 
mutant mice. Hum Mol Genet 15(11):1884-93. 
Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, 
et al. 2015. Genetic studies of body mass index yield new insights for obesity biology. Nature 
518(7538):197-206. 
Locke DP, Sharp AJ, McCarroll SA, McGrath SD, Newman TL, Cheng Z, Schwartz S, Albertson DG, Pinkel D, 
Altshuler DM, et al. 2006. Linkage disequilibrium and heritability of copy-number polymorphisms 
within duplicated regions of the human genome. Am J Hum Genet 79(2):275-90. 
Loos RJ, Barroso I, O'rahilly S, Wareham NJ. 2007. Comment on "A common genetic variant is associated 
with adult and childhood obesity". Science 315(5809):187; author reply 187. 
Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Inouye M, Freathy RM, Attwood AP, 
Beckmann JS, et al. 2008. Common variants near MC4R are associated with fat mass, weight and 
risk of obesity. Nat Genet 40(6):768-75. 
References 
192 
 
Lubrano-Berthelier C, Dubern B, Lacorte JM, Picard F, Shapiro A, Zhang S, Bertrais S, Hercberg S, 
Basdevant A, Clement K, et al. 2006. Melanocortin 4 receptor mutations in a large cohort of 
severely obese adults: Prevalence, functional classification, genotype-phenotype relationship, and 
lack of association with binge eating. J Clin Endocrinol Metab 91(5):1811-8. 
Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A, Sebat J, Troge J, et al. 
2003. Representational oligonucleotide microarray analysis: A high-resolution method to detect 
genome copy number variation. Genome Res 13(10):2291-305. 
Luke A, Wu X, Zhu X, Kan D, Su Y, Cooper R. 2003. Linkage for BMI at 3q27 region confirmed in an 
african-american population. Diabetes 52(5):1284-7. 
Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker 
DF, Killian JM, Garcia CA, et al. 1991. DNA duplication associated with charcot-marie-tooth disease 
type 1A. Cell 66(2):219-32. 
Lustig Y, Barhod E, Ashwal-Fluss R, Gordin R, Shomron N, Baruch-Umansky K, Hemi R, Karasik A, Kanety 
H. 2014. RNA-binding protein PTB and microRNA-221 coregulate AdipoR1 translation and 
adiponectin signaling. Diabetes 63(2):433-45. 
Ma L, Tataranni PA, Bogardus C, Baier LJ. 2004. Melanocortin 4 receptor gene variation is associated 
with severe obesity in pima indians. Diabetes 53(10):2696-9. 
MacDonald JR, Ziman R, Yuen RK, Feuk L, Scherer SW. 2014. The database of genomic variants: A 
curated collection of structural variation in the human genome. Nucleic Acids Res 42(Database 
issue):D986-92. 
Maes HH, Neale MC, Eaves LJ. 1997. Genetic and environmental factors in relative body weight and 
human adiposity. Behav Genet 27(4):325-51. 
Magi R and Morris AP. 2010. GWAMA: Software for genome-wide association meta-analysis. BMC 
Bioinformatics 11:288,2105-11-288. 
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon 
LR, Chakravarti A, et al. 2009. Finding the missing heritability of complex diseases. Nature 
461(7265):747-53. 
Marabita F, Almgren M, Lindholm ME, Ruhrmann S, Fagerstrom-Billai F, Jagodic M, Sundberg CJ, Ekstrom 
TJ, Teschendorff AE, Tegner J, et al. 2013. An evaluation of analysis pipelines for DNA methylation 
profiling using the illumina HumanMethylation450 BeadChip platform. Epigenetics 8(3):333-46. 
Mauldin JP, Nagelin MH, Wojcik AJ, Srinivasan S, Skaflen MD, Ayers CR, McNamara CA, Hedrick CC. 2008. 
Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in 
macrophages of patients with type 2 diabetes mellitus. Circulation 117(21):2785-92. 
References 
193 
 
Mazen I, El-Gammal M, Abdel-Hamid M, Farooqi IS, Amr K. 2011. Homozygosity for a novel missense 
mutation in the leptin receptor gene (P316T) in two egyptian cousins with severe early onset 
obesity. Mol Genet Metab 102(4):461-4. 
McCarroll SA and Altshuler DM. 2007. Copy-number variation and association studies of human disease. 
Nat Genet 39(7 Suppl):S37-42. 
McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN. 2008. Genome-
wide association studies for complex traits: Consensus, uncertainty and challenges. Nat Rev Genet 
9(5):356-69. 
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel 
S, Daly M, et al. 2010. The genome analysis toolkit: A MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res 20(9):1297-303. 
McRae AF, Powell JE, Henders AK, Bowdler L, Hemani G, Shah S, Painter JN, Martin NG, Visscher PM, 
Montgomery GW. 2014. Contribution of genetic variation to transgenerational inheritance of DNA 
methylation. Genome Biol 15(5):R73. 
Mejia-Benitez MA, Bonnefond A, Yengo L, Huyvaert M, Dechaume A, Peralta-Romero J, Klunder-Klunder 
M, Garcia Mena J, El-Sayed Moustafa JS, Falchi M, et al. 2015. Beneficial effect of a high number of 
copies of salivary amylase AMY1 gene on obesity risk in mexican children. Diabetologia 58(2):290-4. 
Meselson M, Yuan R, Heywood J. 1972. Restriction and modification of DNA. Annu Rev Biochem 41:447-
66. 
Meyre D, Lecoeur C, Delplanque J, Francke S, Vatin V, Durand E, Weill J, Dina C, Froguel P. 2004. A 
genome-wide scan for childhood obesity-associated traits in french families shows significant 
linkage on chromosome 6q22.31-q23.2. Diabetes 53(3):803-11. 
Meyre D, Delplanque J, Chevre JC, Lecoeur C, Lobbens S, Gallina S, Durand E, Vatin V, Degraeve F, 
Proenca C, et al. 2009. Genome-wide association study for early-onset and morbid adult obesity 
identifies three new risk loci in european populations. Nat Genet 41(2):157-9. 
Michels KB, Binder AM, Dedeurwaerder S, Epstein CB, Greally JM, Gut I, Houseman EA, Izzi B, Kelsey KT, 
Meissner A, et al. 2013. Recommendations for the design and analysis of epigenome-wide 
association studies. Nat Methods 10(10):949-55. 
Miller CA, Hampton O, Coarfa C, Milosavljevic A. 2011. ReadDepth: A parallel R package for detecting 
copy number alterations from short sequencing reads. PLoS One 6(1):e16327. 
Mills RE, Luttig CT, Larkins CE, Beauchamp A, Tsui C, Pittard WS, Devine SE. 2006. An initial map of 
insertion and deletion (INDEL) variation in the human genome. Genome Res 16(9):1182-90. 
Moayyeri A, Hammond CJ, Valdes AM, Spector TD. 2013. Cohort profile: TwinsUK and healthy ageing 
twin study. Int J Epidemiol 42(1):76-85. 
References 
194 
 
Mohn F, Weber M, Schubeler D, Roloff TC. 2009. Methylated DNA immunoprecipitation (MeDIP). 
Methods Mol Biol 507:55-64. 
Moise AR, Lobo GP, Erokwu B, Wilson DL, Peck D, Alvarez S, Dominguez M, Alvarez R, Flask CA, de Lera 
AR, et al. 2010. Increased adiposity in the retinol saturase-knockout mouse. FASEB J 24(4):1261-70. 
Monda KL, Chen GK, Taylor KC, Palmer C, Edwards TL, Lange LA, Ng MC, Adeyemo AA, Allison MA, Bielak 
LF, et al. 2013. A meta-analysis identifies new loci associated with body mass index in individuals of 
african ancestry. Nat Genet 45(6):690-6. 
Montagne L, Raimondo A, Delobel B, Duban-Bedu B, Noblet FS, Dechaume A, Bersten DC, Meyre D, 
Whitelaw ML, Froguel P, et al. 2014. Identification of two novel loss-of-function SIM1 mutations in 
two overweight children with developmental delay. Obesity (Silver Spring) 22(12):2621-4. 
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed 
SN, Hurst JA, et al. 1997. Congenital leptin deficiency is associated with severe early-onset obesity 
in humans. Nature 387(6636):903-8. 
Morgan HD, Sutherland HG, Martin DI, Whitelaw E. 1999. Epigenetic inheritance at the agouti locus in 
the mouse. Nat Genet 23(3):314-8. 
Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, 
Yoshimura A. 2004. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance 
to diet-induced obesity. Nat Med 10(7):739-43. 
Moslehi R, Goldstein AM, Beerman M, Goldin L, Bergen AW, Framingham Heart Study. 2003. A genome-
wide linkage scan for body mass index on framingham heart study families. BMC Genet 4 Suppl 
1:S97. 
Murray SS, Oliphant A, Shen R, McBride C, Steeke RJ, Shannon SG, Rubano T, Kermani BG, Fan JB, Chee 
MS, et al. 2004. A highly informative SNP linkage panel for human genetic studies. Nat Methods 
1(2):113-7. 
Need AC, McEvoy JP, Gennarelli M, Heinzen EL, Ge D, Maia JM, Shianna KV, He M, Cirulli ET, Gumbs CE, 
et al. 2012. Exome sequencing followed by large-scale genotyping suggests a limited role for 
moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet 91(2):303-12. 
Neel JV. 1999. Diabetes mellitus: A "thrifty" genotype rendered detrimental by "progress"? 1962. Bull 
World Health Organ 77(8):694,703; discussion 692-3. 
Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. 2009. Rare variants of IFIH1, a gene implicated in 
antiviral responses, protect against type 1 diabetes. Science 324(5925):387-9. 
Ng PC and Henikoff S. 2003. SIFT: Predicting amino acid changes that affect protein function. Nucleic 
Acids Res 31(13):3812-4. 
References 
195 
 
Ng SF, Lin RC, Laybutt DR, Barres R, Owens JA, Morris MJ. 2010. Chronic high-fat diet in fathers programs 
beta-cell dysfunction in female rat offspring. Nature 467(7318):963-6. 
Nguyen DQ, Webber C, Ponting CP. 2006. Bias of selection on human copy-number variants. PLoS Genet 
2(2):e20. 
Norman RA, Thompson DB, Foroud T, Garvey WT, Bennett PH, Bogardus C, Ravussin E. 1997. 
Genomewide search for genes influencing percent body fat in pima indians: Suggestive linkage at 
chromosome 11q21-q22. pima diabetes gene group. Am J Hum Genet 60(1):166-73. 
Norman RA, Tataranni PA, Pratley R, Thompson DB, Hanson RL, Prochazka M, Baier L, Ehm MG, Sakul H, 
Foroud T, et al. 1998. Autosomal genomic scan for loci linked to obesity and energy metabolism in 
pima indians. Am J Hum Genet 62(3):659-68. 
Norris JM, Langefeld CD, Scherzinger AL, Rich SS, Bookman E, Beck SR, Saad MF, Haffner SM, Bergman 
RN, Bowden DW, et al. 2005. Quantitative trait loci for abdominal fat and BMI in hispanic-
americans and african-americans: The IRAS family study. Int J Obes (Lond) 29(1):67-77. 
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. 2006. Prevalence of overweight 
and obesity in the united states, 1999-2004. JAMA 295(13):1549-55. 
O'Rahilly S, Farooqi IS, Yeo GS, Challis BG. 2003. Minireview: Human obesity-lessons from monogenic 
disorders. Endocrinology 144(9):3757-64. 
Ozata M, Ozdemir IC, Licinio J. 1999. Human leptin deficiency caused by a missense mutation: Multiple 
endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new 
targets for leptin action, greater central than peripheral resistance to the effects of leptin, and 
spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 84(10):3686-95. 
Palmer LJ, Buxbaum SG, Larkin E, Patel SR, Elston RC, Tishler PV, Redline S. 2003. A whole-genome scan 
for obstructive sleep apnea and obesity. Am J Hum Genet 72(2):340-50. 
Panoutsopoulou K and Zeggini E. 2009. Finding common susceptibility variants for complex disease: 
Past, present and future. Brief Funct Genomic Proteomic 8(5):345-52. 
Park H, Kim JI, Ju YS, Gokcumen O, Mills RE, Kim S, Lee S, Suh D, Hong D, Kang HP, et al. 2010. Discovery 
of common asian copy number variants using integrated high-resolution array CGH and massively 
parallel DNA sequencing. Nat Genet 42(5):400-5. 
Paternoster L, Evans DM, Nohr EA, Holst C, Gaborieau V, Brennan P, Gjesing AP, Grarup N, Witte DR, 
Jorgensen T, et al. 2011. Genome-wide population-based association study of extremely 
overweight young adults--the GOYA study. PLoS One 6(9):e24303. 
Pearce LR, Atanassova N, Banton MC, Bottomley B, van der Klaauw AA, Revelli JP, Hendricks A, Keogh 
JM, Henning E, Doree D, et al. 2013. KSR2 mutations are associated with obesity, insulin resistance, 
and impaired cellular fuel oxidation. Cell 155(4):765-77. 
References 
196 
 
Peier A, Kosinski J, Cox-York K, Qian Y, Desai K, Feng Y, Trivedi P, Hastings N, Marsh DJ. 2009. The 
antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated 
predominantly by the neuromedin U receptor 2 (NMUR2). Endocrinology 150(7):3101-9. 
Peiffer DA, Le JM, Steemers FJ, Chang W, Jenniges T, Garcia F, Haden K, Li J, Shaw CA, Belmont J, et al. 
2006. High-resolution genomic profiling of chromosomal aberrations using infinium whole-genome 
genotyping. Genome Res 16(9):1136-48. 
Perrone L, Marzuillo P, Grandone A, del Giudice EM. 2010. Chromosome 16p11.2 deletions: Another 
piece in the genetic puzzle of childhood obesity. Ital J Pediatr 36:43. 
Perry GH, Ben-Dor A, Tsalenko A, Sampas N, Rodriguez-Revenga L, Tran CW, Scheffer A, Steinfeld I, 
Tsang P, Yamada NA, et al. 2008. The fine-scale and complex architecture of human copy-number 
variation. Am J Hum Genet 82(3):685-95. 
Petersen AK, Zeilinger S, Kastenmuller G, Romisch-Margl W, Brugger M, Peters A, Meisinger C, Strauch K, 
Hengstenberg C, Pagel P, et al. 2014. Epigenetics meets metabolomics: An epigenome-wide 
association study with blood serum metabolic traits. Hum Mol Genet 23(2):534-45. 
Pettitt DJ, Baird HR, Aleck KA, Bennett PH, Knowler WC. 1983. Excessive obesity in offspring of pima 
indian women with diabetes during pregnancy. N Engl J Med 308(5):242-5. 
Philippe J, Stijnen P, Meyre D, De Graeve F, Thuillier D, Delplanque J, Gyapay G, Sand O, Creemers JW, 
Froguel P, et al. 2015. A nonsense loss-of-function mutation in PCSK1 contributes to dominantly 
inherited human obesity. Int J Obes (Lond) 39(2):295-302. 
Pickett LA, Yourshaw M, Albornoz V, Chen Z, Solorzano-Vargas RS, Nelson SF, Martin MG, Lindberg I. 
2013. Functional consequences of a novel variant of PCSK1. PLoS One 8(1):e55065. 
Piotrowski A, Bruder CE, Andersson R, Diaz de Stahl T, Menzel U, Sandgren J, Poplawski A, von Tell D, 
Crasto C, Bogdan A, et al. 2008. Somatic mosaicism for copy number variation in differentiated 
human tissues. Hum Mutat 29(9):1118-24. 
Price RA, Li WD, Bernstein A, Crystal A, Golding EM, Weisberg SJ, Zuckerman WA. 2001. A locus affecting 
obesity in human chromosome region 10p12. Diabetologia 44(3):363-6. 
Pritchard JK. 2001. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 
69(1):124-37. 
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly 
MJ, et al. 2007. PLINK: A tool set for whole-genome association and population-based linkage 
analyses. Am J Hum Genet 81(3):559-75. 
Radford EJ, Ito M, Shi H, Corish JA, Yamazawa K, Isganaitis E, Seisenberger S, Hore TA, Reik W, Erkek S, et 
al. 2014. In utero effects. in utero undernourishment perturbs the adult sperm methylome and 
intergenerational metabolism. Science 345(6198):1255903. 
References 
197 
 
Ramachandrappa S, Raimondo A, Cali AM, Keogh JM, Henning E, Saeed S, Thompson A, Garg S, 
Bochukova EG, Brage S, et al. 2013. Rare variants in single-minded 1 (SIM1) are associated with 
severe obesity. J Clin Invest 123(7):3042-50. 
Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaenisch R. 2000. Non-CpG methylation is 
prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl 
Acad Sci U S A 97(10):5237-42. 
Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Perusse L, Bouchard C. 2006. 
The human obesity gene map: The 2005 update. Obesity (Silver Spring) 14(4):529-644. 
Razin A and Cedar H. 1977. Distribution of 5-methylcytosine in chromatin. Proc Natl Acad Sci U S A 
74(7):2725-8. 
Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, 
et al. 2006. Global variation in copy number in the human genome. Nature 444(7118):444-54. 
Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D, Soderhall C, Scheynius A, Kere J. 
2012. Differential DNA methylation in purified human blood cells: Implications for cell lineage and 
studies on disease susceptibility. PLoS One 7(7):e41361. 
Relton CL, Groom A, St Pourcain B, Sayers AE, Swan DC, Embleton ND, Pearce MS, Ring SM, Northstone 
K, Tobias JH, et al. 2012. DNA methylation patterns in cord blood DNA and body size in childhood. 
PLoS One 7(3):e31821. 
Ren D, Li M, Duan C, Rui L. 2005a. Identification of SH2-B as a key regulator of leptin sensitivity, energy 
balance, and body weight in mice. Cell Metab 2(2):95-104. 
Ren D, Zhou Y, Morris D, Li M, Li Z, Rui L. 2007. Neuronal SH2B1 is essential for controlling energy and 
glucose homeostasis. J Clin Invest 117(2):397-406. 
Ren H, Francis W, Boys A, Chueh AC, Wong N, La P, Wong LH, Ryan J, Slater HR, Choo KH. 2005b. BAC-
based PCR fragment microarray: High-resolution detection of chromosomal deletion and 
duplication breakpoints. Hum Mutat 25(5):476-82. 
Rhythm. Rhythm initiates clinical trial of RM-493 for obesity caused by genetic variant [Internet]; c2013 
[cited 2014 September 20]. Available from: 
http://www.rhythmtx.com/NEWS/releases/2013%200924%20Rhythm%20RM-493%20MC4R-
Deficiency%20Trial.html . 
Ribases M, Gratacos M, Fernandez-Aranda F, Bellodi L, Boni C, Anderluh M, Cristina Cavallini M, Cellini E, 
Di Bella D, Erzegovesi S, et al. 2005. Association of BDNF with restricting anorexia nervosa and 
minimum body mass index: A family-based association study of eight european populations. Eur J 
Hum Genet 13(4):428-34. 
Riggs AD. 1975. X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet 14(1):9-25. 
References 
198 
 
Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. 1998. Obesity associated with a mutation in 
a genetic regulator of adipocyte differentiation. N Engl J Med 339(14):953-9. 
Ross JS and Cronin M. 2011. Whole cancer genome sequencing by next-generation methods. Am J Clin 
Pathol 136(4):527-39. 
Rotimi CN, Comuzzie AG, Lowe WL, Luke A, Blangero J, Cooper RS. 1999. The quantitative trait locus on 
chromosome 2 for serum leptin levels is confirmed in african-americans. Diabetes 48(3):643-4. 
Rozen S and Skaletsky H. 2000. Primer3 on the WWW for general users and for biologist programmers. 
Methods Mol Biol 132:365-86. 
Rui L, Yuan M, Frantz D, Shoelson S, White MF. 2002. SOCS-1 and SOCS-3 block insulin signaling by 
ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277(44):42394-8. 
Saeed S, Butt TA, Anwer M, Arslan M, Froguel P. 2012. High prevalence of leptin and melanocortin-4 
receptor gene mutations in children with severe obesity from pakistani consanguineous families. 
Mol Genet Metab 106(1):121-6. 
Sanchez J, Priego T, Pico C, Ahrens W, De Henauw S, Fraterman A, Marild S, Molnar D, Moreno LA, 
Peplies J, et al. 2012. Blood cells as a source of transcriptional biomarkers of childhood obesity and 
its related metabolic alterations: Results of the IDEFICS study. J Clin Endocrinol Metab 97(4):E648-
52. 
Sandholt CH, Hansen T, Pedersen O. 2012. Beyond the fourth wave of genome-wide obesity association 
studies. Nutr Diabetes 2:e37. 
Saunders CL, Chiodini BD, Sham P, Lewis CM, Abkevich V, Adeyemo AA, de Andrade M, Arya R, Berenson 
GS, Blangero J, et al. 2007. Meta-analysis of genome-wide linkage studies in BMI and obesity. 
Obesity (Silver Spring) 15(9):2263-75. 
Scherag A, Dina C, Hinney A, Vatin V, Scherag S, Vogel CI, Muller TD, Grallert H, Wichmann HE, Balkau B, 
et al. 2010. Two new loci for body-weight regulation identified in a joint analysis of genome-wide 
association studies for early-onset extreme obesity in french and german study groups. PLoS Genet 
6(4):e1000916. 
Schneeman BO, Inman MD, Stern JS. 1983. Pancreatic enzyme activity in obese and lean zucker rats: A 
developmental study. J Nutr 113(4):921-5. 
Schork NJ, Murray SS, Frazer KA, Topol EJ. 2009. Common vs. rare allele hypotheses for complex 
diseases. Curr Opin Genet Dev 19(3):212-9. 
Scully T. 2012. Diabetes in numbers. Nature Outlook 485(7398):S2–S3. 
Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, Najjar S, Nagaraja R, Orru M, Usala G, et al. 2007. 
Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-
related traits. PLoS Genet 3(7):e115. 
References 
199 
 
Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi M, et al. 
2004. Large-scale copy number polymorphism in the human genome. Science 305(5683):525-8. 
Seki Y, Williams L, Vuguin PM, Charron MJ. 2012. Minireview: Epigenetic programming of diabetes and 
obesity: Animal models. Endocrinology 153(3):1031-8. 
Sha BY, Yang TL, Zhao LJ, Chen XD, Guo Y, Chen Y, Pan F, Zhang ZX, Dong SS, Xu XH, et al. 2009. Genome-
wide association study suggested copy number variation may be associated with body mass index 
in the chinese population. J Hum Genet 54(4):199-202. 
Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, Pertz LM, Clark RA, Schwartz S, 
Segraves R, et al. 2005. Segmental duplications and copy-number variation in the human genome. 
Am J Hum Genet 77(1):78-88. 
Shastry BS. 2009. Copy number variation and susceptibility to human disorders (review). Mol Med Rep 
2(2):143-7. 
Shi H, Tzameli I, Bjorbaek C, Flier JS. 2004. Suppressor of cytokine signaling 3 is a physiological regulator 
of adipocyte insulin signaling. J Biol Chem 279(33):34733-40. 
Shugart YY, Chen L, Day IN, Lewis SJ, Timpson NJ, Yuan W, Abdollahi MR, Ring SM, Ebrahim S, Golding J, 
et al. 2009. Two british women studies replicated the association between the Val66Met 
polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur J Hum Genet 
17(8):1050-5. 
Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge RJ, Pers TH, 
Fischer K, Justice AE, et al. 2015. New genetic loci link adipose and insulin biology to body fat 
distribution. Nature 518(7538):187-96. 
Silventoinen K, Hasselbalch AL, Lallukka T, Bogl L, Pietilainen KH, Heitmann BL, Schousboe K, Rissanen A, 
Kyvik KO, Sorensen TI, et al. 2009. Modification effects of physical activity and protein intake on 
heritability of body size and composition. Am J Clin Nutr 90(4):1096-103. 
Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, Aneas I, Credidio FL, Sobreira DR, 
Wasserman NF, et al. 2014. Obesity-associated variants within FTO form long-range functional 
connections with IRX3. Nature 507(7492):371-5. 
Smith ZD and Meissner A. 2013. DNA methylation: Roles in mammalian development. Nat Rev Genet 
14(3):204-20. 
Sobreira NL, Cirulli ET, Avramopoulos D, Wohler E, Oswald GL, Stevens EL, Ge D, Shianna KV, Smith JP, 
Maia JM, et al. 2010. Whole-genome sequencing of a single proband together with linkage analysis 
identifies a mendelian disease gene. PLoS Genet 6(6):e1000991. 
Souren NY, Tierling S, Fryns JP, Derom C, Walter J, Zeegers MP. 2011. DNA methylation variability at 
growth-related imprints does not contribute to overweight in monozygotic twins discordant for 
BMI. Obesity (Silver Spring) 19(7):1519-22. 
References 
200 
 
Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, 
Naslund E, Britton T, et al. 2008. Dynamics of fat cell turnover in humans. Nature 453(7196):783-7. 
Speakman JR. 2010. FTO effect on energy demand versus food intake. Nature 464(7289):E1; discussion 
E2. 
Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Allen HL, Lindgren CM, Luan J, 
Magi R, et al. 2010. Association analyses of 249,796 individuals reveal 18 new loci associated with 
body mass index. Nat Genet 42(11):937-48. 
Steemers FJ, Chang W, Lee G, Barker DL, Shen R, Gunderson KL. 2006. Whole-genome genotyping with 
the single-base extension assay. Nat Methods 3(1):31-3. 
Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, 
Sigmundsson T, Buizer-Voskamp JE, et al. 2008. Large recurrent microdeletions associated with 
schizophrenia. Nature 455(7210):232-6. 
Stein R, Sciaky-Gallili N, Razin A, Cedar H. 1983. Pattern of methylation of two genes coding for 
housekeeping functions. Proc Natl Acad Sci U S A 80(9):2422-6. 
Steinberg MH and Adewoye AH. 2006. Modifier genes and sickle cell anemia. Curr Opin Hematol 
13(3):131-6. 
Stepanow S, Reichwald K, Huse K, Gausmann U, Nebel A, Rosenstiel P, Wabitsch M, Fischer-Posovszky P, 
Platzer M. 2011. Allele-specific, age-dependent and BMI-associated DNA methylation of human 
MCHR1. PLoS One 6(5):e17711. 
Stoger R. 2008. Epigenetics and obesity. Pharmacogenomics 9(12):1851-60. 
Storey JD. 2002. A direct approach to false discovery rates. Journal of the Royal Statistical Society.Series 
B (Statistical Methodology) 64(3):479-98. 
Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, 
et al. 2007. Relative impact of nucleotide and copy number variation on gene expression 
phenotypes. Science 315(5813):848-53. 
Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. 1998. A leptin missense mutation associated with 
hypogonadism and morbid obesity. Nat Genet 18(3):213-5. 
Stutzmann F, Tan K, Vatin V, Dina C, Jouret B, Tichet J, Balkau B, Potoczna N, Horber F, O'Rahilly S, et al. 
2008. Prevalence of melanocortin-4 receptor deficiency in europeans and their age-dependent 
penetrance in multigenerational pedigrees. Diabetes 57(9):2511-8. 
 
References 
201 
 
Sun D, Fu X, Li S, Li Q, Chen T, Lian Y,et al. 2014. Race-specific association between DNA methylation and 
body mass index: the Bogalusa Heart Study [Internet]; c2014 [cited 2014 . Available from: 
http://www.ashg.org/2014meeting/abstracts/fulltext/f140122628.htm . 
Szpiech ZA, Xu J, Pemberton TJ, Peng W, Zollner S, Rosenberg NA, Li JZ. 2013. Long runs of homozygosity 
are enriched for deleterious variation. Am J Hum Genet 93(1):90-102. 
Tabassum R, Jaiswal A, Chauhan G, Dwivedi OP, Ghosh S, Marwaha RK, Tandon N, Bharadwaj D. 2012. 
Genetic variant of AMD1 is associated with obesity in urban indian children. PLoS One 7(4):e33162. 
Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. 2009. Consanguinity and reproductive 
health among arabs. Reprod Health 6:17,4755-6-17. 
Talbert ME, Langefeld CD, Ziegler J, Mychaleckyj JC, Haffner SM, Norris JM, Bowden DW. 2009. 
Polymorphisms near SOCS3 are associated with obesity and glucose homeostasis traits in hispanic 
americans from the insulin resistance atherosclerosis family study. Hum Genet 125(2):153-62. 
Tan JT, Dorajoo R, Seielstad M, Sim XL, Ong RT, Chia KS, Wong TY, Saw SM, Chew SK, Aung T, et al. 2008. 
FTO variants are associated with obesity in the chinese and malay populations in singapore. 
Diabetes 57(10):2851-7. 
Tang W, Zou JJ, Chen XF, Zheng JY, Zeng HZ, Liu ZM, Shi YQ. 2011. Association of two polymorphisms 
within and near SOCS3 gene with obesity in three nationalities in xinjiang province of china. Acta 
Pharmacol Sin 32(11):1381-6. 
Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S. 2013. A beta-
mixture quantile normalization method for correcting probe design bias in illumina infinium 450 k 
DNA methylation data. Bioinformatics 29(2):189-96. 
Therneau T. Coxme: Mixed Effects Cox Models. R package version 2.2-4. [Internet]; c2015 [cited 2015 
April 17]. Available from: http://CRAN.R-project.org/package=coxme . 
Therneau T, Atkinson E, Sinnwell T, Schaid D, McDonnell S. Kinship2: Pedigree functions. R package 
version 1.6.0. [Internet]; c2014 [cited 2015 April 17]. Available from: http://CRAN.R-
project.org/package=kinship2 . 
Thiele H and Nurnberg P. 2005. HaploPainter: A tool for drawing pedigrees with complex haplotypes. 
Bioinformatics 21(8):1730-2. 
Thompson RF, Fazzari MJ, Greally JM. 2010. Experimental approaches to the study of epigenomic 
dysregulation in ageing. Exp Gerontol 45(4):255-68. 
Thomson JP, Skene PJ, Selfridge J, Clouaire T, Guy J, Webb S, Kerr AR, Deaton A, Andrews R, James KD, et 
al. 2010. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature 
464(7291):1082-6. 
References 
202 
 
Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, Styrkarsdottir 
U, Gretarsdottir S, Thorlacius S, Jonsdottir I, et al. 2009. Genome-wide association yields new 
sequence variants at seven loci that associate with measures of obesity. Nat Genet 41(1):18-24. 
Tolson KP, Gemelli T, Gautron L, Elmquist JK, Zinn AR, Kublaoui BM. 2010. Postnatal Sim1 deficiency 
causes hyperphagic obesity and reduced Mc4r and oxytocin expression. J Neurosci 30(10):3803-12. 
Tonjes A, Scholz M, Loeffler M, Stumvoll M. 2006. Association of Pro12Ala polymorphism in peroxisome 
proliferator-activated receptor gamma with pre-diabetic phenotypes: Meta-analysis of 57 studies 
on nondiabetic individuals. Diabetes Care 29(11):2489-97. 
Tsaprouni LG, Yang TP, Bell J, Dick KJ, Kanoni S, Nisbet J, Vinuela A, Grundberg E, Nelson CP, Meduri E, et 
al. 2014. Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect 
is partially reversible upon cessation. Epigenetics 9(10):1382-96. 
Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, Laposky A, Losee-Olson S, Easton A, 
Jensen DR, et al. 2005. Obesity and metabolic syndrome in circadian clock mutant mice. Science 
308(5724):1043-5. 
Tuzun E, Sharp AJ, Bailey JA, Kaul R, Morrison VA, Pertz LM, Haugen E, Hayden H, Albertson D, Pinkel D, 
et al. 2005. Fine-scale structural variation of the human genome. Nat Genet 37(7):727-32. 
Urban AE, Korbel JO, Selzer R, Richmond T, Hacker A, Popescu GV, Cubells JF, Green R, Emanuel BS, 
Gerstein MB, et al. 2006. High-resolution mapping of DNA copy alterations in human chromosome 
22 using high-density tiling oligonucleotide arrays. Proc Natl Acad Sci U S A 103(12):4534-9. 
Urnov FD and Wolffe AP. 2001. Above and within the genome: Epigenetics past and present. J Mammary 
Gland Biol Neoplasia 6(2):153-67. 
Vaisse C, Clement K, Guy-Grand B, Froguel P. 1998. A frameshift mutation in human MC4R is associated 
with a dominant form of obesity. Nat Genet 20(2):113-4. 
Villalobos-Comparan M, Villamil-Ramirez H, Villarreal-Molina T, Larrieta-Carrasco E, Leon-Mimila P, 
Romero-Hidalgo S, Jacobo-Albavera L, Liceaga-Fuentes AE, Campos-Perez FJ, Lopez-Contreras BE, et 
al. 2012. PCSK1 rs6232 is associated with childhood and adult class III obesity in the mexican 
population. PLoS One 7(6):e39037. 
Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, 
et al. 2000. Genomewide search for type 2 diabetes-susceptibility genes in french whites: Evidence 
for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent 
replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 67(6):1470-80. 
Walder K, Hanson RL, Kobes S, Knowler WC, Ravussin E. 2000. An autosomal genomic scan for loci linked 
to plasma leptin concentration in pima indians. Int J Obes Relat Metab Disord 24(5):559-65. 
Walley AJ, Asher JE, Froguel P. 2009. The genetic contribution to non-syndromic human obesity. Nat Rev 
Genet 10(7):431-42. 
References 
203 
 
Walters RG, Coin LJ, Ruokonen A, de Smith AJ, El-Sayed Moustafa JS, Jacquemont S, Elliott P, Esko T, 
Hartikainen AL, Laitinen J, et al. 2013. Rare genomic structural variants in complex disease: Lessons 
from the replication of associations with obesity. PLoS One 8(3):e58048. 
Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D, Andersson J, Falchi M, Chen F, Andrieux 
J, Lobbens S, et al. 2010. A new highly penetrant form of obesity due to deletions on chromosome 
16p11.2. Nature 463(7281):671-5. 
Wang H, Dong S, Xu H, Qian J, Yang J. 2012. Genetic variants in FTO associated with metabolic 
syndrome: A meta- and gene-based analysis. Mol Biol Rep 39(5):5691-8. 
Wang K, Li WD, Glessner JT, Grant SF, Hakonarson H, Price RA. 2010a. Large copy-number variations are 
enriched in cases with moderate to extreme obesity. Diabetes 59(10):2690-4. 
Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M. 2007. PennCNV: An 
integrated hidden markov model designed for high-resolution copy number variation detection in 
whole-genome SNP genotyping data. Genome Res 17(11):1665-74. 
Wang X, Zhu H, Snieder H, Su S, Munn D, Harshfield G, Maria BL, Dong Y, Treiber F, Gutin B, et al. 2010b. 
Obesity related methylation changes in DNA of peripheral blood leukocytes. BMC Med 8:87,7015-
8-87. 
Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. 2011. Health and economic burden of the 
projected obesity trends in the USA and the UK. Lancet 378(9793):815-25. 
Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW. 2005. Analysis of 
repetitive element DNA methylation by MethyLight. Nucleic Acids Res 33(21):6823-36. 
Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, Garg S, Henning E, Blackburn H, Loos RJ, 
Wareham NJ, et al. 2013. Genome-wide SNP and CNV analysis identifies common and low-
frequency variants associated with severe early-onset obesity. Nat Genet . 
Willer CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, Heid IM, Berndt SI, Elliott AL, Jackson AU, Lamina C, et 
al. 2009. Six new loci associated with body mass index highlight a neuronal influence on body 
weight regulation. Nat Genet 41(1):25-34. 
Willyard C. 2014. Heritability: The family roots of obesity. Nature 508(7496):S58-60. 
Wilson AF, Elston RC, Tran LD, Siervogel RM. 1991. Use of the robust sib-pair method to screen for 
single-locus, multiple-locus, and pleiotropic effects: Application to traits related to hypertension. 
Am J Hum Genet 48(5):862-72. 
Wolffe AP and Matzke MA. 1999. Epigenetics: Regulation through repression. Science 286(5439):481-6. 
Wong KK, deLeeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, MacAulay C, Ng RT, Brown CJ, 
Eichler EE, et al. 2007. A comprehensive analysis of common copy-number variations in the human 
genome. Am J Hum Genet 80(1):91-104. 
References 
204 
 
World Health Organization. Obesity and overweight [Internet]; c2015a [cited 2015 Febreuary/3rd]. 
Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ . 
Growth reference 5-19 years [Internet]; c2015b [cited 2015 February 5]. Available from: 
http://www.who.int/growthref/who2007_bmi_for_age/en/ . 
Global health observatory data repository [Internet]; c2015c [cited 2015 February 5]. Available from: 
http://apps.who.int/gho/data/node.main.A900A?lang=en . 
Wu X, Cooper RS, Borecki I, Hanis C, Bray M, Lewis CE, Zhu X, Kan D, Luke A, Curb D. 2002. A combined 
analysis of genomewide linkage scans for body mass index from the national heart, lung, and blood 
institute family blood pressure program. Am J Hum Genet 70(5):1247-56. 
Xie C and Tammi MT. 2009. CNV-seq, a new method to detect copy number variation using high-
throughput sequencing. BMC Bioinformatics 10:80,2105-10-80. 
Xu X, Su S, Barnes VA, De Miguel C, Pollock J, Ownby D, Shi H, Zhu H, Snieder H, Wang X. 2013. A 
genome-wide methylation study on obesity: Differential variability and differential methylation. 
Epigenetics 8(5):522-33. 
Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, 
Kubota T, et al. 2007. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of 
adiponectin binding and metabolic actions. Nat Med 13(3):332-9. 
Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric Traits (GIANT) 
Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Madden PA, 
Heath AC, Martin NG, Montgomery GW, et al. 2012. Conditional and joint multiple-SNP analysis of 
GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet 
44(4):369,75, S1-3. 
Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. 1999. Obesity in the mouse model of pro-
opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5(9):1066-70. 
Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S. 1998. A frameshift mutation in MC4R 
associated with dominantly inherited human obesity. Nat Genet 20(2):111-2. 
Yoo KY, Shin HR, Chang SH, Choi BY, Hong YC, Kim DH, Kang D, Cho NH, Shin C, Jin YW. 2005. Genomic 
epidemiology cohorts in korea: Present and the future. Asian Pac J Cancer Prev 6(3):238-43. 
Yu Y, Zhu H, Miller DT, Gusella JF, Platt OS, Wu BL, Shen Y, Children's Hospital Boston Genotype 
Phenotype Study Group. 2011. Age- and gender-dependent obesity in individuals with 16p11.2 
deletion. J Genet Genomics 38(9):403-9. 
Zaghlool SB, Al-Shafai M, Al Muftah WA, Kumar P, Falchi M, Suhre K. 2015. Association of DNA 
methylation with age, gender, and smoking in an arab population. Clin Epigenetics 7(1):6,014-0040-
6. eCollection 2015. 
References 
205 
 
Zegers D, Beckers S, Hendrickx R, Van Camp JK, de Craemer V, Verrijken A, Van Hoorenbeeck K, Verhulst 
SL, Rooman RP, Desager KN, et al. 2014. Mutation screen of the SIM1 gene in pediatric patients 
with early-onset obesity. Int J Obes (Lond) 38(7):1000-4. 
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. 1994. Positional cloning of the mouse 
obese gene and its human homologue. Nature 372(6505):425-32. 
Zhao J, Goldberg J, Vaccarino V. 2013. Promoter methylation of serotonin transporter gene is associated 
with obesity measures: A monozygotic twin study. Int J Obes (Lond) 37(1):140-5. 
Zhu X, Zhou A, Dey A, Norrbom C, Carroll R, Zhang C, Laurent V, Lindberg I, Ugleholdt R, Holst JJ, et al. 
2002. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine 
peptide processing defects. Proc Natl Acad Sci U S A 99(16):10293-8. 
 206 
 
Appendices 
 
 
Appendices 
207 
 
Appendix 1 
Supplementary Materials 
Appendices 
208 
 
Appendix 1.1Study ethical approval 
 
 
 
 
 
 
 
Appendices 
209 
 
 
 
 
 
 
 
 
 
Appendix 1.2 Information content plots given by Method A marker set 
Appendices 
210 
 
 
 
 
 
 
 
 
 
Appendices 
211 
 
Appendices 
212 
 
 
 
 
 
 
 
 
Appendices 
213 
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Appendix 1.4 Nonparametric linkage analysis results for the 22 autosomes 
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Chr Linkage 
Trait 
Linkage 
Region Start 
Linkage 
Region End 
Overlapping 
ROH pools 
Genes within linkage region 
3 Obesity 54,807,240 73,964,127 S1(6), S4(2), 
S5(3) 
ARF4,DNASE1L3,FHIT,FLNB,GPR27,MITF,PDHB,PPIAP16,PTPRG,ATXN7,TMF1,WNT5A,SLMAP,ACOX2,CADPS,SUCLG2,HESX1,UBA3,MAGI1,PSMD6,ARL6IP5,RPP14, 
FAM107A,PDZRN3,FRMD4B,C3orf63,RYBP,LRIG1,ERC2,APPL1,FOXP1,ARHGEF3,IL17RD,PXK,FEZF2,FLJ10213,SHQ1,LMOD3,ADAMTS9,ABHD6,LRTM1,C3orf14,PROK2,THOC7,ID2
B,KBTBD8,SLC25A26,FAM3D,LOC131691,C3orf49,S100A1L,SYNPR,LOC132205,ASB14,PSMC1P,FAM19A4,PPP4R2,PRICKLE2,C3orf67,KCTD6,DNHD2, 
PDE12,FAM116A,NPCDR1,C3orf64,CCDC66,EIF4E3,PSMD12P,hCG_1813818,LOC344709,SPATA12,DNAH12L,LOC375350,LOC389127,LOC391540,LOC391541, 
FAM19A1,LOC642487,LOC642567,CCDC137P,LOC654340,GLT8D4,LOC730057,LOC100128160,LOC100128209,LOC100128353,LOC100128448,LOC100128936, 
LOC100129031,LOC100129282,LOC100129765,LOC100130345,LOC100131083,LOC100131151,LOC100131568,LOC100132534,LOC100132946. 
5 FFM % 140,372,222 158,131,574 S12(2), S13(2) ADRB2,ANXA6,ASSP10,ATOX1,CAMK2A,CD74,CDX1,CSF1R,CSNK1A1,DIAPH1,DPYSL3,SLC26A2,ERPL2,FAT2,FGF1,GLRA1,GLULL1,GM2A,GPX3,GRIA1,NR3C1,NDST1, 
HTR4,ITK,MFAP3,PCDH1,PCDHGC3,PDE6A,PDGFRB,POU4F3,PPP2R2B,RPL7P,RPS14,RPS20P4,SGCD,SLC6A7,SPARC,SPINK1,TAF7,TCOF1,PCDHGB4,ADAM19,HDAC3, 
CNOT8,HAND1,MED7,RNF14,CLINT1,PCDHGA8,KIAA0141,JAKMIP2,GNPDA1,G3BP1,TNIP1,C5orf4,FAM114A2,TCERG1,SPINK5,SOX30,SYNPO,ABLIM3,KIAA0194, 
ARHGAP26,LARP1,GEMIN5,PCDHGA12,CCDC69,PCDHB5,HAVCR1,CYFIP2,IL17B,MRPL22,PCDHB1,DCTN4,PCDH12,LARS,RBM27,PCDHB18,PCDHB17,THG1L,GALNT10,RBM22,PC
DHGC5,PCDHGC4,PCDHGB7,PCDHGB6,PCDHGB5,PCDHGB3,PCDHGB2,PCDHGB1,PCDHGA11,PCDHGA10,PCDHGA9,PCDHGA7,PCDHGA6,PCDHGA5, 
PCDHGA4,PCDHGA3,PCDHGA2,PCDHGA1,PCDHGB8P,PCDHB15,PCDHB14,PCDHB13,PCDHB12,PCDHB11,PCDHB10,PCDHB9,PCDHB8,PCDHB7,PCDHB6,PCDHB4, 
PCDHB3,PCDHB2,NMUR2,KCTD16,PCDHB16,HMHB1,ARAP3,PCYOX1L,SH3TC2,SAP30L,NDFIP1,FBXO38,YIPF5,TIGD6,SPRY4,SLC25A2,PCDHB19P,PCDHGB9P,SPINK7,HAVCR2,MS
T150,FCHSD1,TIMD4,ZNF300,MYOZ3,SCGB3A2,PPARGC1B,MRPL11P2,AFAP1L1,GRPEL2,LSM11,GPR151,LOC134466,SLC36A2,SPINK5L3,LOC153469, 
PPP1R2P3,FAM71B,PRELID2,SH3RF2,PLAC8L1,STK32A,SLC36A1,hCG_1980447,RELL2,SLC36A3,KIF4B,ARSI,LOC345471,IRGM,ICHTHYIN,C5orf46,FLJ41603, 
LOC402233,SPINK6,SPINK5L2,C5orf40,LOC442142,GRXCR2,SPINK9,LOC644198,LOC644762,LOC650866,LOC727846,LOC728264,LOC728287,LOC729080,LOC729123,hCG_1641
617,LOC729421,LOC100128116,LOC100128121,LOC100128543,LOC100128833,LOC100128898,LOC100130088,LOC100130177,LOC100130260, 
LOC100131033,LOC100131520,LOC100131740,LOC100132712. 
5 Bone 
mass 
82,904,528 123,449,266 S6(2), S7(2), 
S8(1), S9(1), 
S17(2), S20(2), 
S35(1) 
APC,CAMK4,CAST,CCNH,CDO1,CETN3,CHD1,AP3S1,COX7C,HAPLN1,CSNK1G3,CTNNAP1,DMXL1,EFNA5,FER,GJA1P1,GLRX,HSD17B4,KCNN2,LNPEP,LOX,MAN2A1, 
MCC,MEF2C,PAM,PCSK1,PGGT1B,PPIC,PTMAP2,RASA1,RPS17P2,RPS20P3,SNX2,SRP19,NR2F1,ZRSR1,XBPP1,ST8SIA4,REEP5,ATG12,C5orf13,RAB9P1,SNCAIP,TTC37,PJA2,EDIL3,
POLR3G,RHOBTB3,ELL2,KIAA0825,HISPPD1,TNFAIP8,SNX24,TMED7,PRR16,COMMD10,ERAP1,FLJ11235,GIN1,FLJ11292,TRIM36,RIOK2,FEM1C,SEMA6A,ARRDC3,EPB41L4A,ERA
P2,FBXL17,YTHDC2,MCTP1,FLJ12078,NUDT12,SPATA9,TSSK1B,FAM172A,GPR98,ANKRD32,TSLP,C5orf30,SLC25A46,PRDM6,FTMT,C5orf26, 
LYSMD3,SLCO6A1,LOC133789,LOC133790,ZNF474,POU5F2,STARD4,WDR36,LOC134505,CEP120,LOC153364,TMEM161B,SRFBP1,ARSK,FAM81B,CCDC112,DCP2, 
LIX1,C5orf27,LVRN,PSME2P1,C5orf36,GPR150,DTWD2,NBPF22P,RGMB,LOC285706,RFESD,FAM170A,LOC345571,LOC345576,FAM174A,LOC348958,SLCO4C1,TICAM2,MRPS35
P2,LOC391807,CCT7P2,LOC391811,LOC391813,KRT18P42,LOC391825,KRT18P16,hCG_1640785,LOC402219,YTHDF1P,LOC402221,DDX18P4,LOC402226,LOC402287,OR7H2P,L
OC441066,FLJ42709,LOC441097,LOC441098,FLJ35946,ARGFXP1,LOC642737,LOC642909,FLJ43080,LOC643031,LOC643534,LOC643992, 
LOC644100,LOC644146,LOC644285,LOC645125,LOC645181,LOC645261,LOC645323,LOC647954,SNORA13,LOC727938,LOC728093,LOC728104,LOC728217, 
LOC728254,LOC728342,LOC728366,LOC728460,LOC728682,LOC728711,LOC728979,LOC729011,LOC729040,LOC731157,LOC100127986,LOC100128407, 
LOC100128691,LOC100128694,LOC100129010,LOC100129099,LOC100129233,LOC100129283,LOC100129369,LOC100129374,LOC100129526,LOC100129563, 
LOC100129564,LOC100129716,LOC100129959,LOC100129962,LOC100130087,LOC100130089,LOC100130252,FABP5L6,LOC100130699,LOC100130703, 
LOC100130786,LOC100130882,LOC100130968,LOC100131040,LOC100131042,LOC100131066,LOC100131073,LOC100131236,LOC100131280,LOC100131573, 
LOC100132014,LOC100132020,LOC100132456,LOC100132811,LOC100133050,LOC100133054,LOC100133277. 
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Chr Linkage 
Trait 
Linkage 
Region Start 
Linkage 
Region End 
Overlapping 
ROH pools 
Genes within linkage region 
5 FFM% 134,769,827 162,385,429 S12(2), S13(2) ADRA1B,ADRB2,ANXA6,ASSP10,ATOX1,CAMK2A,CD14,CD74,CDC25C,CDX1,CSF1R,CSNK1A1,CTNNA1,DIAPH1,DPYSL3,SLC26A2,HBEGF,EBF1,EGR1,ERPL2,ETF1, 
FABP6,FAT2,FGF1,GABRA1,GABRA6,GABRB2,GABRG2,GFRA3,GLRA1,GLULL1,GM2A,GPX3,GRIA1,NR3C1,HARS,HSPA9,NDST1,HTR4,IK,IL9,IL12B,ITK,LECT2,SMAD5, 
MFAP3,NDUFA2,NEUROG1,NPY6R,PCDH1,PCDHGC3,PDE6A,PDGFRB,PFDN1,POU4F3,PPP2R2B,PURA,RPL7P,RPS14,RPS20P4,SGCD,SLC6A7,SPARC,SPINK1,SPOCK1, 
TAF7,TCOF1,TGFBI,TTC1,UBE2D2,WNT8A,NME5,EIF4EBP3,PCDHGB4,CDC23,ADAM19,HDAC3,PTTG1,CNOT8,HAND1,MED7,MYOT,NRG2,CXCL14,SMAD5OS,RNF14, 
CLINT1,PCDHGA8,PCDHA9,MATR3,KIAA0141,JAKMIP2,SLC23A1,GNPDA1,SRA1,KIF20A,G3BP1,APBB3,TNIP1,SLU7,C5orf4,FAM114A2,BRD8,TCERG1,HNRNPA0, 
SPINK5,SOX30,SYNPO,ABLIM3,KIAA0194,ARHGAP26,ATP10B,LARP1,HARS2,GEMIN5,PCDHGA12,LRRTM2,CCDC69,PCDHB5,FBXL21,KLHL3,PCDHA14,HAVCR1, 
SNORD63,SNORA74A,CYFIP2,PKD2L2,IL17B,MRPL22,PCDHB1,DCTN4,MGC29506,PAIP2,PCDH12,FAM13B1,FAM53C,REEP2,LARS,CXXC5,JMJD1B,RBM27,PCDHB18, 
PCDHB17,WDR55,ANKHD1,THG1L,TMCO6,GALNT10,RBM22,PCDHGC5,PCDHGC4,PCDHGB7,PCDHGB6,PCDHGB5,PCDHGB3,PCDHGB2,PCDHGB1,PCDHGA11, 
PCDHGA10,PCDHGA9,PCDHGA7,PCDHGA6,PCDHGA5,PCDHGA4,PCDHGA3,PCDHGA2,PCDHGA1,PCDHA@,PCDHACT,PCDHGB8P,PCDHB15,PCDHB14,PCDHB13, 
PCDHB12,PCDHB11,PCDHB10,PCDHB9,PCDHB8,PCDHB7,PCDHB6,PCDHB4,PCDHB3,PCDHB2,PCDHAC2,PCDHAC1,PCDHA13,PCDHA12,PCDHA11,PCDHA10,PCDHA8, 
PCDHA7,PCDHA6,PCDHA5,PCDHA4,PCDHA3,PCDHA2,PCDHA1,NMUR2,TRPC7,KCTD16,PCDHB16,HMHB1,LOC63920,SIL1,ARAP3,PCYOX1L,CCNJL,SH3TC2,SAP30L, 
NDFIP1,FBXO38,YIPF5,TIGD6,SPRY4,SLC4A9,SLC25A2,PCDHB19P,PCDHGB9P,PSD2,C5orf32,SPINK7,HAVCR2,MST150,FCHSD1,TIMD4,ZNF300,MYOZ3,SLC35A4, 
PWWP2A,C1QTNF2,SCGB3A2,PPARGC1B,MRPL11P2,AFAP1L1,GRPEL2,LSM11,GPR151,LOC134466,UBLCP1,C5orf20,SLC36A2,SPINK5L3,LOC153328,LOC153469, 
ZMAT2,PPP1R2P3,FAM71B,PRELID2,SH3RF2,PLAC8L1,RNF145,LOC202051,DNAJC18,STK32A,SLC36A1,hCG_1980447,RELL2,SLC36A3,KIF4B,TMEM173,ARSI, 
LOC345471,IRGM,ICHTHYIN,DND1,LOC389332,LOC389333,C5orf46,FLJ41603,LOC391834,LOC391836,LOC402233,SPINK6,ANKHD1. 
10 Muscle 
mass % 
77,379,512 93,347,297 S1(5), S35(3) ACTA2,ANXA11,FAS,BMPR1A,EIF5AP1,GLUD1,GRID1,HTR7,IFIT2,IFIT1,IFIT3,KCNMA1,LIPA,MAT1A,PTEN,RGR,RPS24,SFTPA1B,SFTPA2B,SFTPD,SNCG,MBL1P1,LIPF, 
CH25H,PAPSS2,DLG5,MINPP1,KIF20B,PPIF,RPP30,NRG3,C10orf116,POLR3A,LDB3,WAPAL,IFIT5,LRIT1,ANKRD1,GHITM,PANK1,KIAA1128,FAM35A,C10orf59,ZMIZ1, 
STAMBPL1,MMRN2,C10orf57,TSPAN14,C10orf58,DYDC2,PCGF5,ATAD1,PCDH21,OPN4,ANKRD22,LOC118945,LOC119358,NUDT9P1,AGAP11,LIPJ,CFLP1,DYDC1, 
EIF5AL1,HECTD2,PLAC9,ZCCHC24,FAM22E,FLJ37201,LOC283050,LIPM,LRIT2,RPL7AP8,IMPDH1P5,SH2D4B,C10orf99,SLC16A12,LOC389990,LOC389992,LOC399783, 
LOC401646,BMS1P3,LOC439992,LOC439994,IFIT1L,TPRX1P1,TPRX1P2,LOC642300,LOC642361,LOC642413,LOC642521,LOC642538,EIF5AL3,LOC642666,LOC642934,FAM25A,LI
PK,LIPN,hCG_2024094,LOC643599,LOC647532,LOC650623,SFTPA1,LOC727749,FAM22C,LOC727879,LOC727923,LOC727960,LOC728027,LOC728050, 
FAM22A,FAM22D,LOC728190,LOC728218,LOC729187,SFTPA2,FAM22B,LOC729815,LOC100128292,LOC100128309,LOC100128465,LOC100128756,LOC100128990,LOC100129
156,LOC100129552,LOC100130253,LOC100130698,LOC100130759,LOC100130879,LOC100131132,DDX18P6,LOC100131699,LOC100132116, 
LOC100132402,LOC100132477,LOC100132487,LOC100132592,LOC100132987,LOC100133190. 
10 Waist  130,744,348 133,198,982 S5(3), S11(3)  MGMT,GLRX3,CTAGEP,EBF3,TCERG1L,LOC387723,LOC100129103. 
10 FFM % 105,727,659 117,718,290 S20(1), S1(5), 
S35(3), S14(2), 
S20(1) 
ADD3,ADRA2A,ADRB1,CASP7,COL17A1,DUSP5,HABP2,ABLIM1,MXI1,NRAP,TCF7L2,TECTB,XPNPEP1,SHOC2,SMC3,GSTO1,DCLRE1A,SMNDC1,SORCS3,ATRNL1, 
RNU4P5,PDCD4,ACSL5,C10orf118,TDRD1,GPAM,FAM160B1,ZDHHC6,hCG_1776259,C10orf81,C10orf79,AFAP1L2,ITPRIP,YWHAZP5,NCRNA00081,SORCS1,GSTO2, 
C10orf78,TRUB1,VTI1A,LOC143188,CCDC147,RBM20,LOC282997,VWA2,NHLRC2,AURKAPS2,GUCY2G,PPIAP19,LOC644511,LOC645318,LOC645360,LOC724065, 
LOC751602,LOC100128304,LOC100129732,LOC100129859,LOC100130175,LOC100130319,LOC100130409,LOC100131338,LOC100132397,LOC100132573, 
LOC100132839,LOC100132843,LOC100133269. 
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chr Linkage 
Trait 
Linkage 
Region Start 
Linkage 
Region End 
Overlapping 
ROH pools 
Genes within linkage region 
10 BMR 63,043,987 121,480,161 S1(5), S35(3), 
S14(1), S20(5) 
ACTA2,ADD3,ADK,ADRA2A,ADRB1,ANXA2P3,ANXA7,ANXA11,FAS,ARL3,ATQL4,BMPR1A,CALM2P2,CAMK2G,CASP7,ENTPD1,CHUK,ABCC2,COL13A1,COL17A1,COX15,CPN1,CYP
2C19,CYP2C8,CYP2C9,CYP2C18,CYP17A1,CYP26A1,DNA2,DNTT,DUSP5,EGR2,EIF4EBP2,EIF5AP1,EMX2,FGF8,GFRA1,GLUD1,GLUDP3,GOT1,PRLHR,GRK5, 
GRID1,HABP2,HELLS,HHEX,HK1,HNRNPH3,TLX1,HPS1,HTR7,IDE,IFIT2,IFIT1,IFIT3,KCNMA1,KIF11,ABLIM1,LIPA,MAT1A,MXI1,NDUFB8,NFKB2,NODAL,NRAP,P4HA1, 
PAX2,PCBD1,PDE6C,PGAM1,PITX3,PLAU,PNLIP,PNLIPRP1,PNLIPRP2,PPA1,PPIAP13,PPP1R3C,PPP3CB,PRF1,SRGN,PSAP,PSD,PTEN,ALDH18A1,RBP4,RGR,RGS10, 
RPS24,SCD,SFRP5,SFTPA1B,SFTPA2B,SFTPD,FBXW4,SLC18A2,SLIT1,SNCG,SUPV3L1,TACR2,TAF5,TCF7L2,TECTB,TIAL1,TLL2,VCL,VDAC2,WNT8B,XPNPEP1,SLC25A16, 
SHOC2,NDST2,MBL1P1,LIPF,EIF3A,GBF1,LDB1,SGPL1,BTRC,CH25H,PKD2L1,BTAF1,PAPSS2,INA,PDLIM1,SMC3,NEURL,DDX21,LGI1,NOLC1,DLG5,GSTO1,CHST3,BAG3,VPS26A,MI
NPP1,KIF20B,SEC24C,SH3PXD2A,SLK,SPOCK2,ZNF518A,DCLRE1A,FRAT1,PPIF,ACTR1A,SMNDC1,NPM3,CBARA1,RPP30,SORBS1,ERLIN1,LBX1,NRG3, 
MGEA5,PRDX3,C10orf116,VAX1,POLR3A,LDB3,ECD,RAB11FIP2,CPEB3,ZNF365,NT5C2,PDCD11,SORCS3,KIAA0913,WAPAL,PPRC1,RRP12,TBC1D12,DNAJC9,DNMBP, 
FRAT2,SIRT1,MYST4,TSPAN15,IFIT5, RP11. 
13 Waist  34,637,818 61,201,257 S8(5) ATP7B,CALM2P3,RCBTB2,CPB2,ELF1,ESD,FKBP1P3,FOXO1,MLNR,GTF2F2,GUCY1B2,HTR2A,KPNA3,LCP1,MAB21L1,SMAD9,NEK3,PCDH8,RB1,RFXAP,TPT1,TRPC4, 
TNFSF11,SUCLA2,DLEU2,TSC22D1,CCNA1,DCLK1,RAD17P2,COX7CP1,ITM2B,MTRF1,UTP14C,P2RY5,SLC25A15,LHFP,TRIM13,MRPS31,DLEU1,OLFM4,POSTN,SUGT1, 
LECT1,WBP4,AKAP11,EXOSC8,FNDC3A,KIAA0564,ZC3H13,SPG20,LRCH1,INTS6,CKAP2,OR7E37P,OR7E36P,NUFIP1,PCDH17,C13orf15,MED4,DNAJC15,ALG5,VPS36, 
PHF11,UFM1,SOHLH2,ENOX1,RCBTB1,NUDT15,KIAA1704,FAM48A,THSD1,FABP3P2,CYSLTR2,C13orf1,COG6,PCDH20,MGC5590,NARG1L,RNASEH2B,DHRS12, 
C13orf18,C13orf23,OR7E101P,TDRD3,CDADC1,CAB39L,DIAPH3,COX17P,CCDC70,COG3,SETDB2,KBTBD7,EBPL,KBTBD6,EPSTI1,ARL11,WDFY2,LOC121838,RP11. 
14 Obesity 54,221,757 78,870,408 S1(4), S2(1) ACTN1,ACYP1,PARP1P2,ARG2,ZFP36L1,ENTPD5,DLST,EIF2S1,ERH,ESR2,ESRRB,FDPSL3,FNTB,FOS,FUT8,GCH1,GPX2,GSTZ1,HIF1A,HSPA2,KTN1,LGALS3,LTBP2,MAX, 
MAP3K9,ALDH6A1,MNAT1,MTHFD1,SIX6,OTX2,PGF,PIGH,PPM1A,PPP2R5E,PRKCH,PSEN1,PSMA3,ABCD4,RAD51L1,RAP1AP,ARID4A,RTN1,SFRS5,SIX1,SLC8A3, 
SLC10A1,SNAPC1,SPTB,TGFB3,ZBTB25,DPF3,NUMB,ADAM21,ADAM20,WDR22,ALKBH1,EIF2B2,PNMA1,COX5AP1,AKAP5,SPTLC2,RGS6,KIAA0247,KIAA0586,DLGAP5,KIAA0317,
MED6,GPHN,VTI1B,BATF,NPC2,AHSA1,EXOC5,ACOT2,TMED10,C14orf1,WDHD1,VASH1,KIAA0831,ZBTB1,SNW1,PCNX,DAAM1,TTLL5,SYNE2,ANGEL1 
,ZFYVE26,TTC9,PLEKHG3,SIPA1L1,WDR21A,PLEK2,TIMM9,MLH3,KCNH5,POMT2,YBX1P1,COQ6,FCF1,RDH11,COX16,DACT1,ATP6V1D,C14orf100,DHRS7,SIX4,ZFYVE1,C14orf101,
FBXO34,C14orf105,EXDL2,C14orf115,SYNJ2BP,SLC39A9,FLVCR2,C14orf118,C14orf108,ACTR10,YLPM1,C14orf162,ADCK1,TMEM63C,PELI2,RHOJ,GALNTL1,PLEKHH1,TRMT5,ZNF
410,NGB,RBM25,C14orf133,SMOC1,C14orf4,MPP5,C14orf135,GPR135,FAM164C,C14orf169,C14orf45,SGPP1,C14orf156,DNAL1,RPS6KL1, 
SYT16,KIAA1737,C14orf56,PAPLN,MAGOHP,CHURC1,C14orf43,LIN52,NEK9,MAPK1IP1L,C14orf179,WDR89,RBM8B,C14orf149,RPS29P1,SOCS4,NAT12,UBA52P3, 
PPIAP5,LOC122867,GPHB5,PTBP1P,FRDAP,C14orf148,CYCSP1,JDP2,ISCA2,ACOT4,RDH12,RPL24P3,ADAM21P,NUP50P1,C14orf50,SLC38A6,C14orf37,PTGR2, 
FAM161B,C14orf166B,RPLP1P1,THSD3,RPSAP3,FAM71D,C14orf83,TMEM30B,C14orf174,UBE2L7P,RPL21P9,PROX2,ZDHHC22,TMED8,C14orf178,BLZF2P,C14orf55, 
C14orf39,COX7AP1,DDX18P1,EIF2S2P,PPIAP6,HMGB1P,HMGN1P1,HNRPCP,SNORD56B,GCATP,RPL21P10,RPL21P8,ABI1P,SRMP2,RPL12P7,SF3B4P,RPL22P2, 
HSBP1P1,HSPEP2,RPL36AP2,RPL36AP3,MOCS3P,RPL41P4,RPL7AP5,RPL7AP6,RPS12P1,PTTG4P,RPS24P2,RPS2P2,MAD2L1P,NCOA4P,NDUFB8P1,NT5CP1,NT5CP2, 
PSMA3P,VSX2,SLC35F4,LRRC9,RAB15,FLJ31306,TBPL2,TOMM20L,AKR1B1P5,LOC390483,HEATR4,FLJ22447,C14orf181,FLJ44817,LOC401777,LOC440180,LOC440181,C14orf53,
LOC441687,ACOT1,ACOT6,LOC645431,LOC645683,C14orf34,LOC645798,FLJ43390,LOC646279,FTHL13,LOC646548,TMEM90A,LOC646701,RPS28P1, 
LOC653695,RPL37P5,LOC729451,LOC729637,RPL31P4,C14orf38,LOC729850,LOC729868,LOC729941,LOC730011,LOC731223,LOC100036574,LOC100128233, 
LOC100128793,C14orf33,RPL9P5,LOC100129185,LOC100129782,LOC100129913,LOC100129928,LOC100130048,LOC100130174,LOC100130399,LOC100130473, 
LOC100130542,LOC100130614,LOC100130953,LOC100130971,LOC100131379,LOC100131497,LOC100131580,LOC100131708,LOC100131950,LOC100132365, LOC100132603. 
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chr Linkage 
Trait 
Linkage 
Region Start 
Linkage 
Region End 
Overlapping 
ROH pools 
Genes within linkage region 
18 FFM % 4,468,352 33,015,239 S35(3), S14(1) AQP4,C18orf1,CDH2,CIDEA,DSC1,DSC2,DSC3,DSG1,DSG2,DSG3,DTNA,GALNT1,GATA6,GNAL,IMPA2,LAMA3,MC2R,MC5R,MEP1B,NDUFV2,NPC1,PPIAP14,PTPN2, 
PTPRM,RBBP8,ROCK1,SNRPD1,SS18,TAF4B,TTR,ZFP161,ZNF24,NOL4,RNMT,NAPG,RIOK3,VAPA,B4GALT6,PPP4R1,SLMO1,ZNF271,RALBP1,AFG3L2,MAPRE2,RAB31, 
KIAA1012,EPB41L3,ANKRD12,KIAA0802,SLC39A6,ZNF521,C18orf10,CABYR,RNU4P3,C18orf8,RNF138,RNF125,MOCOS,CEP192,RPRD1A,ELP2,IMPACT,SPIRE1,PSMG2,TWSG1,CH
MP1B,MIB1,KLHL14,HRH4,FAM38B,CTAGE1,FAM59A,MPPE1,OR4K7P,ARHGAP28,CEP76,KIAA1772,FLJ11996,FHOD3,ASXL3,SEH1L,CHST9,C18orf21, 
TXNDC2,ZNF397,TUBB6,C18orf45,L3MBTL4,CABLES1,ESCO1,OSBPL1A,C18orf19,KRT18P8,INO80C,TTC39C,PSMA8,C18orf15,MCART2,DSG4,C18orf16,ANKRD29, 
WBP2P1,APCDD1,C18orf18,ZNF519,ABHD3,RAB12,ZNF396,LAMA1,C18orf58,LOC284230,KCTD1,LOC284269,LOC339290,LRRC30,LOC342705,DKFZp779B1634, 
ANKRD30B,C18orf34,FGF7P1,RAC1P1,HNRPA1L3,A26B2,LOC390831,LOC390834,OR4K8P,LOC390843,ARIH2P,hCG_1642947,LOC390848,FLJ38028,FLJ45994, 
CXADRP3,MGC26718,LOC440487,LOC440489,LOC440491,LOC441811,WBP11P1,DHFRP1,PA2G4P3,LOC642597,LOC644669,LOC645355,TTMA,LOC645387, 
LOC645423,LOC645573,LOC645859,AMAC1L1,LOC646044,LOC646053,LOC646065,LOC646171,LOC646203,LOC646359,LOC646442,LOC646583,LOC646595, 
LOC646629,LOC646778,LOC646842,LOC647983,LOC648532,LOC728211,LOC728473,LOC728592,CIAPIN1P,LOC728606,LOC729309,LOC729391,LOC729589, 
LOC729602,LOC729774,LOC729804,LOC729863,LOC729950,LOC730045,LOC732448,LOC791126,ZNF397OS,LOC100128219,LOC100128238,LOC100128324,  
LOC100128776,LOC100128893,LOC100128925,LOC100129355,LOC100129556,LOC100129769,LOC100129773,LOC100130055,LOC100130329,LOC100130404, 
LOC100130468,LOC100130480,LOC100130487,LOC100131036,LOC100131282,LOC100131500,LOC100131915,LOC100131966,LOC100132255,LOC100132664, LOC100132679. 
18 Muscle 
mass % 
4,468,352 33,015,239 S35(3), S14(1) AQP4,C18orf1,CDH2,CIDEA,DSC1,DSC2,DSC3,DSG1,DSG2,DSG3,DTNA,GALNT1,GATA6,GNAL,IMPA2,LAMA3,MC2R,MC5R,MEP1B,NDUFV2,NPC1,PPIAP14,PTPN2, 
PTPRM,RBBP8,ROCK1,SNRPD1,SS18,TAF4B,TTR,ZFP161,ZNF24,NOL4,RNMT,NAPG,RIOK3,VAPA,B4GALT6,PPP4R1,SLMO1,ZNF271,RALBP1,AFG3L2,MAPRE2,RAB31, 
KIAA1012,EPB41L3,ANKRD12,KIAA0802,SLC39A6,ZNF521,C18orf10,CABYR,RNU4P3,C18orf8,RNF138,RNF125,MOCOS,CEP192,RPRD1A,ELP2,IMPACT,SPIRE1,PSMG2,TWSG1,CH
MP1B,MIB1,KLHL14,HRH4,FAM38B,CTAGE1,FAM59A,MPPE1,OR4K7P,ARHGAP28,CEP76,KIAA1772,FLJ11996,FHOD3,ASXL3,SEH1L,CHST9,C18orf21, 
TXNDC2,ZNF397,TUBB6,C18orf45,L3MBTL4,CABLES1,ESCO1,OSBPL1A,C18orf19,KRT18P8,INO80C,TTC39C,PSMA8,C18orf15,MCART2,DSG4,C18orf16,ANKRD29, 
WBP2P1,APCDD1,C18orf18,ZNF519,ABHD3,RAB12,ZNF396,LAMA1,C18orf58,LOC284230,KCTD1,LOC284269,LOC339290,LRRC30,LOC342705,DKFZp779B1634, 
ANKRD30B,C18orf34,FGF7P1,RAC1P1,HNRPA1L3,A26B2,LOC390831,LOC390834,OR4K8P,LOC390843,ARIH2P,hCG_1642947,LOC390848,FLJ38028,FLJ45994, 
CXADRP3,MGC26718,LOC440487,LOC440489,LOC440491,LOC441811,WBP11P1,DHFRP1,PA2G4P3,LOC642597,LOC644669,LOC645355,TTMA,LOC645387, 
LOC645423,LOC645573,LOC645859,AMAC1L1,LOC646044,LOC646053,LOC646065,LOC646171,LOC646203,LOC646359,LOC646442,LOC646583,LOC646595, 
LOC646629,LOC646778,LOC646842,LOC647983,LOC648532,LOC728211,LOC728473,LOC728592,CIAPIN1P,LOC728606,LOC729309,LOC729391,LOC729589, 
LOC729602,LOC729774,LOC729804,LOC729863,LOC729950,LOC730045,LOC732448,LOC791126,ZNF397OS,LOC100128219,LOC100128238,LOC100128324, 
LOC100128776,LOC100128893,LOC100128925,LOC100129355,LOC100129556,LOC100129769,LOC100129773,LOC100130055,LOC100130329,LOC100130404, 
LOC100130468,LOC100130480,LOC100130487,LOC100131036,LOC100131282,LOC100131500,LOC100131915,LOC100131966,LOC100132255,LOC100132664, LOC100132679. 
20 FFM% 53,647,394 58,795,536 S10(1), S11(3), 
S24(2) 
ATP5E,BMP7,CSTF1,CTSZ,EDN3,GNAS,MC3R,PCK1,PPP1R3D,AURKA,TFAP2C,RAE1,STX16,VAPB,HMG1L1,SYCP2,SPO11,SLMO2,TH1L,C20orf43,PPP4R1L,RBM38, 
PMEPA1,CASS4,RAB22A,CDH26,C20orf177,MGC4294,NPEPL1,TUBB1,ZBP1,C20orf108,PHACTR3,RPS4L,C20orf85,MRPS16P,ZNF831,GCNT7,CBLN4,CTCFL,RPL39P, 
ANKRD60,MTCO2L,LOC149773,GNASAS,APCDD1L,PTMAP6,C20orf106,C20orf197,LOC284757,C20orf66,C20orf107,LOC645605,LOC728902,LOC729296, 
LOC100128291,LOC100128608,LOC100128748,LOC100129576,LOC100129869,LOC100130156,LOC100131175,LOC100131365,LOC100131710,LOC100131806, LOC100133271. 
20 Bone 
mass 
217,281 56,511,689 S1(4), S2(4), S3(4), 
S4(4), S7(3), S8(3), 
S9(2), S10(1), 
S11(2), S24(2) 
ACTGP3,ADA,ADRA1D,JAG1,AHCY,ASIP,AVP,BCL2L1,BCL2L7P1,BFSP1,BMP2,BMP7,BPI,ENTPD6,CD40,CDC25B,CEBPB,CENPB,CHGB,CSE1L,CSNK2A1,CST1,CST2,CST3,CST4,CST5,
CSTF1,CSTP1,CSTP2,CYB5P4,CYP24A1,DNMT3B,E2F1,EIF4EP1,EPB41L1,EYA2,FDXP1,FKBP1A,FOXS1,GGT7,GHRH,GNRH2,GSS,HCK,FOXA2,HNF4A,ID1, 
IDH3B,INSM1,EIF6,ITPA,KCNB1,KCNG1,KCNS1,LBP,MC3R,MMP9,MYBL2,NFATC2,NKX2. 
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Appendix 1.7Large CNVs (>500kb) detected in the sample set. 
 
 
 
Chr Start (hg19) End (hg19) Size 
(kb) 
# of 
SNPs 
CNV State Sample ID Family 
 ID 
Age 
 (y) 
BMI 
 (kg/m2) 
Phenotype Overlapping genes 
 
 
2 87392157 87995393 603.2 36 Het Deletion DMF5S2 4 56 32.9 Obese LINC00152,MIR4435-1,MIR4435-2 
2 87392157 87995393 603.2 36 Het Deletion DMF5S5 4 53 28.1 Overweight 
2 87392157 87972393 580.2 35 Het Deletion DMF5S1 4 41 33.6 Obese 
5 46324183 49548900 3224.7 92 Het Deletion QO_F5_05 5 20 39.9 Obese NA 
5 46324183 49548900 3224.7 92 Het Deletion QO_F9_08 9 23 30.2 Obese 
6 110883633 111591037 707.4 401 Het Duplication DMF3S1 3 51 35.4 Obese AMD1,CDK19,GSTM2P1,GTF3C,KIAA1919,RPF2,SLC16A10 
6 110887169 111591037 703.9 396 Het Duplication DMF3S2 3 54 28.7 Overweight 
8 42942128 43789824 847.7 400 Het Duplication QO_F8_02 8 45 36.7 Obese FNTA,SGK196,HGSNAT,A26A1,LOC347028,hCG_1795560,LOC643654,LOC
100128173,LOC100130474,LOC100130767,LOC100131789 
8 42937273 43788229 851.0 402 Het Duplication QO_F8_03 8 19 42.6 Obese 
9 68996222 69992206 996.0 35 Het Deletion QO_F5_04 5 18 19 Normal ANKRD20A4,BX255923.3,CBWD5,CBWD6,FOXD4L6,LOC100133920,PGM5
P2 
9 68996222 69881429 885.2 33 Het Deletion QO_F5_06 5 14 30.1 Obese 
10 46949421 47703946 754.5 264 Het Duplication QO_F7_11 7 18 39.8 Obese ANXA8L2,FAM21B,ANTXRL,LOC340844,SLC9A3P4,CTGLF11P,ASAH2C,LOC
728449 
10 46949421 47703946 754.5 264 Het Duplication QO_F7_03 7 26 20.1 Normal 
10 46949421 47703946 754.5 264 Het Duplication QO_F7_02 7 52 36.1 Obese 
11 50677929 51373124 695.2 80 Het Deletion QO_F5_05 5 20 39.9 Obese OR4C7P,OR4R2P,OR4A8P,OR4A7P,OR4A5,OR4A3P,OR4C46,OR4A6P,OR4
A2P,OR4A4P 
 
11 50751699 51373124 621.4 57 Het Deletion QO_F4_01 1 62 26.6 Overweight 
11 50691976 51373124 681.1 74 Het Deletion QO_F8_04 8 14 21.29 Normal 
11 50691976 51373124 681.1 74 Het Deletion QO_F9_08 9 23 30.2 Obese 
14 25099980 25612838 512.9 469 Het Duplication QO_F5_05 5 20 39.9 Obese GZMB,STXBP6 
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Chr Start (hg19) End (hg19) Size 
(kb) 
# of 
SNPs 
CNV State Sample ID Family 
 ID 
Age 
 (y) 
BMI 
 (kg/m2) 
Phenotype Overlapping genes 
 
14 106,103,358 106,917,103 813.7 85 Het Duplication QO_F6_09 6 55 24.7 Normal IGHVIII-82,IGHVIII-76-1,IGHVIII-67-4,IGHVIII-67-3,IGHVIII-67-2,IGHVIII-51-
1,IGHVII-78-1,IGHVII-74-1,IGHVII-67-1,IGHVII-65-1,IGHVII-62-1,IGHVII-60-
1,IGHVII-53-1,IGHVII-51-2,IGHV7-81,IGHV756,IGHV578,IGHV5-51,IGHV4-
80,IGHV4-61,IGHV4-59,IGHV4-55,IGHV3-79,IGHV376,IGHV3-75,IGHV3-
74,IGHV3-73,IGHV3-72,IGHV3-71,IGHV3-66,IGHV365,IGHV3-64,IGHV3-
63,IGHV3-62,IGHV3-60,IGHV3-57,IGHV3-54,IGHV353,IGHV3-52,IGHV2-
70,IGHV1-69,IGHV1-68,IGHV1-
67,IGHV158,LOC192127,LOC192130,C14orf99. 
14 19,457,976 20,402,122 944.1 43 Het Duplication QO_F7_11 7 18 39.8 Obese ANG,APEX1,NP,RNASE1,RNASE4,RNASE6,TEP1,PARP2,FAM12A,OSGEP,CC
NB1IP1,FAM12B,OR4K5,OR4K1,OR4K16P,OR4K15,RPPH1,TMEM55B,TTC5
,RNASE11,OR4K14,OR4L1,OR11H6,KLHL33,LOC254028,OR11P1P,RANBP2
0P,RNASE10,OR6S1,OR4Q2,OR4K13,OR4U1P,OR4T1P,OR4K17,OR4N5,OR
11G1P,OR11G2,OR11H5P,OR11H7,OR11H4,RNASE9,RNASE12,SNORD126
,LOC100128220,GAFA1,LOC100131302,LOC100132444,LOC100133314 
16 29,581,764 30,199,579 617.8 300 Het Deletion QO_F4_02 1 32 51.8 Obese ALDOA,ASPHD1,C16orf54,C16orf92,CDIPT,CDIPTAS1,CORO1A,DOC2A,FA
M57B,GDPD3,HIRIP3,INO80E, 
KCTD13,KIF22,MAPK3,MAZ,MVP,PAGR1,PPP4C,PRRT2,QPRT,SEZ6L2,SLC7
A5P1,SPN,TAOK2,TBX6,TMEM219,YPEL3 
19 797,032 1,498,203 701.2 526 Het Duplication QO_F4_02 1 32 51.8 Obese ATP5D,CIRBP,CNN2,CFD,ARID3A,EFNA2,ELA2,GAMT,GPX4,POLR2E,RPS15,
STK11,MED16,APC2,ABCA7,SBNO2,HMHA1,DAZAP1,PCSK4,C19orf24,WD
R18,KISS1R,MUM1,MIDN,C19orf22,C19orf6,REEP6,GRIN3B,PLK5P,C19orf
23,C19orf25,C19orf26,ADAMTSL5,NDUFS7,LOC401895,LOC729119 
19 1,788,247 2,294,552 506.3 368 Het Duplication QO_F4_02 1 32 51.8 Obese AMH,CSNK1G2,MKNK2,OAZ1,SF3A2,AP3D1,LSM7,PLEKHJ1,BTBD2,FAM10
8A1,KLF16,DOT1L,C19orf36,SCAMP4,ADAT3,JSRP1,MOBKL2A,C19orf34,C
19orf35,LINGO3,LOC728187,UNQ6493 
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Appendix 1.8 UCSC browser tracks for the seven large non-centromeric CNVs detected in the study 
CNV on chromosome 2: 
 
 
CNV on chromosome 6: 
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CNV on chromosome 14: 
 
 
CNV on chromosome 16: 
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Appendix 1.9 The top 100 CpG hits in association with BMI 
Marker Chr Position P-value Gene 
symbol 
Gene name 
cg17501210 6 166970252 8.23 X10
-8
 RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 
cg18181703 17 76354621 1.72 X10
-6
 SOCS3 suppressor of cytokine signaling 3 
cg23943013 5 79551904 2.88 X10
-6
 SERINC5 serine incorporator 5 
cg05864010 11 85376948 4.60 X10
-6
 CREBZF CREB/ATF bZIP transcription factor 
cg06183831 1 9883466 7.42 X10
-6
 CLSTN1 calsyntenin 1 
cg14551938 8 49173274 8.68 X10
-6
 NA NA 
cg07146912 3 73671377 8.90 X10
-6
 PDZRN3 PDZ domain containing ring finger 3 
cg13057167 14 103750565 1.06X10
-5
 NA NA 
cg03717755 6 16136539 1.12X10
-5
 MYLIP myosin regulatory light chain interacting protein 
cg25499461 19 46389574 1.12X10
-5
 IRF2BP1 interferon regulatory factor 2 binding protein 1 
cg11519238 1 183605567 1.13X10
-5
 NA NA 
cg19570406 X 152684911 1.18X10
-5
 ZFP92 ZFP92 zinc finger protein 
cg22192069 6 13305324 1.20X10
-5
 TBC1D7 TBC1 domain family, member 7 
cg15924102 1 234852892 1.28X10
-5
 NA NA 
cg13808918 2 220041352 1.37X10
-5
 CNPPD1 cyclin Pas1/PHO80 domain containing 1 
cg14276242 17 5095449 1.44X10
-5
 ZNF594 zinc finger protein 594 
cg27563121 15 52405647 1.82X10
-5
 BCL2L10 BCL2-like 10 (apoptosis facilitator) 
cg15453943 5 104434827 1.86X10
-5
 RAB9BP1 RAB9B, member RAS oncogene family pseudogene 1 
cg23898951 10 4511903 1.88X10
-5
 NA NA 
cg20158159 10 75683345 2.00X10
-5
 C10orf55 chromosome 10 open reading frame 55 
cg03786327 13 100644473 2.02X10
-5
 NA NA 
cg18306516 10 81103258 2.05X10
-5
 NA NA 
cg04763450 17 79455576 2.07X10
-5
 NA NA 
cg04705499 19 46796459 2.12X10
-5
 NA NA 
cg10661002 7 25018503 2.27X10
-5
 OSBPL3 oxysterol binding protein-like 3 
cg16264888 12 82752007 2.41X10
-5
 NA NA 
cg02450666 1 236845763 2.54X10
-5
 NA NA 
cg00491523 16 6913336 2.58X10
-5
 RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 1 
cg15930703 2 225775142 2.79X10
-5
 DOCK10 dedicator of cytokinesis 10 
cg19748509 6 29910778 2.79X10
-5
 HLA-A major histocompatibility complex, class I, A 
cg13223561 2 132433923 2.85X10
-5
 NA NA 
cg18369680 20 41984014 3.10X10
-5
 NA NA 
cg24179288 6 29867285 3.11X10
-5
 NA NA 
cg09260951 22 39096513 3.16X10
-5
 JOSD1 Josephin domain containing 1 
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Marker Chr Position P-value Gene 
symbol 
Gene name 
cg23975840 12 117042895 3.52X10
-5
 NA NA 
cg13882285 9 125111986 3.98X10
-5
 NA NA 
cg23345151 18 77292947 4.13X10
-5
 NA NA 
cg14258335 X 2843196 4.29X10
-5
 ARSD arylsulfatase D 
cg06711873 19 22804548 4.44X10
-5
 NA NA 
cg05012044 19 12171668 4.46X10
-5
 NA NA 
cg22697239 11 44626708 4.47X10
-5
 CD82 CD82 molecule 
cg10270055 21 43221559 4.52X10
-5
 PRDM15 PR domain containing 15 
cg25810999 17 39156115 4.68X10
-5
 KRTAP3-2 keratin associated protein 3-2 
cg09103591 22 50699708 4.70X10
-5
 MAPK12 mitogen-activated protein kinase 12 
cg26113962 1 23546304 4.71X10
-5
 NA NA 
cg05660681 19 53233083 4.76X10
-5
 ZNF611 zinc finger protein 611 
cg19169586 4 82157420 4.81X10
-5
 NA NA 
cg03238359 11 60623567 4.83X10
-5
 PTGDR2 prostaglandin D2 receptor 2 
cg07977178 11 63997715 4.83X10
-5
 DNAJC4 DnaJ (Hsp40) homolog, subfamily C, member 4 
cg22141781 12 95397704 4.84X10
-5
 NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 12 
cg23877906 8 67898826 4.90X10
-5
 NA NA 
cg04150276 14 53256600 4.99X10
-5
 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 
cg19750657 13 38935967 5.15X10
-5
 UFM1 ubiquitin-fold modifier 1 
cg09966847 14 77943678 5.16X10
-5
 ISM2 isthmin 2 
cg05298224 6 32016360 5.23X10
-5
 TNXB tenascin XB 
cg03889700 4 2869818 5.24X10
-5
 ADD1 adducin 1 (alpha) 
cg07573872 19 1126342 5.30X10
-5
 SBNO2 strawberry notch homolog 2 (Drosophila) 
cg03455746 6 29802584 5.34X10
-5
 NA NA 
cg23866916 19 1155738 5.40X10
-5
 SBNO2 strawberry notch homolog 2 (Drosophila) 
cg24833065 19 55694352 5.53X10
-5
 PTPRH protein tyrosine phosphatase, receptor type, H 
cg17115737 7 75580813 5.60X10
-5
 POR P450 (cytochrome) oxidoreductase 
cg10504000 11 2402391 5.63X10
-5
 CD81 CD81 molecule 
cg14819942 15 35414228 5.81X10
-5
 NA NA 
cg11389960 15 31277661 5.94X10
-5
 MTMR10 myotubularin related protein 10 
cg12046183 6 29859829 6.19X10
-5
 NA NA 
cg27313201 1 154165904 6.27X10
-5
 TPM3 tropomyosin 3 
cg11772086 5 112535690 6.35X10
-5
 MCC mutated in colorectal cancers 
cg27337752 7 65955680 6.64X10
-5
 NA NA 
cg24748448 17 3493352 6.65X10
-5
 TRPV1 transient receptor potential cation channel, subfamily 
V, member 1 
cg05933510 1 9257092 6.73X10
-5
 NA NA 
cg26250400 19 15921959 6.76X10
-5
 NA NA 
cg06988236 6 30293962 6.85X10
-5
 NA NA 
cg20850195 17 62223337 6.96X10
-5
 NA NA 
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Marker Chr Position P-value Gene 
symbol 
Gene name 
cg02716826 9 33447032 7.10X10
-5
 NA NA 
cg05546241 6 29921779 7.27X10
-5
 NA NA 
cg16266227 1 202129204 7.32X10
-5
 PTPN7 protein tyrosine phosphatase, non-receptor type 7 
cg23344992 4 3681759 7.47X10
-5
 NA NA 
cg11070191 1 39582205 7.56X10
-5
 MACF1 microtubule-actin crosslinking factor 1 
cg16620797 3 46741803 7.58X10
-5
 TMIE transmembrane inner ear 
cg20275928 17 79283959 7.66X10
-5
 LINC00482 long intergenic non-protein coding RNA 482 
cg01251710 6 887156 7.70X10
-5
 NA NA 
cg05101437 7 92262970 7.71X10
-5
 CDK6 cyclin-dependent kinase 6 
cg04519918 16 57278807 7.75X10
-5
 ARL2BP ADP-ribosylation factor-like 2 binding protein 
cg22393213 2 237478526 7.87X10
-5
 ACKR3 atypical chemokine receptor 3 
cg23989336 17 79283915 7.96X10
-5
 LINC00482 long intergenic non-protein coding RNA 482 
cg14824301 11 61515894 8.17X10
-5
 NA NA 
cg16853770 12 123355562 8.41X10
-5
 VPS37B vacuolar protein sorting 37 homolog B (S. cerevisiae) 
cg04389058 3 57041402 8.43X10
-5
 ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 
cg15585264 19 41770827 8.48X10
-5
 HNRNPUL1 heterogeneous nuclear ribonucleoprotein U-like 1 
cg11494773 7 48128242 8.56X10
-5
 UPP1 uridine phosphorylase 1 
cg22111074 3 49690653 8.61X10
-5
 BSN bassoon presynaptic cytomatrix protein 
cg00574958 11 68607622 8.74X10
-5
 CPT1A carnitine palmitoyltransferase 1A (liver) 
cg10080732 17 1626575 8.85X10
-5
 WDR81 WD repeat domain 81 
cg02470521 2 176971304 8.87X10
-5
 HOXD11 homeobox D11 
cg06791867 11 44880944 9.09X10
-5
 TSPAN18 tetraspanin 18 
cg00611535 12 56367227 9.14X10
-5
 RAB5B RAB5B, member RAS oncogene family 
cg17058475 11 68607737 9.15X10
-5
 CPT1A carnitine palmitoyltransferase 1A (liver) 
cg02342053 9 37592791 9.26X10
-5
 TOMM5 translocase of outer mitochondrial membrane 5 
homolog (yeast) 
cg16030261 14 104669590 9.32X10
-5
 NA NA 
cg02958600 2 181738051 9.48X10
-5
 NA NA 
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Appendix 2.1 Permission for reproducing Figure 1 
NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
Mar 25, 2015 
 
 
 
This is a License Agreement between Mashael Al-Shafai ("You") and Nature Publishing Group 
("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by Nature Publishing Group, 
and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see information 
listed at the bottom of this form. 
License Number 
3596161453793 
License date 
Mar 25, 2015 
Licensed content publisher 
Nature Publishing Group 
Licensed content publication 
Nature Reviews Genetics 
Licensed content title 
The genetics of human obesity 
Licensed content author 
Christopher G. Bell, Andrew J. Walley and Philippe Froguel 
Licensed content date 
Feb 10, 2005 
Volume number 
6 
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Issue number 
3 
Type of Use 
reuse in a dissertation / thesis 
Requestor type 
academic/educational 
Format 
print and electronic 
Portion 
figures/tables/illustrations 
Number of figures/tables/illustrations 
1 
High-res required 
no 
Figures 
FIGURE 1 | Physiological regulation of energy balance. 
Author of this NPG article 
no 
Your reference number 
None 
Title of your thesis / dissertation 
Family-based Investigation of the Genetics and Epigenetics of Obesity in Qatar 
Expected completion date 
Sep 2015 
Estimated size (number of pages) 
150 
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Total 
0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this material for 
this purpose, and for no other use,subject to the conditions below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of this 
material. However, you should ensure that the material you are requesting is original to 
Nature Publishing Group and does not carry the copyright of another entity (as credited in the 
published version). If the credit line on any part of the material you have requested indicates 
that it was reprinted or adapted by NPG with permission from another source, then you should 
also seek permission from that source to reuse the material. 
  
2. Permission granted free of charge for material in print is also usually granted for any electronic 
version of that work, provided that the material is incidental to the work as a whole and that 
the electronic version is essentially equivalent to, or substitutes for, the print version.Where 
print permission has been granted for a fee, separate permission must be obtained for any 
additional, electronic re-use (unless, as in the case of a full paper, this has already been 
accounted for during your initial request in the calculation of a print run).NB: In all cases, 
web-based use of full-text articles must be authorized separately through the 'Use on a Web 
Site' option when requesting permission. 
  
3. Permission granted for a first edition does not apply to second and subsequent editions and for 
editions in other languages (except for signatories to the STM Permissions Guidelines, or 
where the first edition permission was granted for free). 
  
4. Nature Publishing Group's permission must be acknowledged next to the figure, table or 
abstract in print. In electronic form, this acknowledgement must be visible at the same time 
as the figure/table/abstract, and must be hyperlinked to the journal's homepage. 
 
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] (reference citation), 
copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], advance online 
publication, day month year (doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX) 
 
Note: For republication from the British Journal of Cancer, the following credit lines 
apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
[JOURNAL NAME] (reference citation), copyright (year of publication)For AOP papers, the 
credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
[JOURNAL NAME], advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX)  
 
  
6. Adaptations of single figures do not require NPG approval. However, the adaptation should be 
credited as follows: 
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Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] (reference citation), 
copyright (year of publication) 
 
Note: For adaptation from the British Journal of Cancer, the following credit line 
applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
[JOURNAL NAME] (reference citation), copyright (year of publication) 
  
7. Translations of 401 words up to a whole article require NPG approval. Please 
visithttp://www.macmillanmedicalcommunications.com for more information.Translations of 
up to a 400 words do not require NPG approval. The translation should be credited as follows: 
 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] (reference 
citation), copyright (year of publication). 
 
Note: For translation from the British Journal of Cancer, the following credit line 
applies. 
Translated by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
[JOURNAL NAME] (reference citation), copyright (year of publication) 
We are certain that all parties will benefit from this agreement and wish you the best in the use of 
this material. Thank you. 
Special Terms: 
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Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-
978-646-2777. 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required. 
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Appendix 2.2 Permission request for reproducing Figures 3 and 5 
 
Dear Mashal,  
  
Thank you for your e-mail and apologies that this was not picked up before.  
I have requested our inside sales department in a separate e-mail to follow up or re-direct this to 
the correct person.  
I hope you will have an answer in time.  
  
Kind regards, 
 
SihamBasri 
Customer Service Representative 
 
Illumina Netherlands B.V. 
Freddy van Riemsdijkweg 15 
5657 EE Eindhoven 
 
Click here for global contact information. 
 
Sign up for an online account on MyIllumina 
 
 
-----<Email Received>----- 
From: res-te4@qatar-med.cornell.edu 
Sent: 5/28/2015 04:26 AM PDT 
To: customerservice@illumina.com 
CC: 
Subject: FW: Permissions for reproducing figures 
  
Dear Siham 
I hope this email finds you well. 
I have not heard back yet regarding my request in the email below. 
I will highly appreciate if you can follow up in this regard especially that my thesis submission 
date is soon (8th of June), and I need to provide permissions for the figures I reproduced. 
  
Thanks in advance. 
  
Best regards 
Mashal 
 
From: Customer Service [customerservice@illumina.com] 
Sent: Monday, March 23, 2015 5:20 PM 
To: Mashael Al-Shafai; emeainsidesales@illumina.com 
Subject: RE: Permissions for reproducing figures 
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Dear Mashael Al-Shafai, 
Thank you for contacting Illumina customer service. 
Your query was forwarded to our inside sales department. You will be contacted soon.  
  
Kind regards, 
 
SihamBasri 
Customer Service Representative 
 
Illumina Netherlands B.V. 
Freddy van Riemsdijkweg 15 
5657 EE Eindhoven 
 
Click here for global contact information. 
 
Sign up for an online account on MyIllumina 
 
 
-----<Email Received>----- 
From: res-te4@qatar-med.cornell.edu 
Sent: 3/23/2015 07:01 AM PDT 
To: customerservice@illumina.com 
CC: 
Subject: Permissions for reproducing figures 
  
  
Dear Illumina 
I'm a PhD student at Imperial College London. I'm have generated SNP genotyping data, whole 
genome sequencing and genome wide methylation data using the Illumina service, through a 
contract with Prof KarstenSuhre from WCMC. 
I want to reproduce the tow figures attached in this email for my thesis to Illustrate how the 
Illumina's SNP genotyping and the methylation profiling technologies work. 
  
I will highly appreciate if you can provide me with written permission for using these two figures 
if possible. 
  
  
Best regards 
  
Mashael Al-Shafai 
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Appendix 2.3 Permission for reproducing Figure 4 
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Appendix 2.4 Permission for reproducing Figure 18 
 
 
 
        
